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Chapter 1 
Introduction and Outline of thesis 

Introduction 
Benign prostatic hyperplasia (BPH) resulting in bladder outlet obstruction is 
one of the most significant problems affecting men today. Approximately 
90 % of men will have histologic evidence of BPH by age 90.' This non 
malignant enlargement of the prostate may lead in most men aged over 50, to 
troublesome lower urinary tract symptoms (LUTS) and about 25 % of all men 
will undergo prostatectomy by the eight decade of life.2 
For already more than 60 years transurethral resection of the prostate (TURP) 
is the "golden standard" in the treatment of bladder outlet obstruction. 
Although this procedure has a high success rate, 20-25% of patients do not 
have satisfactory long term outcome and there is a reoperation rate of up to 
15% over an 8 year observation period.3'4 Furthermore, despite a reduction in 
mortality rate from 2,5% to 0,2% over the last 25 years, morbidity remained 
relatively constant at 18% in the first 90 days after TURP.5 Adverse 
experiences secondary to TURP are well-known. These include bladder neck 
contracture (2,8%) and urethral stricture (0,6%-6,3%), incontinence (0,2%-
19%) and erectile dysfunction (0%-40%). Retrograde ejaculation is 
essentially expected after TURP (55%-90%). Complication of a more severe 
nature including the "TUR-syndrome"(0,8-l,5%), cardiac dysfunction (2%) 
and blood transfusion (2,5%-14%) continue to be a result of this 
procedure.2'5,6 
For these reasons and also because of the high costs induced by the treatment 
of BPH for the National Health Care systems, which will be higher in the near 
future due to ageing of the population, investigators began to look for 
alternative means of therapy to treat bladder outlet obstruction. As a result 
numerous new therapies have emerged, including medical management 
directed toward either relaxing the prostate smooth muscle (alpha-receptor 
blockade)7,8 or shrinking the prostate adenoma (5 alpha-reductase inhibitors)9, 
and several minimal invasive procedures with the intention to remove 
prostatic tissue.10"14 Balloondilatation of the prostatic urethra or placing of 
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Stents have either been abandoned, or reserved for the unfit patient.1516 
The development of new minimal invasive therapies today is based on 
producing enough heat into the prostate to cause thermal damage of the tissue 
and thereby creating a prostatic cavity. Different sources are used, varying 
from high intensity focused ultrasound to microwaves, radiofrequency and 
laseri ight. 
Laser 
The word "laser" is an acronym for "Light Amplification by the Stimulated 
Emission of Radiation". As recently as 1960, Maiman generated the first 
beam of laser light.17 Three properties make the laser unique. First, the light is 
monochromatic and as opposed to natural light sources, which are emitting 
light over the entire visible spectrum, the laser emits light over a very narrow, 
well-defined wavelength. Second, laser light is coherent, which means that 
each peak, and valley of the sine wave curves align exactly; thus laser light is 
perfectly in phase in contrast to normal light, which is non coherent. Finally, 
the laser beam is non divergent, whereas normal light radiates in all 
directions. Because of these properties laser light is very suitable for 
transportation of energy over a great distance. 
Tissue effects 
The principle which determines the tissue effects and, therefore the 
therapeutic potential of a laser, is the thermal transformation of the light 
energy. Laser interacts with tissue in four ways: 
- Absorption, which is essential for conversion of light energy into thermal 
energy 
- Reflection; the light is reflected away from the tissue surface. 
- Scattering; the light is reflected internally by various tissue components 
and thus resulting in a more diffuse absorption. 
- Transmission, which means penetration of light through the tissue, and 
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therefore the greater the transmission the lower the absorption and the 
less energy is transferred to the tissue. 
The absorption of the laser light, and as a result the development of thermal 
energy and/or damage, by the tissue is determined by the wavelength of the 
laser light, the colour of the tissue and other tissue characteristics. In addition, 
the power density of a laser has important implications regarding the tissue 
effects and depth of penetration. Power density is the result of power output 
of the laser source, the transmission of the fiber and the irradiated surface 
area (spot size), defined by the characteristics of the fiber used and its 
distance to the tissue.18 As power density increases, the temperature of the 
irradiated area rises. 
With laser prostatectomy, removal of abundant tissue is possibly the key 
mechanism. In case of laser irradiation, tissue removal can be obtained in two 
different ways: indirectly by heating of the tissue to a maximum of 100°C 
thus causing the coagulated tissue to slough and/or absorb after the procedure, 
or instantaneously by vaporising the tissue while temperatures rise over 
300°C. Either way depends on the power density at the tissue surface in 
combination with the irradiation time. 
The most commonly used laser in urology is the Nd:YAG laser, which is 
composed of neodymium ions in a Yttrium-aluminum-garnet lattice and emits 
light with a wavelength of 1064 nm. Light at this wavelength is poorly 
absorbed by water and haemoglobin allowing transmission through irrigation 
solutions commonly used during transurethral procedures. Another 
characteristic of Nd:YAG laser light, making it very useful in urology, is the 
possibility of transmission by fiber optics through small quartz fibers, which 
are easily passed through standard cystoscopes. 
Type of laser applications 
There are four types of fiber systems that have been used to treat the prostate: 
bare fibers, right angle fibers, contact tips and interstitial fibers. 
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In the past bare fibers were used by Kandel19 to treat the prostate in a canine 
model and by Shanberg20 who performed transurethral incision of the prostate 
in men. Both found this to be a slow procedure and Shanberg described a 
significant incidence of postoperative bleeding. 
One of the first side firing devices developed to apply laser energy to the 
prostate was the TULIP (transurethral ultrasound-guided laser-induced 
prostatectomy) system. The TULIP system combines a real-time ultrasound 
transducer and a Nd:YAG laser delivery system within a 20 French 
transurethral probe. Treatment is done under ultrasound guidance. The laser 
light is delivered through a prism within the device which deflects the beam 
from a standard laser fiber at 90° from the probe toward the tissue. The distal 
end of the probe is covered by a special sterile sleeve at the end of which is 
an encompassing balloon (36 or 48 Fr.). The disadvantages are that it 
precludes the use of direct vision, the technique has a long learning curve, 
and the equipment is very expensive. 
Free beam, side firing devices, for example the Urolase, the Prolase, and the 
Ultraline have the advantage of direct cystoscopic control. These fibers differ 
in mechanism and angle of beam deflection, beam profile and spot size. 
Depending on those beam characteristics and the distance of the fiber to the 
prostatic surface, either coagulation or vaporisation can be created. Most of 
these fibers can be passed through a standard 23 French cystoscope. All of 
these fibers have their own treatment protocol, which vary in power setting 
(amount of Joules and time per application) and the place or technique of 
laserapplications. 
Contact tips were developed to achieve such a high power density which 
would result in direct vaporisation of the tissue and therefore creating 
immediately a prostatic cavity. The contact tip may be coated with an infrared 
absorber, or it may become slightly coated with carbon after contact with the 
tissue. This increases the absorption of laser light at the fibertip and as a 
result induces high temperatures at the prostatic surface resulting in 
vaporisation. Experiences with this system up to now has learned that this 
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procedure is slow and tedious, especially in larger prostates. 
Interstitial application of laser energy delivers heat directly into the prostate 
rather than from an adjacent position. A laser fiber with a tip which produces 
a diffuse or a conical beam, is passed through a standard cystoscope and 
placed interstitially within the prostate to cause multiple areas of coagulation 
necrosis. Potential advantages of this procedure seems to be the fact that the 
urothelium of the prostatic urethra remains intact and consequently no 
sloughing of tissue develops, thus avoiding postoperative problems as 
irritative voiding complaints. The necrotic tissue will be resorbed in time, 
leading to an atrophic, shrunken prostate gland. Disadvantages are the 
learning curve and less visual control of laser energy effect. 
Outline of thesis 
When using a free beam side firing laser device there will be loss of laser 
energy due to transmission of the laser light through the fiber and also 
because of absorption of laser energy at the coupling between the end of the 
fiber to the device which reflects the laserbeam. During a laser prostatectomy 
this loss of laser energy will increase due to contamination or even damage of 
the fibertip. In the first part of chapter 2 the results of transmission 
measurements in a laboratory setting and visual inspection of two types of 
laser fibers after a laser prostatectomy are described. In the second part 
transmission measurements were performed in eight types of laser fibers 
before use, and in three types of fibers before and after a laser prostatectomy. 
Transmission measurements were performed with a power meter (Aquarius), 
developed in the Medical Laser Center, University Hospital Utrecht, which 
can perform transmission measurements under clinical conditions, that is, 
under water and at a relatively high power input. The influence of the decay 
of laser fibers during laser prostatectomy is presented in the last part. The 
transmission measurements described in the second part are correlated with 
the clinical outcome parameters of the laser prostatectomies 
In the first part of chapter 3 the results of a prospective study comparing the 
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clinical outcome parameters after laser prostatectomy with two different 
types of laser fibers are presented. The second part presents the results of a 
Dutch multicenter study to investigate the inter-operator variability. In 5 
different centers laser prostatectomies were performed with the same type of 
laser fiber. A total of 233 patients were included. 
Pressure/flow study analysis is considered to be the "gold standard" to 
objectively determine the grade of bladder outlet obstruction. The first part 
of chapter 4 describes a prospective study of advanced urodynamics with 
pressure-flow analysis in forty patients before and 6 months after laser 
prostatectomy with three different types of laser fibers. The second part 
presents the result of a prospective study of pressure-flow analysis in 79 
patients before and after laser treatment. Two different types of laserfibers 
were used. In this study a comparison was made between patients who were 
minimally obstructed and patients who were severely obstructed before laser 
prostatectomy. 
One of the major reasons for the development of alternative treatments for 
TURP is the high morbidity rate of this procedure. The first part of chapter 5 
presents the results of the incidence of urinary tract infections following laser 
prostatectomy. The influence of antibiotic prophylaxis was also studied. A 
total of 116 patients was evaluated of which 73 patients received antibiotics. 
The second part presents the results of the assessment of quality of life before 
and after laser prostatectomy in 103 patients. Correlations between objective 
outcome parameters and symptom scores on one hand and quality of life 
assessment on the other are also presented. 
Finally, in chapter 6 a review of lasers in benign prostatic obstruction is 
presented ending with future perspectives. 
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Durability of laser fibers 
World J Urol 13: 83, 1995 
Abstract 
In 90 patients treated with laser prostatectomy, using the Urolase (n=50) or 
Ultraline (n=40) laserfiber, the fiber tip durability was investigated. In general 
the Urolase fiber tips were less damaged than the Ultraline fiber tips. At 
visual inspection, 62% of the Urolase fiber tips were graded as minimally 
damaged in comparison with 28% of the Ultraline group. The Urolase fiber 
tips are more susceptible than the Ultraline fiber tips to damage caused by 
tissue contact, whereas the latter seems more fragile. Transmission 
measurements were performed in a laboratory setting to estimate the loss of 
energy output at the fiber tip due to damage. These measurements showed a 
major loss in almost all fibers. None of the Ultraline fibers had less than 10% 
transmission loss, and 18% of the Urolase fibers had a transmission value of 
more than 90%. Finally there seemed to be a poor correlation between the 
visual aspects of the fibers used and the changes in transmission. 
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Introduction 
Benign prostatic hyperplasia ( BPH ) has a high prevalence in men over 50 
years of age. Almost 50% of men with macroscopic BPH will develop 
voiding complaints, and the majority of these men will eventually require 
surgery.' 
For more than 60 years, the "gold standard" of surgical therapy for this 
problem has been transurethral electroresection of the prostate (TURP). 
Although the mortality has been reduced from 2.5% to 0.2% over the past 25 
years, the morbidity has remained unchanged at 18%.2 Because of this rather 
high morbidity, many (minimally invasive) alternative treatment methods 
were introduced during the last decade, such as medical management, 
balloon dilatation, prostatic stents, hyperthermia, and thermotherapy. 
Although the morbidity has decreased, these alternatives have not been 
capable of replacing TURP because none of these methods has thus far 
reached the same results as TURP. 
Following the canine feasibility studies of Johnson et al.3 in 1991 and the first 
laserprostatectomies performed with a sidefiring device in men by Costello et 
al.4 in 1992, the laser was introduced for the treatment of symptomatic BPH. 
Recent reports show that the results after laser prostatectomy are comparable 
with those achieved after TURP.5"9 However, laser treatment also has its 
limitations. Except for the contact devices currently under investigation, 
during the procedure the amount of tissue destruction cannot be controlled 
accurately by the surgeon. A factor associated with tissue destruction is the 
amount of energy delivered to the prostate that will eventually be absorbed by 
the prostate gland. This depends on a number of variables, such as reflection 
of laser light, changes in tissue characteristics during lasing, tissue cooling 
via increased prostatic blood flow, the colour of the prostate, and loss of 
power output due to fiber tip decrease during the laser procedure. The present 
study was performed to investigate the posttreatment decrease in the quality 
of the laser fibers currently used at our department. 
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Fig. 1 Visual aspects of the laser fibers, a New Ultraline fiber, b Severely 
damaged Ultraline fiber, с New Urolase fiber, d Severely damaged Urolase 
fiber. 
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Material and Methods 
Laser prostatectomy was performed with the Urolase or Ultraline fiber. The 
techniques used have been described extensively in an article by de la Rosette 
et al..10 After the treatment, the energy delivered by the laser source was 
noted, and the laser fibers were cleaned with a swab and sterile water. 
To asses the effect of laser prostatectomy on the quality of laser fibers we 
visually examined the fibers used. The fiber tips were independently inspec-
ted by two observers involved in the performance of the laser treatment, who 
graded the fiber tips on a scale ranging from 1 to 5 according to the degree of 
damage to the fibertip (1= undamaged, 5=severely damaged; Fig. 1). The 
grades given by the two observers were added up and the result was 
considered the score for a particular fiber. Transmission measurements to 
assess the percentage of energy loss were performed in a laboratory setting 
developed by the Department of Physics. The setting consisted of a power 
source, a LED (light emitting diode), producing light with a wavelength near 
Fig. 2 Laboratory setting used to perform the transmission measurements 
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that of Nd:YAG laserlight; a coupling device to connect the fiber; an 
especially developed cylinder in which the fiber tip just fits; an electric eye in 
the cylinder connected to a power meter to measure the output from the fiber 
tip (Fig. 2). 
Each fiber was connected to the power source and the fiber tip was then 
introduced into the cylinder. The electronic eye in the cylinder was situated 
close to the fiber tip for optimal registration of the fiber output. The fiber was 
manipulated by hand to produce the position with the maximum power 
output. The energy input was set at 5 mW. We first performed the 
measurements on new fibers and these results were used as baseline values. 
Thus, the transmission measured in used fibers are expressed as a percentage 
of that noted in a new fiber. These measurements were also done 
independently by the two investigators. 
Results 
Visual aspects 
The Urolase fiber tips were less affected than the Ultraline fibers tips. In the 
Urolase group, 31 fibers (62%) were graded as minimally damaged in 
comparison with fibers (28%) in the Ultraline group. Moreover, the Ultraline 
fibers appeared to be more fragile; 9 of the 40 fibers were broken at the tip 
during or after the laserprocedure. On the other hand, 6 Urolase fibers (12%) 
Table 1. Presentation of the visual aspects of the laser fibers used 
versus the number of fibers in each subgroup 
Fibertip 
Grade 2-4 
Grade 5-7 
Grade 8-10 
Defect 
Same grade 
Damage 
None-minimal 
Moderate 
Severe 
Urolase 
(n = 50) 
31 
13 
6 
0 
38/50 
Ultraline 
(π = 40) 
11 
18 
2 
9 
24/31 
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were severely damaged, frequently due to direct contact with the prostate 
tissue resulting in burning of the fiber tip. Severe damage was found in only 2 
Ultraline fibers (5%). The majority of the fibers showed the same result at 
inspection by the two investigators (Table 1). 
Transmission measurements 
Overall the Urolase fibers had less transmission loss than the Ultraline fibers 
(Table 2). None of the Ultraline fibers had less than 10% transmission loss, 
whereas 9 of the 50 Urolase fibers (18%) had a transmission value of more 
than 90%. Only in 5 Ultraline fibers (13%) was the transmission above 80% 
as compared to 20 Urolase fibers (40%). 
Table 2. Presentation of the loss of transmission and the number 
of patients in each group 
% Transmission Urolase (n) Ultraline (η) 
>90 9 0 
> 80 20 5 
> 70 27 9 
>60 36 16 
> 50 38 24 
For both fibers we could not find a relation between the amount of energy 
delivered through the fiber and the loss of transmission (Fig. 3, 4). On 
average 50-60 kJ was delivered to the prostate, resulting in a transmission 
of 60%-70% at the end of treatment, depending on the type of fiber used. 
There seemed to be a correlation between the visual aspect of the Urolase 
fiber tip and the loss of transmission, but the variation is too great for 
conclusions to be drawn for a given single fiber. A similar correlation for the 
Ultraline fibers was not detected. The majority of the Ultraline fiber tips 
showed moderate damage that did not seem to be correlated to the level of 
transmission (Fig. 5, 6). 
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Fig. 3 The relation between the amount of energy delivered and the loss of 
transmission for the Urolase fiber. 
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Fig. 4 The relation between the amount of energy delivered and the loss of 
transmission for the Ultraline fiber 
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Fig. 6 The relation between visual aspects of the Ultraline fiber and the loss 
of transmission 
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Discussion 
The NdrYAG laser achieves the deepest tissue penetration of all available 
surgical lasers, and its energy is selectively absorbed by tissue proteins, 
causing deep thermal necrosis and resulting in tissue ablation. It is only 
natural, then, that use of the NdrYAG device for laser prostatectomy should 
be explored. 
Many different laser fibers are appearing on the market for treatment of BPH. 
The (non)contact laser fibers, such as the Urolase and Ultraline fiber, redirect 
the beam laterally so as to allow better tissue ablation. However, there is no 
reason to assume that these fibers are equivalent. The redirecting mechanisms 
include highly engineered reflecting mirrors (e.g., the Urolase fiber) or quartz 
refractive prisms (e.g., the Ultraline fiber). The beams are deflected at various 
angles and the spot size differs from one fiber to the next. In the ideal setting, 
the amount of energy delivered to tissue is, among other factors, determined 
by the power setting (watts) and the length of time over which the beam is 
activated (seconds). The product of these two parameters is the amount of 
energy delivered and is measured in joules. In most situations it is impossible 
to determine specifically how much energy has been absorbed. 
The optimal Nd:YAG power setting, time for energy delivery and type of 
applicator for laser treatment remain under investigation. Some power 
transmission is lost in the bending mechanism and this varies depending on 
the efficiency of the process used. The dosimetry protocols for the devices are 
rather similar although the devices themselves vary significantly as to the 
power density at the urethral wall. From studies by van Swol et al." we have 
learned that the optical characteristics of the devices may differ significantly, 
mainly due to the method of beam deflection. It was concluded that besides 
the prostate geometry and the blood perfusion, the power density at the 
urethral wall should be taken into account in the dosimetry for an effective 
BPH treatment. Shanberg et al.12 presented a study determining the depth of 
penetration of the laser in the human prostate at varying dosimetry. Using the 
Prolase II laser fiber, their data indicated that for this type of fiber there 
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appeared to be an optimal power setting and pulse duration for the greatest 
depth of penetration. Kabalin9 has shown that for the Urolase fiber the 40 
Watts, 90 sec. setting provides optimal results for laserprostatectomy. 
However, before laser energy is applied to the prostate, it must be transmitted 
from the laser source by the laser fiber. The present study shows that a diffe-
rence in transmission measurements can be found for the two fibers tested. 
None of the Ultraline fibers had less than 10% transmission loss, whereas 
almost 20% of the Urolase fibers had a transmission of over 90%. Therefore 
we may conclude that the Urolase fibers seem more durable than the Ultraline 
fibers. We were somewhat surprised by this result because we assumed that 
the Urolase fiber would be more fragile because contact with prostate tissue 
easily damages this device. On the other hand the observed damage to the 
Ultraline fibers may be explained by the observation that this fiber was also 
used in contact. This may eventually result in growth of particles on the fiber 
tip, causing a decrease in these laser fibers. The effect of this process is 
difficult to judge in terms of the quality of the laser fiber posttreament. The 
correlation between the visual aspect of the Ultraline fiber tip and the 
transmission was poor. In contrast with these findings were the results 
obtained in the Urolase group. There appeared to be a good correlation 
between the visual aspect of the Urolase fiber tip and the loss of transmission. 
Consequently one may decide to use a second fiber if the visual aspect of the 
Urolase fiber looks poor, whereas it is more difficult to judge the quality of 
the Ultraline fiber. Moreover, we must stress that a normal visual aspect of 
the fibertip of a given fiber does not guarantee that the quality of the fiber is 
good. Therefore, it may be important to measure loss of transmission during 
laser treatment. 
The system described in the present study was used with a low power input. 
We realise that it would be ideal to perform these studies at 40 or 60 Watts, 
but this would make the measurements more difficult to perform. The 
currently used method is simple, reproducible, and easy to perform. The 
outcome of these measurements represents the minimal loss of transmission; 
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thus, at higher power settings the loss may be much greater. 
Although the outcome of the transmission measurements show major 
differences for the two fibers used, the clinical results are more or less 
similar. We think that because use of the Ultraline fiber involves a higher 
power setting and a smaller beam, this may compensate for the loss in 
transmission and result in a more or less identical power density. 
Thus, considering the variety of devices available at present, one would 
expect these to differ in terms of response and outcome. To our surprise, the 
results achieved with the fibers used in the present study were similar, 
according to a study by de la Rosette et al..10 One may come to the conclusion 
that it is the general effect of laser energy on tissue that is most important 
rather than the device or technique used. However, the degradation of the 
fiber tip may not be reflected in the results achieved over the short term, but 
may differ significantly in the long term. Therefore, we think that efficacy 
studies should determine not only fiber characteristics but also fiber 
durability. If the fiber performance is being tested during the treatment, the 
investigator may decide to increase the power input or to replace the 
laserfiber. 
Conclusion 
Laser ablation of the prostate represents an exciting potential application of 
laser technology. The optimal technique as well as technology are clearly 
evolving and the efficacy of various side-firing devices for the treatment of 
BPH is under investigation. A difference in durability was found between the 
two fibers tested. Therefore future studies should consider measurement of 
fiber durability and correlate these findings with the outcome of treatment 
and long-term follow up results. 
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Summary 
Objectives The aim of this study was the assessment of the quality of side-
firing fibers that are being used for laser prostatectomy, either by a laser light 
transmission measurement or by visual inspection. 
Methods A power meter ("Aquarius") was developed to measure the actual 
power transmitted through a side-firing fiber and delivered to the prostatic 
tissue. The power measurements were performed under clinical conditions, 
that is, under water and at relatively high input power. Furthermore, a 
protocol was developed for visual inspection of the fibers. Eight types of side-
firing fibers were measured before use. Before and after a procedure, three 
fiber types were measured: Prolase II (28 samples), Ultraline (23 samples), 
and Urolase (44 samples). All these fibers were used in standard treatment 
protocols. 
Results At 60 W the transmission of new fibers (not used) ranged between 
49% and 83% when compared to a bare fiber. After use, a large variation was 
found in transmitted power between different samples of one device. A 
correlation with total transmitted power was not present. At higher power 
input, vapor bubbles are generated at the tip of the fibers. Depending on the 
fiber design, these bubbles have a major impact on the transmission. Only for 
the Urolase fiber was there a significant correlation between visual inspection 
and the transmission of used samples at 10, 20, and 40 W. 
Conclusions The transmission strongly varies between fibers and between 
different samples of one fiber during clinical use. Moreover, the transmission 
does not correlate with visual inspection. A power measurement during a 
clinical treatment will contribute to a more controlled procedure and to a 
better comparison of clinical laser prostatectomy studies. 
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Introduction 
The possible use of the neodymium:yttrium-aluminum-garnet laser as a 
minimal invasive treatment of benign prostatic hyperplasia was already 
reported in 1988.',2 The inability, however, to direct the laser light to the 
prostatic tissue resulted in an ineffective laser treatment. In 1990 the first 
canine experiments were performed using a side-firing fiber that could be 
inserted through a cystoscope3 or that was incorporated in a transurethral 
ultrasound device.4 In both cases the laser light was directed almost 
perpendicular to the prostatic tissue. These initial experiments were soon 
followed by other canine and later by human studies5,6 to find the optimal 
laser prostate treatment that is to compete with the gold standard, 
transurethral resection of the prostate. Until now, however, there is no 
consensus regarding treatment strategy for laser prostatectomy. To achieve 
such consensus two questions need to be answered: How can we most 
effective apply laser energy to the prostate? Does the delivered energy depend 
on the type of device and does the energy delivery change with time? 
The success of a laser prostatectomy can be defined as the relieve of 
symptoms, caused by obstructive prostatic tissue, by the application of laser 
energy with minimal complications. Removal of abundant tissue is possibly 
the key mechanism. In the case of laser irradiation, tissue removal can be 
obtained in two different ways: indirectly by heating of the tissue to a 
maximum of 100°C, thus causing the coagulated tissue to slough after the 
procedure, or instantaneously by vaporizing the tissue while temperatures rise 
over 300°C. Either way depends on the power density at the tissue surface in 
combination with the irradiation time.7 The power density is the result of 
power output of the laser source and the transmission of the fiber, and the 
irradiated surface area (spot size), defined by the characteristics of the side-
firing fiber that is used and its distance to the tissue.8 This implies that, 
although using the same laser source and the same power settings, each type 
of fiber may deliver a different amount of energy to the tissue. Consequently, 
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the results of different laser prostatectomy studies may not be comparable. 
Presently, more than fifteen different side-firing fibers are commercially 
available. All are designed to deflect the laser light laterally, thus directing it 
to the prostatic tissue. In a previous study,9 we showed that the method used 
to deflect the laser light highly influences the power density on the prostatic 
tissue. Two types of side-firing fibers can be distinguished, depending on the 
deflection method that is used: metal reflector and total internal reflector. 
During a laser procedure, changes in fiber characteristics may occur, due to 
deterioration of parts of the fiber that transmit or reflect the laser light. Both 
transmission and beam characteristics may change, thus influencing the tissue 
effects and the clinical outcome in the long term. Therefore, clinical and 
experimental studies are difficult to compare with respect to (ideal) power 
settings, since the total amount of energy irradiating the tissue can only be 
estimated within limits. 
Apart from laser-related parameters, the tissue composition and the blood 
perfusion also play an important role in laser-tissue interaction. Blood vessels 
will cool the tissue surface efficiently and prevent heat deposition in deeper 
tissue layers.10" Characterization of prostatic tissue prior to treatment may 
result in a better understanding of the clinical results. 
In this study a method will be presented to measure the transmission of a 
side-firing fiber under controlled conditions similar to clinical settings. 
Consequently, the power that actually reaches the tissues, and thus 
responsible for the tissue effects, can be determined. The measurements were 
done before and after clinical procedures, to monitor the behavior of side-
firing fibers during use. 
Material and Methods 
Prior to clinical use, transmission measurements were performed on various 
samples of eight types of side-firing fibers. Three were metal reflectors: 
RotaLase (Xintec), SideFire (Myriadlase), and UroLase (Bard). Five were 
total internal reflectors: Angled Delivery Device (ADD; Laserscope), 
30 
Laseguide (Laser Peripherals), ProLase II (Cytocare), SideFiber 
(Ceramoptec), and UltraLine (Herasus Lasersonics). 
Before and after clinical application, the transmission of three types of fibers 
was measured: ProLase II (28 samples), UltraLine (23), and UroLase (44). 
Transmission measurements 
The transmission measurement in the experimental setting should be 
performed under conditions approaching those of the actual (clinical) laser 
treatment. Because the medium surrounding the device influences the way the 
laser light travels to the tissue, the measurement should take place under 
water. A measurement should include only that beam that contributes to the 
clinical effect. The transmission may be dependent on the power input, so a 
measurement needs to be performed with a power input similar to the clinical 
power setting. Fig. la is a schematic illustration of a side-firing fiber inserted 
in the prostatic urethra during treatment. In Fig. lb the power meter setup is 
shown schematically and in Fig. le a photograph of the final version of the 
power meter, named "Aquarius", is shown.12 
The detector head (power wizard, Synrad) is positioned behind a glass 
window at the outside of a water-filled container. A side-firing fiber is 
positioned through the fiber support in front of the window (detector). 
Through the use of this support, all fibers are positioned at the same distance 
(5 mm) to the detector. By repositioning the detector head (into another slot) 
the meter can be used to measure end-firing fibers as well (for reference). 
Parameters like distance of fiber to detector remain unchanged. It is possible 
to incorporate a water flush parallel with the fiber (through the support). The 
flow could be adjusted to a maximum of 3.0 ml/s. For each fiber sample the 
measurements were repeated five times. 
Visual inspection 
The simplest way of assessing the status of a side-firing fiber during clinical 
use is by direct visual inspection, as it can be done with minimal interruption 
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urethra 
side-firing fiber 
prostate 
side-firing fiber 
water flush 
detector head 
В ('end-fire mode') 
glass window 
- detector head 
('side-fire mode') 
Fig. 1 A side-firing fiber in the prostatic urethra during laser light irradiation 
(A) and the same side-firing fiber positioned in the experimental power meter 
setup (B); the final version of the setup, the Aquarius power meter (C). 
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of the procedure. It is discussed whether any visual objective characteristics 
of a used fiber correlate to its loss in transmission of laser light. Therefore the 
same fibers for which the transmission was measured during clinical use were 
inspected visually. To obtain an objective measure a classification scheme 
was designed. All fibers were scored in a range from 1 to 5, where 5 is a 
totally damaged fiber and 1 an undamaged fiber.13 As an example, the 
different grades of deterioration for the Urolase fiber are presented in Fig. 2. 
The fibers were evaluated by two independent observers (EtS, JdIR). The sum 
of the obtained scores resulted in a scale from 2 to 10. 
Fig. 2 Visual aspects of the laser fiber. Example of the scoring system for the 
Urolase fiber. Starting from the top right corner with score 1 (undamaged), 
then right to left and top to bottom to the bottom left corner with score 5 
(totally damaged). 
Results 
New fibers 
The measurements were performed at input powers of 10, 20, 40, and 60 W, 
using the Aquarius power meter described before. Three new fiber samples 
were measured for each type. The transmission was calculated relative to the 
transmission of a end-firing fiber with the same diameter as each side-firing 
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fiber. The results of these transmission measurements are presented in Fig. 3. 
The SideFire device has the lowest transmission at 60 W, especially when 
compared to its transmission at lower input power. This may be caused by the 
presence of vapor bubbles (caused by heating of the device) near the 
reflecting mirror, that spreads the beam over a larger area than the detector 
Fig. 3 Results of the transmission measurements of eight new side-firing 
fibers measured with the Aquarius power meter at 10, 20, 40, and 60 W input 
power ( bars indicate standard deviation). ADD = Angled Delivery Device. 
area. The measurements at 60 W of the other "true" reflecting type device, the 
Urolase, did show a large variation, probably for the same reason. 
Nevertheless, it is very likely that vapor bubbles are also generated with the 
other devices (internal reflectors) but, due to their shape, these bubbles do not 
stay in the laser light path. 
Measurements during and after clinical use 
Three different fibers, the Urolase, Ultraline, and Prolase II, were measured 
during and after clinical use and their transmission was compared to that 
before use (that is, of a new fiber). Each type of fiber was applied at its own 
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clinical protocol. The Prolase II was used at 40 W either fixed or moved over 
the tissue (the "painting" method).14 An average energy of 35,000 J was 
transmitted through the 28 samples. The Ultraline was used at 60 W while 
painting over the tissue.15 At average a total of 51,000 J was transmitted 
through the 23 samples. The Urolase was used at 40 W at several fixed clock 
positions, depending on prostate volume.15 The average amount of energy 
transmitted through the 44 Urolase fibers was 44,000 J. The measurements 
were performed at 10, 20, 40, and 60 W. As an example, the transmission at 
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Fig. 4 Scatter plot of the percentage transmission relative to a new fiber at 40 
W of all 28 used Prolase II, 23 used Ultraline, and 44 used Urolase fibers as 
a function of energy transmitted 
40 W of all used Prolase II, Ultraline, and Urolase fibers is presented as a 
function of energy transmitted in a scatter plot in Fig. 4. The mean values and 
standard deviations of the transmission of the three different fiber types are 
presented in Fig. 5. The differences in efficiency of laser light transmission 
are only significant between the Ultraline and the Prolase II at 10, 20, 30, and 
Input P o m (Walt) 
Fig. 5 Mean power transmission of used Prolase II, Ultraline, and Urolase 
fibers at 10, 20, 40, and 60 W input power (bars indicate standard deviation). 
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40 W, between the Urolase and the Prolase II at 10 W and the Urolase and 
Ultraline at 60 W (/ test, two-tailed, Ρ < 0.01). A water flush was 
incorporated in the measuring device with a flow rate of 3 mL/s parallel with 
a used side-firing fiber. The water is used normally for enhanced cooling of 
the fiber tip. The transmission was calculated for five used samples of the 
Prolase II, Ultraline, and Urolase, again at 10, 20, 40, and 60 W. Only at high 
power input (40 and 60 W) did the transmission increase slightly compared to 
the no-flush situation, as less vapor bubbles are generated at the tip. 
Therefore, for further experiments, the transmission measured without flush 
was considered similar to the situation with flush. 
Visual inspection 
The Prolase II, Ultraline, and Urolase were all inspected visually. The scored 
values (in a scale from 2 to 10) were correlated with the transmission 
measurements reported before. The fibers were grouped in two categories 
based on this visual aspect score: medium (score from 2 to 5) and high (score 
from 6 to 10) decay. In Figure 6 the transmission at different input powers is 
presented for these two categories for each of the three fibers. 
Fig. 6 reveals a gross relation between the visual aspect and the transmission 
for the Prolase II and the Urolase fiber. For each individual sample, the 
correlation between the visual aspect and the transmission increased with 
decreasing input power. A significant statistical level could be reached only 
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Fig. 6 77ге relationship between the visual aspect (either medium or high 
decay) and the transmission for the Prolase II, Ultraline, and Urolase at 10, 
20, 40, and 60 W input power (bars indicate standard deviation). *The 
difference in transmission is statistically significant, P<0.01. 
for the Urolase fiber at 10, 20, and 40 W input power (t test, two-tailed, Ρ < 
0.01). Therefore when using 40 or 60 W for a clinical treatment, visual 
inspection does not give sufficient information on the transmission or quality 
of the side-firing fibers discussed here. 
Comment 
Since the clinical introduction of laser prostatectomy, many side-firing fiber 
devices have been developed for this procedure. The results that are reported 
in the literature using these devices are promising regarding both objective 
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and subjective improvements, but there is a large variation. An explanation 
may be the difference in characteristics916'17 and the durability of the fibers 
during use, because for clinical relevance not the power delivered by the laser 
source but the power delivered by the fiber to the tissue is important, the first 
being the parameter reported in the literature. The laser light transmission of 
the fibers is one of the major parameters that describe the characteristics of 
the fiber and that can be used to quantify the durability. 
The transmission of eight different side-firing devices was studied here. Three 
devices (Prolase II, Ultraline, and Urolase) were followed during and after 
clinical use (durability). The study shows a large difference in laser light 
transmission, not only between the new devices, but also after use between 
different samples of one device. In general, the transmission decreased with 
increasing total transmitted energy. However, the correlation was poor. This 
suggests that transmission should be considered for a proper evaluation study 
of a device. The inclusion of a transmission measurement during a clinical 
procedure, as the change in transmission is unpredictable, would be the 
preferred situation. 
Contamination of the reflecting (gold mirror) or transmitting (glass capillary) 
parts of the fiber tip will lead to absorption of laser light. As a result the 
temperature at the contaminated place will rise easily over the boiling 
temperature of water, thus creating vapor bubbles. Of course this happens 
both in clinical application and inside the power meter. The bubbles will 
(back) scatter the light, thus influencing the transmission. As bubbles are 
formed as a result of light absorption, it is impossible to determine the 
independent effect of absorption or scattering on the transmission of laser 
light. In the case of the Urolase fibers at 10, 20, and 40 W, there was a 
significant relationship between visual inspection and transmission. It should, 
however, be remembered that the situation may be different for a particular 
sample. For the other two fibers, Prolase II and Ultraline, no correlation could 
be found. 
Apart from the visual inspection as described here, one can make use of other 
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(cystoscopic) indicators to assess the aging of a side-firing fiber. The absence 
of tissue effects (blanching or carbonization), white flashes generated at the 
tip of the device due to overheating of the tip, or excessive formation of vapor 
bubbles at the tip surface (not coming from the tissue) indicate that the device 
may be deteriorating. A proper transmission measurement can be used to 
confirm these indicators. 
Some parts of the power meter influence the amount of light that is detected. 
The glass window in front of the detector reflects and absorbs a small part of 
the laser light. The amount of water between fiber and detector or tissue 
absorbs some of the laser light as well. The total amount of laser light that not 
reaches the detector is estimated at about 5%. The results presented here are 
not influenced by these "errors", because the measurements are calculated 
relative to an end-firing fiber or relative to a new sample of a side-firing 
device. The mentioned percentile aberrations are constant in all 
circumstances. Only when calculating the energy that actually irradiates the 
tissue in the clinical situation should this 5% difference be considered. 
The patients treated with the Prolase II, Ultraline, and Urolase fibers who 
were included in this study were all evaluated, regarding symptom score and 
voiding parameters.1415 The change in these parameters, however, did not 
correlate with the decay in transmission of these fibers as assessed in this 
study. Although the number of patients is small, the absence of correlation 
may be explained by the fact that transmission of the fiber does not decrease 
linearly during a procedure. In that case, more accuracy can be obtained by 
measuring at fixed intervals during a procedure. 
Although the transmission is an important factor to take into account, at least 
for the transmission differences considered here, it does not disqualify one of 
these side-firing fibers for laser prostatectomy. It does, however, strongly 
indicate that the transmission should be considered when comparing different 
fibers. By measuring the delivered energy to the tissue more accurately with a 
setup as the "Aquarius" power meter, one will be able to compare the results 
of different laser prostatectomy studies and understand the differences better. 
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Conclusions 
The present study shows a difference in laser light transmission between side-
firing devices for laser prostatectomy. This transmission may change during 
clinical application in an unpredictable way. Despite the same device and 
applying the same power settings, the energy delivered to the tissue during a 
clinical procedure can vary significantly 
Power measurement during a clinical treatment will contribute to a more 
controlled procedure and to a better comparison of clinical laser 
prostatectomy studies. 
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The influence of the decay of laser fibers during 
laser prostatectomy on the clinical results. 
Submitted 
Summary 
Objective To assess the influence of the decay of a laser fiber during a laser 
prostatectomy on the clinical outcome parameters. 
Materials and Methods Three types of side-firing laser fibers ( 34 Urolase, 
20 Ultraline and 14 Prolase II ) were visually inspected after a laser 
prostatectomy and transmission measurements were performed using a power 
meter (Aquarius). These results were correlated with the clinical outcome 
parameters. 
Results Despite differences in the amount of loss in transmission for the 
fibers used, we could not establish any significant effect on clinical outcome 
parameters, such as improvement in maximal flow rate or IPSS symptom 
score. The visual aspect of the Urolase fibers was significantly related to the 
amount of transmission loss, while no such relation for the other two types of 
fibers was found. Prostate size and the total amount of energy delivered by 
the laser source did also not relate with the clinical outcome parameters. 
Conclusion To determine the relation between the energy absorbed in the 
prostate and clinical outcome parameters, a large number of patients must be 
evaluated and any parameter that can be controlled needs to be monitored. 
For the latter the power meter as presented here is a useful complimentary 
tool. 
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Introduction 
Since the canine feasibility studies of Johnson et al.1 and Roth et al.2 in 1991 
and the first laser prostatectomies with a side-firing device in men published 
by Costello et al.3 in 1992, laser prostatectomy has been established as an 
alternative for the treatment of symptomatic benign prostatic enlargement 
(ΒΡΕ). An increasing number of papers document results after laser 
prostatectomy comparable to those achieved after transurethral 
electroresection of the prostate (TURP).4"8 Although laser prostatectomy has 
several advantages over TURP (e.g. minimal bleeding, no fluid absorption, 
shorter hospital stay), there are still some disadvantages of laser treatment of 
the prostate. Amongst others, irritative voiding complaints can occur up to 4-
6 weeks post-treatment as well as a prolonged duration of catheterization and 
a higher incidence of urinary tract infection.9 Consequently, the development 
of laser applications and the techniques used are still evolving to improve the 
clinical outcome and reduce the post-treatment morbidity. 
Although the majority of studies10"14 showed good subjective and objective 
results, the amount of improvement varies considerably. Because the laser 
source in all these studies was the same (i.e. an Nd:YAG laser), the 
differences in clinical outcome may be explained by differences in 1) side-
firing devices, 2) laser-technique, 3) power setting and amount of laser energy 
delivered, 4) prostatic tissue variables (volume, stroma-to-epithelial ratio, 
blood circulation, colour of the mucosa) and 5) other factors that will 
influence power density, such as distance of the fiber tip to the prostatic tissue 
surface, angle at which the laser beam enters the prostate, vapor bubble 
formation at the fibertip. To develop the optimal treatment dosimetry studies 
were performed with different fibers and applying different techniques.15'19 
Some of the previous mentioned variables will change during treatment. 
Changes in blood circulation and colour of the mucosa influence both the 
amount of laser energy absorbed and the induced temperature rise. The 
degradation of the quality of a laser fiber during a treatment influences the 
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amount of energy delivered to the prostate and thus affects clinical outcome. 
To investigate the influence on the clinical outcome caused by a change of 
laser fiber properties, the present study was conducted. 
Material and Methods 
Treatment 
In a group of 68 patients with complaints due to ΒΡΕ a laser treatment was 
performed with the Urolase, Ultraline or Prolase II side-firing fiber. The 
Urolase fiber was used in a four quadrant technique in a 40 Watts 90 sec. 
setting. The Ultraline and the Prolase fiber were used in a painting manner in 
a 60 and 40 Watts setting respectively. After treatment the energy delivered 
by the laser source was recorded. All treatments were performed with a new 
fiber. 
Assessment of clinical outcome 
All patients underwent a screening program including history (IPSS symptom 
score), physical examination (including DRE), urine culture and urinalysis, 
laboratory investigations ( including PSA) and transrectal ultrasonography. 
Objective voiding parameters were evaluated by uroflowmetry, post voiding 
residual and urodynamic investigations with pressure flow study analysis. 
Visual inspection 
To asses a possible relation between the clinical outcome of laser 
prostatectomy and the quality of the laser fibers, we examined the used laser 
fibers visually. Only fibers which were used during an entire laser 
prostatectomy were inspected, thus fibers which were burned to destruction 
during a laser treatment and replaced by a new fiber were excluded. The fiber 
tips were inspected by two independent observers (E te S and J de la R), who 
scored the fiber tips from 1 to 5 according to the degree of damage ( 1 = 
undamaged, 5 = severely damaged). The sum of the scores given by the two 
observers was considered to be the score for a particular fiber. This method 
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has been extensively described in another paper. 
Transmission measurements 
To assess the percentage of energy loss transmission measurements were 
performed with a power meter, developed by the Laser Center in Utrecht, the 
Netherlands. This specially designed water-cooled power meter, named 
"Aquarius", measures the transmission of the laser fibers under clinical 
conditions being under water and at a high power setting ( 40-60 Watt ). All 
laser fibers were cleaned with a brush and water and inserted in the water-
filled power meter. All fibers were positioned at the same distance to the 
detector. Water flow parallel with the fiber could be incorporated with a flow 
of 3.0 ml/sec.21 As a reference, transmission measurements were performed 
of new fibers. 
Statistical analysis 
To investigate if there was a statistical dependency between transmission loss 
and the clinical outcome parameters, the Kendall test for rank correlation was 
used. According to the clinical outcome, patients were considered a responder 
(excellent and good), an intermediate responder (fair) and a non responder as 
Table 1. Response criteria for the IPSS symptom score and the maximum flow 
rate (MFR) in ml/s according to the 2nd International Consultation on BPH. 
IPSS 
MFR 
Parameter 
post/pre ratio 
post score 
post/pre ratio 
post score 
Response criteria 
Responder 
Excellent 
-
< 7 
-
>18 
Good 
<, 60% 
and 
<ИЗ 
2:130% 
and 
>12 
Intermediate 
Fair 
< 80% 
and 
<20 
>130% 
and 
> 6 
Non-responder 
None 
> 80% 
or 
>20 
< 130% 
or 
<6 
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recommended by the WHO (Table 1). The Kruskal-Wallis test was used to 
investigate if the amount of transmission loss was the same for each response 
category. 
Results 
Clinical data and results from fiber investigations were available from a total 
of 68 laser procedures (34 Urolase, 20 Ultraline and 14 Prolase II ). In Table 
2 the clinical outcome data are shown for the three fibers. The results for the 
Prolase II fiber were somewhat less than those for the Urolase and the 
Ultra line. 
Table 2. Mean IPSS and maximal flow rates (MFR) with standard deviation 
(Sd)for the three types of fibers. 
MFR 
IPSS 
pre 
post (6 months) 
100% χ (post-pre)/pre 
pre 
post (6 months) 
100% χ (post-pre)/pre 
Urolase (n=34) 
mean 
7.7 
17.3 
162 
21.5 
6.0 
-73 
Sd 
2.9 
5.7 
163 
5.1 
7.4 
33 
Type of fiber 
Ultraline (n=20) 
mean 
7.2 
16.3 
160 
20.3 
5.5 
-69 
Sd 
2.6 
6.5 
164 
5.4 
4.3 
28 
Prolase (n=14) 
mean 
9.1 
14.4 
83 
18.3 
7.3 
-62 
Sd 
4.1 
6.9 
128 
6.0 
4.9 
21 
There was an average increase of 83 % in maximal flow rate and a 62 % 
decrease in IPSS symptom score for the Prolase II group; this was 162 % and 
73 % for the Urolase group and 160 % and 69 % for the Ultraline group. The 
loss of transmission was at average 33% for the Urolase fibers, 28% for the 
Ultraline fibers and 48% for the Prolase II fibers (Table 3). Other variables 
which could have influenced the clinical outcome data are the total energy 
delivered by the laser and the volume of the prostate. As is shown in Table 3 
as well the mean total energy is 43,159 Joules for the Urolase group, 48,255 
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Table 3. Mean transmission percentage, total amount of energy delivered 
(Joules) and prostate volume (ml) for the three types of fibers. 
% transmission 
total energy (Joules) 
Prostate vol. (cc.) 
Urolase (n=34) 
mean 
67 
43,159 
48 
Sd 
18 
15,116 
17 
Type of fiber 
Ultraline (n=20) 
mean 
72 
48,255 
47 
Sd 
10 
14,211 
17 
Prolase (n=14) 
mean 
52 
35,119 
61 
Sd 
19 
16,534 
19 
Joules for the Ultraline group and 35,Π9 Joules for the Prolase II group. The 
mean volume of the prostate for the Urolase group is 48 ml, for the Ultraline 
group 47 ml and for the Prolase II group 61 ml. Table 4 shows the results of 
the visual inspection of the fibers. At the time of inspection there were 33 
Urolase, 18 Ultraline and 12 Prolase fibers. Altogether, more fibers were 
severely damaged in the Ultraline and the Prolase II groups. This is probably 
Table 4. Results of visual inspection of the three types of fibers after a laser 
prostatectomy. Grade 2-4 is not to slightly damaged, grade 5-10 is moderate 
to severely damaged 
Type of fiber 
Visual aspect 
not inspected 
grade 2-4 
grade 5-10 
Urolase 
(n) 
1 
21 
12 
Ultraline 
(η) 
2 
6 
12 
Prolase 
(η) 
2 
3 
9 
a result of using these fibers in a painting way while accidentally making 
contact. For all three fibers, with the Kendall correlation test no significant 
relation between the amount of transmission loss and both the relative 
changes in maximum flowrate and symptom scores (Table 5) could be found. 
Using the Kruskal-Wallis test there is no significant difference in the amount 
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Table 5. Kendall correlations (r) between loss of transmission and absolute 
(Δ (post-pre)) and relative (100% χ post/pre) changes in maximal flow rate 
(MFR) and IPSS. (ns = not significant) 
Type of fiber 
MFR 
(ml/s) 
IPSS 
Δ (post-pre) 
100% χ post/pre 
A(post-pre) 
100% χ post/pre 
Urolase 
г 
0,016 
-0,06 
-0,05 
-0,11 
Ρ 
ns 
ns 
ns 
ns 
Ultraline 
r 
0,038 
0,096 
0,092 
-0.06 
Ρ 
ns 
ns 
ns 
ns 
Prolase 
r Ρ 
0,054 ns 
0,182 ns 
0,306 ns 
0,122 ns 
of transmission loss between the response categories for the maximum flow 
rate (Table 6a). But for the Urolase group there seemed to be a significant 
difference in loss of transmission between the response categories for the 
symptom scores (Table 6b). Concerning the maximum flow rate, the 
responders percentage is 82 % for the Urolase group, 70 % for the Ultraline 
group and 43 % for the Prolase II group. For the IPSS symptom score the 
responders percentages are 88 % , 85 % and 79 % respectively. 
The visual aspects of the Urolase fibers were related to the amount of 
transmission loss. The more visually damaged the fiber tip, the higher the 
Table 6. Relation between the different responder groups for maximal flow 
rate (a) and IPSS (b) and transmission percentage in the three types of fibers, 
with the Kruskal-Wallis test, (ns = not significant) 
6a 
% Transmission 
Urolase Ultraline Prolase 
mean Sd mean Sd η mean Sd 
Responder 
Intermediate 
Non responder 
Kruskal-Wallis 
28 
3 
3 
71 
50 
51 
ns 
15 
28 
24 
14 
4 
2 
71 
73 
75 
ns 
10 
14 
10 
6 
3 
5 
49 
69 
47 
ns 
11 
27 
21 
50 
% Transmission 
6b Urolase Ultraline Prolase 
η mean Sd η mean Sd η mean Sd 
Responder 
Intermediate 
Non responder 
Kruskal-Wallis 
30 71 
2 42 
2 31 
ρ =0.0077 
14 
10 
4 
17 
1 
2 
71 
67 
77 
ns 
11 
-
8 
11 
3 
0 
51 
57 
-
ns 
19 
26 
-
transmission loss. For both other fibers the same, however not significant, 
trend was observed (Table 7). 
We couldn't find any correlation using the Kruskal-Wallis test between the 
clinical outcome parameters and both the total amount of delivered energy 
and the prostate volume. 
Table 7. Relation between transmission percentage in the three types of fibers 
and the visual aspects, using the Kruskal-Wallis test, (ns = not significant) 
Visual aspects 
grade 2-4 
grade 5-10 
Kruskal-Wallis 
Urolase 
η mean Sd 
21 75 12 
12 51 14 
ρ = 0.0002 
% Transmission 
η 
6 
12 
Ultraline 
mean 
75 
69 
ns 
Sd 
6 
12 
η 
3 
9 
Prolase 
mean 
68 
50 
ns 
Sd 
14 
21 
Discussion 
Since the first publications of side-firing laser devices in the treatment of 
symptomatic ΒΡΕ by Costello and McCullough,23 several reports were 
published which showed subjective and objective improvement after laser 
prostatectomy.10"14 Laser treatment has potential less complications compared 
to the "gold standard" TURP. The few randomised studies performed until 
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now showed no significant difference in clinical outcome between laser 
prostatectomy and transurethral electroresection of the prostate. " At present 
more than 10 different fibers are under investigation in clinical trials to 
perform laser prostatectomy. 
The beam characteristics of these different types of fibers have been 
investigated. These studies showed a wide variety in beam characteristics 
amongst the devices and thus in power density on the tissue.24'25 Aside from 
the physical differences, the fibers are clinically applied using various 
techniques (contact vs. non contact, fixed position vs. painting) and various 
laser settings (60 Watts for 60 sec, 40 Watts for 90 sec. or 15 Watts for 180 
sec). The dosimetry for some side-firing devices was derived from studies in 
a potato model and in canine prostates leading to a specific protocol for each 
type of fiber.16'9 However, in human studies, there were no significant 
differences in clinical results comparing various devices and techniques.13" 
15-26
 Only the clinical outcome of the Prolase II fiber at 40 Watts in the present 
study was not as good as those of the other two fibers (Table 2). In another 
study using the Prolase II fiber at 60 W better results were obtained.14 
Because many parameters are involved and the number of patients in each 
study is relatively small, it is not surprising that no significant data could be 
found in each of these studies indicating optimal settings. Despite the large 
scatter in the clinical data, the average clinical outcome was satisfying and 
comparable with results after TURP. In order to obtain significant data one 
has to control and measure all parameters as good as possible starting with the 
power density at the tissue and the total energy delivered to the tissue. These 
parameters can be derived from a simple transmission measurement under 
clinical conditions before and after the treatment as performed in this study. 
In the present study we could not find a correlation between the transmission 
decrease and the clinical outcome parameters for the three investigated fibers. 
The only significant correlation found was between the transmission loss in 
the Urolase fibers and the symptomatic responders. Although significant we 
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have to realise that there were only two patients in the non responder group. 
Overall the fact that all the non responder groups consists of only a few 
patients will make it difficult to find any significant relation between baseline 
parameters and clinical outcome. Furthermore, the degradation process of the 
fibers leading to the loss in transmission is considered to occur linearly during 
the procedure. We do not know whether this loss of transmission is gradually 
or whether it is the result of a particular event during the laser procedure. As a 
result one fiber may have a transmission loss already at the beginning while 
another one looses transmission just before the end of a laser prostatectomy. 
The result may be that both have the same transmission loss at the end of the 
laser procedure, but the total energy delivered to the tissue will be less for the 
first fiber as compared to the second. Measuring the transmission during the 
treatment, e.g. when fiber tip changes occur or at fixed intervals (e.g. after 
every 10,000 J), leads to a more accurate determination of the energy 
delivered to the tissue and may facilitate to reveal a relation between clinical 
outcome parameters and the actual energy delivered. It was observed that 
under clinical conditions degradation of the fibers leads not only to 
transmission loss but also generated vapor bubbles as the temperature of the 
degraded fiber tip rises above 100°C.21 These bubbles cause additional losses 
and dispersion of the laser beam resulting in a lower power density. 
Apart from actual measurements one can also inspect the fiber tip to describe 
the extent of damage. Concerning this visual aspect, its clear that when a fiber 
is severely damaged (grade 5) we have to replace it by a new fiber. But what 
to do when a fibertip looks slightly to moderately damaged or undamaged? 
The present study showed no significant relation between the visual aspects 
and the amount of transmission loss for the Ultraline and the Prolase II fiber 
but there is a relation for the Urolase fiber. Most likely this is the result of the 
differences in the material the fiber tip is made of, the manner of beam 
deflection and the laser technique used. We had the same result in an earlier 
study in which we performed transmission measurements at very low power 
setting.20 We concluded that visual aspect alone is not a reason to decide if a 
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fiber should be replaced or not. Only transmission measurements form a good 
indication as to the efficacy of a fiber. Transmission measurements applied to 
a larger series of patient treatments may provide sufficient data to determine 
whether there is a relationship between transmission loss and clinical 
outcome. 
Finally, also the influence of prostate volume and total amount of laser energy 
used, was not related with the clinical result 
In conclusion, although differences in transmission decrease for the used 
fibers were obvious, no significant effect on the clinical outcome parameters 
could be found. A considerable number of factors influence the amount of 
energy that eventually will be absorbed in the prostate. Furthermore the 
number of non responders are small. Therefore, to determine the relation 
between the energy absorbed in the prostate and clinical outcome parameters, 
a large number of patients must be evaluated and any parameter that can be 
controlled needs to be monitored. For the latter the power meter as presented 
here is a useful complimentary tool. 
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Abstract 
Laser treatment of benign prostatic hyperplasia has enjoyed a growing 
popularity among urologists over the last few years. Various applicators and 
techniques have been reported. Because this may result in a different overall 
performance, we performed a prospective randomised study comparing the 
results of treatment using the Ultraline fiber (n=44) with that using the Urolase 
fiber (n=49). Although different types of fibers and techniques were used, the 
results of this study were surprisingly similar for both fibers used. The uroflow 
for the Ultraline group increased from an average of 7.9 ml/s at baseline to 19.3 
ml/s at 3 months and 16.9 ml/s at 6 months.. In the patients treated with the 
Urolase fiber the uroflow improved from an average of 7.8 ml/s at baseline to 
19.5 and 16.3mL/s at 3 and 6 months, respectively. The improvement in 
symptoms, reflected by changes in the I-PSS symptom scores, for the Ultraline 
group went from 21.0 at baseline to 7.9 at 3 months, and 6.0 at 6 months. The 
Urolase patients improved from 21.0 at baseline to 8.2 and 5.6 at 3 and 6 
months, respectively. The morbidity mainly consisted of a prolonged need for 
posttreatment catheterization and irritative symptoms for about 2 to 4 weeks. 
From this study we concluded that the results achieved by laser treatment of the 
prostate using the Ultraline and Urolase fiber are both equivocal and excellent; 
however, the morbidity of these treatments remains considerable. 
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Introduction 
Over the last few decades, transurethral resection of the prostate (TURP) has 
been the primary choice of treatment to relieve bladder outlet obstruction and 
symptoms of prostatism. TURP is reported to be a safe and effective procedure. 
The mortality has been reduced to 0.2% but morbidity remains considerable and 
constant at 18%.' The treatment of BPH is currently undergoing significant 
réévaluation. The increasing age of the general population and the greater 
attention paid by older men to the symptoms of prostatism mean that the 
demand for treatment is almost limitless. 
Because of the minor but significant morbidity and the changes in social habits 
and for economic reasons, a number of alternatives to TURP have emerged in 
recent years.2"5 One alternative to TURP that has recently demonstrated 
significant results is the use of a laser to achieve desobstruction.6"8 One of the 
first reports on laser treatment of BPH was published by Costello et al.9 in 1992. 
Since then, various authors have reported their clinical experience in using 
different types of applicators.7'8,10'11 These applicators, however, differ in their 
physical properties, overall performance, and tissue effects. 
The question as to the type of applicator that should be used is fundamental. 
The initial experience with laser treatment of benign prostatic hyperplasia 
(BPH) involved the transurethral ultrasound-guided laser-induced 
prostatectomy (TULIP) device and the Urolase fiber.12 The simplicity of the 
endoscopy-assisted technique made it more attractive than the ultrasound-
guided TULIP device. Moreover, the latter procedure caused more morbidity. 
Following this experience, we proceeded with the side-firing fiber technique. 
These fibers possess vaporising and coagulation properties. In favour of the 
vaporising technique is the observation that tissue is vaporised and a lumen is 
created instantly. On the other hand, a coagulative technique may result in more 
extensive tissue destruction and, thus, should lead to better results. To date, 
long-term data have not been available to demonstrate this correlation with 
clinical results in humans. Therefore, we conducted a study involving a fiber 
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that is primarily used to achieve coagulation (Urolase) and a fiber that can 
achieve both vaporisation and coagulation (Ultraline). 
Patients and methods 
From April 1993 until July 1994, 94 men aged 50 to 85 years (average age, 65 
years) with symptoms of BPH were randomised to receive treatment with the 
Ultraline fiber (Heraeus) or the Urolase fiber (Bard). The major inclusion and 
exclusion criteria for treatment are shown in Table I. 
Table 1. Inclusion and exclusion criteria for laser treatment 
Inclusion criteria Exclusion criteria 
Prostate volume > 30 cm3 Prostatic carcinoma 
Age > 50 years Bacterial prostatitis 
Duration of symptoms > 3 Urethral stricture 
months 
IPSS >12 Neurogenic bladder dysfunction 
Peak uroflow < 15ml/s Urinary tract infection 
Use of drugs influencing bladder 
function 
History ofTURP or TULIP 
Diabetes mellitus 
Bladder residual urine > 350 ml 
Screening included a general history, complete physical examination (including 
a digital rectal examination), routine blood studies, urine microscopy, and 
culture. Urine cytology and prostate-specific antigen (PSA) levels were always 
measured so as to exclude coexisting malignancy. The severity of symptoms 
was scored using the IPSS questionnaire. Men were also questioned regarding 
their sexual function (erection and ejaculation). Uroflowmetry (peak flow, 
Qmax) was performed twice with a minimal voided volume of 100 ml. Residual 
urine was measured with transabdominal ultrasound. To determine the grade of 
outlet obstruction we performed an advanced urodynamic investigation 
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including pressure flow analysis. The upper urinary tract was evaluated using a 
plain abdominal X-ray and renal ultrasound. Transrectal ultrasound of the 
prostate (TRUS) was performed to measure the volume of the prostate and to 
determine the prostate configuration. Flexible urethrocystoscopy was used to 
verify patency of the urethra, and to look for an enlargement of the middle lobe 
and for signs of malignancy. All patients with an abnormal rectal examination, a 
PSA level more than 10 ng/ml (Hybritech), and/or abnormal TRUS underwent 
biopsy. 
Patients were randomised after informed consent had been obtained. The 
Urolase fiber delivery system consists of a 4 m. long Teflon coated fiber with a 
gold-plated dish at the tip, which allows the laser beam to be reflected at a 90° 
angle. Sterile water is used as an irrigant through a standard 23 F cystoscope 
with a 30° angle lens. The Urolase fiber is passed through the working port of 
the cystoscope. The distribution of the laser energy is customised to the 
appearance of each prostate. In general, 40 Watts of energy is applied for 90 s to 
each lateral lobe at the 2, 5, 7, and 10 o'clock positions. In the case of an 
enlarged middle lobe or a prostatic urethra exceeding 2.5 cm in length, further 
applications are provided to ensure complete blanching of the lateral lobes. The 
Ultraline fiber system also consists of a Teflon coated fiber and the beam is 
deflected using a refractive mechanism. The distribution of the laser energy is 
applied by a dragging or so-called "painting" technique with the fiber in contact 
or non-contact mode. A total of 60 Watts of energy is delivered to the prostate 
lobes during a certain period. To provide relief of symptoms, this technique 
relies not on tissue sloughing but rather on the immediate creation of an open 
channel. 
Patients were seen 1, 6, 12, 26, and 52 weeks after treatment. When the 
postvoid residual urine volume was below 100 ml and the micturition was 
restored satisfactory, the indwelling catheter was removed. 
Statistical analysis within each group was done with the Wilcoxon's signed rank 
test (alpha=0.005), whereas Student's /-test (alpha=0.05) was used for compa-
rison between the groups. 
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Results 
The average age of the Ultraline group was 65.0 (range, 50-85) years, and that 
for the Urolase group was 64.6 (range, 52-79) years. The average prostate 
volume as measured with TRUS was 45.7 cm3 for the Ultraline group and 49.7 
cm3 for the Urolase group. There was no statistical difference between the two 
groups for any given parameter at baseline (Table 2). 
In all, 89 patients were available at 12 weeks for assessment and 60 were 
évaluable at 26 weeks. No patient was lost to follow-up, one patient was treated 
by TURP, and one patient needed a bladder-neck incision because of a bladder-
Table 2. Baseline characteristics of the patients evaluated in the 
present study 
Age (years) 
IPSS 
Prostatic volume (cm3) 
Qmax (ml/s) 
Voided volume (ml) 
Residual volume (ml) 
PSA (ng/ml) 
Urolase (n = 49) 
mean (Sd) 
646 
21 0 
49 7 
78 
200 
86 
53 
(7 2) 
(51) 
(17 2) 
(3 0) 
(95) 
(76) 
(4 4) 
Ultraline (η = 44) 
mean (Sd) 
65 0 (6 7) 
21 0 (5 9) 
45 7 (14 9) 
7 9 (2 9) 
196 (89) 
86 (79) 
4 9 (3 9) 
Table 3. Main follow-up indices after Urolase and Ultraline treatment 
Ultraline (η) 
Qmax (ml/s) 
IPSS 
PVR (ml) 
Urolase (n) 
Qmax (ml/s) 
IPSS 
PVR (ml) 
0 
44 
7 9 
21 0 
86 
49 
7 8 
210 
86 
Weeks 
12 
42 
193 
7 9 
25 
47 
195 
8 2 
25 
post-treatment 
26 
32 
16 9 
6 0 
11 
28 
163 
5 6 
12 
52 
7 
197 
6 6 
32 
3 
12 7 
1 7 
50 
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neck sclerosis. 
Table 3 shows the subjective and objective changes noted after treatment. For 
the Ultraline group a significant reduction in IPSS symptom score was shown 
from an average of 21.0 to 7.9 after 12 weeks, to 6.0 after 26 weeks, and 6.6 
after 52 weeks. In the Urolase group the reduction in symptoms was similar to 
the Ultraline group, with changes from 21.0 at the onset to 8.2 after 12 weeks; 
to 5.6 after 26 weeks, and to 1.7 after 52 weeks (Fig 1). 
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Fig. 1 Improvement in symptom scores (IPSS) noted for the a Urolase and b 
Ultraline groups 
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Statistical evaluation revealed a statistically significant reduction in symptom 
score parameters for all values. In the Ultraline group the average improvement 
was 11.9 mL/s after 3 months and 9.6 mL/s after 6 months. In the Urolase group 
the average improvement in uroflow was 11.7 mL/s at 3 months and 8.6 mL/s 
at 6 months (Fig 2). A comparison between the Urolase and Ultraline groups 
after 12 and 26 weeks of follow up showed no statistically significant difference 
with regard to symptom score (P< 0.0001) or peak flow (P< 0.0001). 
The same result was found for the postvoid residual urinary volume (Fig 3). 
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Fig. 2 Improvement in maximal uroflow (Qmax) noted for the a Urolase and b 
Ultraline groups. 
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The TRUS images obtained after treatment showed cavities at 26 weeks in both 
the Ultraline and the Urolase groups (Fig 4). No relation was found between the 
prostate volume and the subjective and objective results obtained. As shown in 
Table 2, PSA serum concentrations were normal before treatment. When they 
were measured at 1 day after treatment, there was an elevation in the average 
PSA value from 5.1 (range, < 1.0-17) ng/mL to a mean value of 91 (range, 3.2-
290) ng/mL After 3 months, the PSA level returned to normal (Fig 5). 
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Fig. 3 Improvement in postvoid residual urinary volume (PVR) noted for the a 
Urolase and b Ultraline groups. 
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No complications occurred during the operation. The predominant 
complications encountered in both groups posttherapy were prolonged 
catheterization, urinary tract infections, and (irritative) miction complaints. No 
incontinence occurred. Patients in the Ultraline group needed an indwelling 
catheter for an average of 18.9 days, and those in the Urolase group did so for 
16.9 days (Fig 6). A retrograde ejaculation was mentioned by 50% of the 
sexually active patients, whereas 14% of the patients complained of diminished 
or absent erectile functions. 
Fig. 4 TRUS image obtained after laser treatment in the a sagittal and b 
transverse planes. A nice cavity can be appreciated 
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Fig. 6 Need for suprapubic catheterization inpatients treated with the 
Ultraline (-) and Urolase (....) fibers 
Discussion 
Laser light is a unique form of energy with characteristic and variable tissue ef­
fects. The Nd:YAG laser produces a tissue effect by converting light energy 
into thermal energy. Prostatic tissue heated between 60°C and 100°C will 
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undergo protein denaturation and coagulation necrosis. Coagulation results in 
delayed sloughing of the prostate for a variable period, usually for several 
weeks after the procedure. At temperatures above 100°C, tissue converts into 
vapors of water and hydrocarbons, thus creating immediate cavitation. In 
general, laser energy applied to the prostate is aimed at desobstruction, resulting 
in improvement in objective and subjective parameters. 
The ultimate acceptance of this laser technology relies not only on an 
improvement in treatment-related morbidity but also on results comparable with 
those of TURP. The most common method of performing laser ablation of BPH 
has been the noncontact coagulation technique, which uses low power in the 
noncontact mode to achieve maximal coagulation and minimal evaporation of 
tissue. Overall laser treatment using the Urolase fiber results in an average 
improvement in uroflow of 50%-100% and in a significant decrease in 
symptoms.7'9'12"14 
As a result of this early experience, laser prostatectomy has become popular 
with many urologists because it is associated with morbidity lower than that 
resulting from TURP. Moreover, the public has become more aware of other 
treatment options for BPH, and many men are hesitant to consider the traditio-
nal option of TURP. Men are particularly concerned regarding the risks of blee-
ding, impotence, and a prolonged postoperative recovery period. Laser 
treatment meets most of these requirements. 
Thus far, the results obtained after laser treatment have been excellent and 
approximated those achieved after TURP. The present study shows an increase 
in uroflow from 7.8 ml/s to 19.5 ml/s at 3 months for the Urolase group and an 
increase from 7.9 ml/s to 19.3 ml/s at 3 months for the Ultraline group. The 
subjective improvement, measured with the IPSS questionnaire also showed 
remarkable results. In Fig. 7 the relation between symptom scores and maximal 
uroflow at baseline and at 3 and 6 months of follow up is presented. 
From this figure it seems obvious that an improvement in uroflow is reflected in 
a simultaneous improvement in symptoms. However, a significant difference 
between laser prostatectomy and standard TURP is the lack of immediate effect 
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Fig. 7 Relation between symptom scores (IPSS) and maximal uroflow (Qmax) 
at ai and b 6 months follow-up (L·). Pre-treatment (+) 
for the former. A standard transurethral prostatectomy removes tissue at the 
time of the procedure and patients often experience a significant improvement 
in urinary stream as soon as the indwelling catheter js removed. Although the 
objective and subjective results achieved by laser therapy using the Urolase or 
Ultraline fiber in the present study were good, considerable morbidity was 
noted. 
There appeared to be a prolonged need for catheterization in both groups. The 
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need for prolonged catheterization can be explained by the laser light effect 
itself. When a Nd:YAG laser beam is incident on prostatic tissue at power 
densities sufficient to coagulate the prostate, the gland shrinks to a minor extent 
due to the coagulation effect on protein and to the desiccation of the tissue. The 
prostate becomes rigid. This is followed by a period of cellular infiltration and 
swelling of the tissue. The patients will almost universally have a period of 
retention lasting for an average of 5-20 days. Norris et al.7 decided to leave the 
catheter indwelling for 5-7 days postoperatively, and only 17% of the patients 
required reinsertion of the catheter because of retention. In the present study we 
inserted a suprapubic catheter prior to treatment. Patients treated with the Ultra-
line fiber needed catheterization for an average of 18.9 days, whereas those 
treated with the Urolase fiber had their catheter removed at average on day 16.9. 
This may also explain the discomfort caused, expressed as irritative symptoms. 
Therefore, it was suggested that one should move away from purely coagulative 
techniques, which do not debulk the prostate to any measurable extent, toward a 
more vaporising-oriented approach. This treatment modality causes tissue to 
convert into vapors of water and hydrocarbons, thus creating immediate 
cavitation. Although we expected to create immediate cavitation using the 
Ultraline fiber, this did not occur. The results achieved with the Ultraline fiber 
are comparable with those found after laser treatment with the Urolase fiber. 
Evaporation of tissue is favored by high-power density, and to obtain maximal 
power density it is important to keep the fiber close to (i.e., in contact with) the 
tissue. That we did not use the Ultraline fiber in constant contact with the tissue 
may explain why the extent of evaporation was less than expected. The main 
reason for not working in constant contact was that we assumed a more rapid 
decay of the fibers as a result of contact lasing. Therefore, we think that the 
effect of the Ultraline fiber, at least in our hands, is a result of coagulation and 
vaporisation. 
Narayan et al.8 presented their results they obtained using the Ultraline fiber at a 
higher power setting. The main findings of their study were that in the short 
term transurethral evaporation of the prostate provided symptomatic relief and 
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improvement in uroflow comparable to that of TURP. As pointed out above, we 
could not confirm this observation in using the Ultraline fiber. From our study 
we conclude that a significant reduction in symptom scores and improvement in 
peak uroflow can be reached with this fiber. The present technique did not, as 
we expected, result in an earlier recovery of adequate spontaneous micturition 
and diminution of the symptoms. We think that the side firing fiber, which are 
mainly used in noncontact mode and at relatively low power setting, are 
currently incapable of creating sufficient cavitation. The results presented by 
Narayan et al. suggest that besides being applied in contact, this fiber should be 
used at a higher power setting. The results of contact lasing are also very 
promising. These lasing devices seem to be capable of destructing prostates 
immediately." 
As over 20 different devices are available at the moment, one would expect that 
these would differ in terms of response and outcome. The question as to the 
type of applicator that should be used is fundamental. In favor of a vaporising 
technique is the fact that tissue is vaporised and a cavity is created instantly. To 
our surprise, the results achieved with the fibers used in this study were similar. 
One might think that the general effect of laser light on tissue would be most 
important, not the device or technique used. However, Anson et al.15 showed 
that pure coagulation treatment using the side firing fibers appeared to show a 
higher success rate for the Urolase fiber as compared with the Myriadlase 
system. Another argument that fibers really differ in both their abilities and the 
outcome of treatment is provided by the results achieved with the contact lasing 
devices." 
Besides the outcome of treatment and the morbidity caused, quality of life is 
another item to be addressed. An increasing number of (young) men with 
symptomatic BPH requiring treatment, are concerned about their sexual 
functions. In the present study, retrograde ejaculation was found in 50% of the 
patients who were sexually active, whereas 14% mentioned diminished or 
absent erectile functions. Norris et al.7 reported retrograde ejaculation in 3 of 37 
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sexually active men. According to Childs et al. '\ absolutely no retrograde 
ejaculation was found after laser prostatectomy. Shanberg et al.16 stated that all 
patients who were sexually active prior to therapy maintained their potency and 
described no change in their erections. All but one patient maintained normal 
antegrade ejaculations as well. This discrepancy may have been caused by more 
extensive treatment near the bladder neck. 
Although the results of laser treatment are encouraging, the morbidity is 
considerably high. This is related to the device and technique used, among other 
factors. The optimal Nd:YAG power setting, time for energy delivery, and type 
of applicator used for laser treatment of the prostate have not yet been defined. 
The objective of laser treatment must be to find the technique that will maintain 
a clinically significant outcome, while causing minimal posttreatment 
morbidity. 
Conclusion 
It is important to recognise that the term laser prostatectomy encompasses a 
wide variety of instruments and techniques. The question of appropriate 
technique and dosimetry has remained an enigma for all urologists. Each laser 
fiber has its own advantages and limitations, and no single formula exists for 
the ideal laser treatment. The present study showed no difference in outcome. 
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Laser treatment of the prostate using the IJ rolase 
fiber: the Dutch experience. 
J Urol, 156: 420, 1996 
Abstract 
Purpose Subjective and objective results were assessed after laser 
prostatectomy with the Urolase fiber at 5 different centers in the Netherlands. 
Materials and Methods Patients were evaluated with the international 
prostatic symptom score (I-PSS) questionnaire, uroflowmetry and post-void 
residual volume measurements. Urodynamic investigations with pressure-
flow analysis were performed at 2 centers. 
Results The data for 233 patients were evaluated. Overall significant 
improvement in mean international prostatic symptom score, maximum flow, 
post-void residual volume and urodynamic parameters was noted. Differences 
in outcome among the centers may be due to a variation of technique or 
different selection criteria. Postoperative morbidity was significant, with 
irritative voiding complaints for 4 to 6 weeks in up to 50% of all patients and 
urinary tract infections in 21.1%. 
Conclusion Laser prostatectomy results in subjective and objective 
improvement, which is operator independent. Despite the observation that 
perioperative (intraoperative and immediate postoperative) morbidity seems 
less severe compared to transurethral resection of the prostate, there is a shift 
toward greater postoperative morbidity. 
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Introduction 
Benign prostatic hyperplasia (BPH) has a high prevalence in men older than 
50 years, the majority of whom will eventually have voiding complaints and 
require treatment.1 Transurethral electroresection of the prostate has proved 
to be safe and effective, with excellent long-term results. The mortality rate 
has been decreased from 2,5 % to 0,2 % but morbidity has remained 
unchanged at 18 % within the first 90 days after transurethral resection of the 
prostate2 and probably is even greater after one year. This morbidity rate is a 
main reason to seek less invasive treatment modalities, causing minimal 
morbidity while maintaining the same results as after transurethral resection 
of the prostate. Despite the challenge of numerous alternative operative and 
nonoperative therapies,3"7 transurethral resection of the prostate and open 
prostatectomy remain the gold standards in the treatment of BPH, mainly 
because the clinical outcome of alternative treatments is significantly less 
successful. A promising, recently introduced alternative treatment of BPH 
seems to be laser energy. 
In 1985 Shanberg et al used laser energy in the treatment of BPH.8 With an 
end firing, bare fiber used in contact with tissue, causing vaporisation, the 
main purpose was to make prostatic incisions. The incidence of postoperative 
bleeding was significant and, furthermore, it was difficult to aim the laser 
beam at the prostatic lobes. Development of a side firing device solved this 
problem, and after canine feasibility studies Costello et al performed laser 
prostatectomies in men with a free beam side firing system under cystoscopic 
guidance.9 Me Cullough et al performed transurethral ultrasound guided laser 
ablation of the prostate (TULIP).10 Also, the understanding and acceptance of 
coagulation as a deeper tissue penetrating effect compared to vaporisation 
allowed for development of an efficient and effective neodymium:YAG laser 
procedure. Since then, several different free beam, side firing laser fibers for 
contact or noncontact use have been developed. Besides side firing fiber 
techniques, other laser applications for interstitial or contact vaporisation 
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were developed and are currently under clinical investigation. 
A widely used and investigated laser fiber is the side firing, noncontact 
Urolase fiber. Most studies using this device to treat BPH showed good 
subjective and objective results.""M However, the extent of improvement 
differed in many studies. We investigated the clinical outcome of laser 
prostatectomy at different centers in the Netherlands. Is laser prostatectomy 
operator dependent or can variation in clinical outcome be explained by 
differences in the treatment protocol? 
The only way to demonstrate effectiveness of treatment for BPH is to perform 
urodynamic investigations before and after procedure. There are few studies 
of urodynamic investigations used to demonstrate effectiveness of laser pros-
tatectomy.15'18 We performed urodynamic investigations before and 6 months 
after treatment of BPH with the Urolase side firing laser at 2 university 
centers. 
Material and Methods 
Each participating center included at least 10 patients who underwent laser 
prostatectomy with the Urolase fiber. Guidelines for selecting patients for 
laser prostatectomy were age greater than 50 years, duration of symptoms 
greater than 3 months, international prostatic symptom score (I-PSS) greater 
than 12, maximum flow less than 15 ml. per second and voided volume 
greater than 100ml. Despite these criteria, 2 centers treated all patients who 
normally would undergo a transurethral resection of the prostate. Therefore, 
from these two centers 3 patients with a maximum flow of more than 15 ml. 
per second and 7 patients with an 1-PSS of less than 12 underwent a laser 
prostatectomy. Patients in urinary retention, or those with urethral stricture, 
previous prostatic surgery, diabetes mellitus or neurogenic bladder dysfuncti-
on were excluded from the study. All patients were evaluated with I-PSS and 
sexual function questionnaires, maximum flow and post-void residual volume 
preoperatively, and at 3, 6 and 12 months postoperatively. Physical 
examination (including digital rectal examination), transrectal ultrasound with 
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measurement of prostate volume, laboratory investigations (including prostate 
specific antigen) and urine cultures were performed preoperatively. Urine was 
also cultured 2 and 4 weeks after removal of the catheter or in cases 
suspicious of urinary tract infection. Urine was considered infected when 
culture yielded more than 105 per ml. of a pure organism. All patients with an 
abnormal digital rectal examination and/or elevated prostate specific antigen 
underwent transrectal ultrasound guided biopsies of the prostate. Patients with 
a histologically proven adenocarcinoma were excluded from the study. 
Urodynamic investigations were performed at 2 centers preoperatively and 6 
months postoperatively with an 8 French transurethral lumen catheter and an 
intravesical microtip pressure sensor. Pressure and flow data were recorded 
digitally with commercially available equipment and urodynamic analysis 
software. To quantify grade of obstruction, different parameters were used, 
including detrusor pressure at maximal flow (grading according to the 
Abrams-Griffith nomogram),19 intersection of quadratic urethral resistance 
relation with the pressure axis of pressure flow (urethral resistance relation: 
URA) and linear passive urethral resistance relation: L.PURR (an 
approximation of the resistance relation by a straight line through minimal 
detrusor pressure and detrusor pressure at maximum flow, with grading 
according to the Schäfer nomogram).20 
All patients were treated via the 4-quadrant technique at the 2, 5, 7 and 10 
o'clock position with a power setting of 40 W. for 90 seconds, which has been 
described previously.14 An enlarged middle lobe was treated with 1 or 2 laser 
applications. Each patient was treated with a new fiber. However, at all 
centers slight modifications were introduced, and additional prostatic tissue 
was treated after the 4-quadrant applications. Before laser therapy was begun 
cystourethroscopy was performed and a Ch.16 suprapubic catheter was 
introduced. The suprapubic catheter was removed when the patient could void 
spontaneously with a residual of less than 50 ml.. Patients were discharged 
from the hospital 1 day postoperatively. 
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The Kruskal-Wallis test was used for statistical comparison of results among 
the different centers. The Wilcoxon signed rank test was used for statistical 
comparison between preoperative and postoperative data. 
Results 
Data from 233 patients treated in 5 centers were evaluated. The distribution 
among the different centers, and mean values at baseline for age, prostate 
volume, maximum flow, post-void residual and I-PSS are shown in Table 1. 
Except fore age and prostate volume, all the other baseline characteristics 
were statistically different among the centers according to the Kruskal-Wallis 
test. When baseline characteristics for the 3 centers that used the inclusion 
criteria were examined there was a difference between the maximum flow 
and post-void residual but not for the I-PSS. There was no difference between 
baseline characteristics for the 2 centers that did not follow the inclusion 
criteria completely. Data for 200, 180 and 85 patients were available for 
evaluation at 3, 6 and 12 months. No 12 months data were available from 
center 3. 
Table 1. Baseline characteristics for centers 1 to 5. (range between brackets) 
Center 
1 2 3 4 5 
No. pts 
Age (yrs) 
Prostate 
vol. (ml.) 
IPSS 
Max. flow 
(ml/s) 
Post-void 
residue 
59 
65.0 
(51.2-79.2) 
48.7 
(30-101) 
21.3 
(12-32) 
7.9 
(2.0-14.0) 
86.5 
(0-385) 
53 
66.7 
(55.0-79.3) 
47.2 
(27-100) 
20.0 
(6-30) 
8.7 
(4.0-23.0) 
120.9 
(0-350) 
31 
66.3 
(54.3-78.9) 
45.3 
(28-96) 
22.6 
(18-31) 
5.7 
(4.0-12.0) 
135.8 
(0-250) 
30 
56.0 
(52,5-79.4) 
51.5 
(17-98) 
17.9 
(9-31) 
9.6 
(3.0-21.0) 
99.0 
(0-350) 
60 
68.7 
(54.9-82.8) 
45.4 
(30-96) 
21.8 
(15-31) 
6.1 
(4.0-12.0) 
115.7 
(0-250) 
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Uroflowmetry. 
Overall, there was an average improvement in mean maximum flow rate plus 
or minus standard deviation from 7.5 ± 3.2 ml. per second (range 2.0 to 
23.0) at baseline to 16.4 ± 5.6 (range 4.0 to 45.0) at 3 months, 16.7 ± 5.2 
(range 4.5 to 33.0) at 6 months and 16.3 ± 5.7 (range 5.0 to 33.5) at 12 
months (Table 2). All centers achieved significant improvement in maximum 
Table 2. Mean maximum flow at baseline, and at 12, 26 and 52 weeks 
postoperatively for centers 1 to 5. (* at 26 weeL·) 
Center 
1 
2 
3 
4 
5 
Totals 
OWk. 
233 pts. 
7.9 
(2.0-14.0) 
8.7 
(4.0-23.0) 
5.7 
(4.0-12.0) 
9.6 
(3.0-21.0) 
6.1 
(4.0-12.0) 
7.5 
(2.0-23.0) 
Mean max. flow (ml/s) 
(range) 
12Wks. 
200 pts. 
18.7 
(6.5-45.0) 
16.8 
(6.0-34.0) 
15.0 
(8.0-21.0) 
12.6 
(4.0-26.0) 
15.8 
(8.0-22.0) 
16.4 
(4.0-45.0) 
26 Wks. 
180 pts. 
17.0 
(6.9-32.0) 
15.8 
(5.0-33.0) 
16.7 
(13.0-22.0) 
14.3 
(4.5-30.0) 
17.6 
(10.0-24.0) 
16.7 
(4.5-33.0) 
52 Wks. 
85 pts 
16.8 
(5.0-33.5) 
13.9 
(5.0-26.0) 
16.9 
(12.0-25.0) 
17.1 
(12.0-22.0) 
16.3 
(5.0-33.5) 
ρ Value* 
< 0.0001 
< 0.0001 
0.0022 
0.031 
< 0.0001 
< 0.0001 
flow rate at 6 months. However, there was a difference in the extent of 
improvement per center. Two centers treated 3 patients with a maximum 
flow of more than 15 ml. per second. Exclusion of data for these 3 patients 
from statistical analysis will not change the aforementioned results 
significantly. 
Mean individual improvement at 6 months was 160.4% or 10.4 ± 4.5 ml. 
per second (range -5 to 26.5). Only 11 patients (6%) had no improvement in 
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maximum flow rate at 6 months. 
Post-void residual. 
Overall, there was an average decrease in post-void residual from 110.4 ± 
84.5 ml. (range 0 to 385) at baseline to 31.8 ± 47.5(range 0 to 200) at 3 
months, 30.2 ± 50.5 (range 0 to 300) at 6 months and 21.3 ± 39.0 (range 0 to 
140) at 12 months. All centers achieved a significant decrease in post-void 
residual at 6 months (Table 3). Mean individual decrease in post-void residual 
at 6 months was 61.7% or 83.9 ± 74.3 ml.(range -100 to 345). Only 13 
patients (7%) had no decrease in post-void residual at 6 months. 
Table 3. Mean post-void residue at baseline, and at 12, 26 and 52 weeks 
postoperatively for centers 1 to 5. (* at 26 weeks) 
Center 
1 
2 
3 
4 
5 
Totals 
OWk. 
233 pts. 
86.5 
(0-385) 
120.9 
(0-350) 
135.8 
(0-250) 
99.0 
(0-350) 
115.7 
(0-250) 
110.4 
(0-385) 
Mean Post-Void residue 
(range) 
12Wks. 
199 pts. 
29.8 
(0-200) 
34.0 
(0-200) 
38.7 
(0-150) 
13.9 
(0-150) 
34.2 
(0-170) 
31.8 
(0-200) 
26 Wks. 
180 pts. 
17.4 
(0-200) 
53.0 
(0-200) 
41.7 
(0-100) 
44.0 
(0-150) 
22.5 
(0-150) 
30.2 
(0-300) 
(ml) 
52 Wks. 
85 pts 
19.7 
(0-140) 
17.3 
(0-130) 
15.0 
(0-60) 
26.8 
(0-135) 
21.3 
(0-140) 
ρ Value* 
< 0.0001 
0.0005 
0.0150 
0.0180 
< 0.0001 
< 0.0001 
I-PSS. 
Because not every patient returned the questionnaire during follow-up, at 3, 6 
and 12 months only 191, 178 and 79 patients, respectively, were evaluated. 
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Overall, there was a decrease in symptom score from 21.1 ± 4.8(range 6 to 
32) at baseline to 7.1 ± 5.4(range 0 to 23) at 3 months, 4.8 ± 5.0 (range 0 to 
35) at 6 months and 3.6 ± 3.7(range 0 to 20) at 12 months. Again all centers 
achieved a significant decrease in symptom score (Table 4). Mean individual 
decrease in symptom score at 6 months was 75.5% or 17.1 ± 6.2 (range -9 to 
30). Only 5 patients (3%) had no decrease in symptom score at 6 months. 
Exclusion of data for the 7 patients with an I-PSS of less than 12 for 
statistical analysis will not change the aforementioned results significantly. 
There was no significant difference between the 6 and 12- months results, 
regarding maximum flow, post-void residual and I-PSS for all centers (except 
center 3 because no 12 months data were available). 
Table 4. Mean IPSS at baseline, and at 12, 26 and 52 weeks postoperatively 
for centers 1 to 5. (* at 26 weeks) 
Center 
1 
2 
3 
4 
5 
Totals 
OWk. 
233 pts. 
21.3 
(12-32) 
20.0 
(6-30) 
22.6 
(18-31) 
17.9 
(9-31) 
21.8 
(15-31) 
21.1 
(6-32) 
Mean IPSS 
12Wks. 
191 pts. 
7.9 
(0-23) 
6.7 
(0-23) 
4.8 
(0-18) 
7.4 
(1-19) 
7.2 
(1-22) 
7.1 
(0-23) 
(range) 
26 Wks. 
178 pts. 
6.1 
(0-35) 
5.7 
(0-26) 
2.9 
(0-7) 
4.7 
(0-10) 
3.6 
(0-18) 
4.8 
(0-35) 
52 Wks. 
79 pts 
4.8 
(0-20) 
3.0 
(0-6) 
3.7 
(2-7) 
3.1 
(0-12) 
3.6 
(0-20) 
ρ Value* 
< 0.0001 
< 0.0001 
0.0007 
0.0117 
< 0.0001 
< 0.0001 
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Sexual function questionnaire. 
Sexual function was assessed using a questionnaire preoperatively and 6 
months postoperatively. There were 127 sexually active patients, defined as 
those with a good erection for sexual intercourse and antegrade ejaculation. 
Of these patients 47% had retrograde ejaculation postoperatively and 12.6% 
complained of erectile function that was insufficient for sexual intercourse or 
absent. 
Pressure-flow studies. 
Urodynamic investigations were performed in 98 patients preoperatively and 
6 months postoperative. There was an improvement in mean detrusor 
pressure at maximum flow from 77,8 ± 33.5 cm. water (range 28 to 182) to 
40,4 ± 20.1 (range 15 to 103). Only 6 patients (6.1%) had no decrease in 
detrusor pressure at maximum flow. There was a similar improvement in the 
linear passive urethral resistance relation when using the Schäfer nomogram, 
as well as in urethral resistance relation (Table 5). Only 3 patients (3.1%) had 
Table 5. Urodynamic parameters before and 26 weeks after laser 
prostatectomy. 
Overall 
Center 1 
Center 5 
URA 
L-PURR 
Pdet at Qmax 
URA 
L-PURR 
Pdet at Qmax 
URA 
L-PURR 
Pdet at Qmax 
Mean 
OWk. 
52.2(13-133) 
3.7 (0-6) 
77.8 (28-182) 
51.9(23-133) 
3.6 (1-6) 
76.5(34-150) 
52.7(13-101) 
3.8 (0-6) 
80.4(28-182) 
(range) 
20.7 
1.2 
40.4 
17.7 
0.9 
35.7 
25.4 
1.7 
47.7 
26 Wks. 
(6-70) 
(0-5) 
(15-103) 
(6-41) 
(0-4) 
(15-78) 
(8-70) 
(0-5) 
(15-103) 
ρ Value 
< 0.0001 
< 0.0001 
< 0.0001 
< 0.0001 
< 0.0001 
< 0.0001 
< 0.0001 
< 0.0001 
< 0.0001 
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no decrease in linear passive urethral resistance relation and 6 (6.1%) had no 
decrease in urethral resistance relation. The Abrams Griffith nomogram 
showed a shift from the obstructed to the equivocal and unobstructed areas 
(Fig. 1). 
20 
0 -I 1 ^ 1 1 1 1 1 
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Qmax (ml/s) 
Fig. 1 Changes in detrusor pressure (Pdet) at maximum flow (Qmax) before 
and 6 months after laser prostatectomy using Abrams-Griffiths nomogram for 
centers 1 and 5. 0 baseline. A 26 weeks. 
Morbidity: 
No complications were encountered during laser prostatectomy. Four patients 
(1,7 %) had urinary retention after removal of the suprapubic catheter and 3 
patients (1,3 %) had clot retention. One of the 3 patients required 
cystourethroscopy with general anaesthesia. No bleeding was noted from the 
prostatic urethra but bleeding occurred at the entry of the suprapubic catheter, 
which was controlled with electrocoagulation. No patient with clot retention 
required blood transfusion. During the first 4 to 6 weeks approximately 50 % 
of the patients complained of irritative voiding symptoms, which consisted 
mainly of stranguria, urgency and frequency. Urinary tract infection was 
diagnosed in 21,1 % of the patients. 
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Reoperation: 
Because of minimal or no improvement after laser treatment transurethral 
resection of the prostate was performed in 11 patients (4.7%), a second laser 
treatment in 4 (1.7%) and bladder neck incision in 3 (1.3%). Visual internal 
urethrotomy was necessary in 1 patient (0.4%) because of urethral stricture. 
Patients who required transurethral resection of the prostate or a second laser 
treatment had residual prostatic tissue at cystourethroscopy. 
Discussion 
Since the first publications of side firing laser fibers for treatment of symp-
tomatic BPH by Costello9 and McCullough et al10, reports on laser 
prostatectomy have increased.""14 Although all these studies revealed 
significant subjective and objective results, there seemed to be a difference in 
extent of improvement. Similar differences among centers were documented 
in our study. However, because of different baseline characteristics the results 
of the individual centers are difficult to compare. All participating centers 
achieved a significant improvement in I-PSS and maximum flow but there 
was a difference in extent of improvement among the centers. A reason for 
this observation may be an alteration in the way laser energy was applied 
despite the fact that most patients were treated according to the same 
protocol. Kabalin and Gill described a significant decrease in amount of 
coagulation necrosis when the laser application was interrupted for 
approximately 30 seconds.21 In addition, the distance of the fibertip to the 
prostatic surface is difficult to standardise and may vary, resulting in different 
power densities and amounts of coagulation necrosis achieved. Another 
explanation for differences in results may be variation in the interpretation of 
the uroflowmetry curves. However, in our study all flow curves were 
reviewed by 2 independent investigators. 
To compare the laser procedure to the gold standard transurethral resection of 
the prostate, a few randomised studies were performed that showed no 
statistically significant differences in objective and subjective results between 
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the 2 procedures.22"25 With regard to morbidity, there appeared to be a shift 
from perioperative and immediate postoperative morbidity, such as the 
transurethral resection syndrome, bleeding and the need for blood transfusion 
(which in the literature is greater for transurethral resection of the prostate), to 
postoperative morbidity, such as transient voiding complaints, prolonged 
catheterization and urinary tract infections (which were greater for laser 
prostatectomy). Naturally, we must note that complications after transurethral 
resection of the prostate probably are more severe than those after laser 
prostatectomy. Approximately 50 % of our patients had irritative voiding 
symptoms lasting 4 to 6 weeks after laser prostatectomy and 21.1% had 
urinary tract infection. Irritative voiding complaints can be explained partly 
by the long catheterization period (17 days in our study). On the other hand, 
several patients with a short catheterization period had irritative voiding 
complaints for approximately 4 weeks. A previous study showed the same 
results, but did not demonstrate a relationship between irritative complaints 
and incidence of urinary tract infection.26 However, that study showed a 
relationship between prolonged catheterization and incidence of urinary tract 
infection, which might also explain the significant incidence of urinary tract 
infection in our study. Use of a suprapubic catheter in our study, which was 
removed only when post-void residual was less than 50 ml., could be the 
reason for this prolonged catheterization. Also, the reoperation rate after 1 
year was great in our study, with a transurethral resection of the prostate in 
4,7% of the cases, second laser treatment in 1,7% and bladder neck incision 
in 1,3%. Visual internal urethrotomy was necessary in 1 patient (0,4%). These 
findings are in contrast to other studies by Kabalin," Norris12 and Leach11 et 
al, who reported only a few patients undergoing a second laser treatment, and 
only Norris12 reported 3 patients undergoing a transurethral resection of the 
prostate after initial laser therapy. This fact may be explained by a shorter 
follow up in these studies or a difference in selection criteria. It generally is 
known that European surgeons usually treat patients with more advanced 
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disease, resulting in treatment of larger prostates, and these patients may be at 
increased risk for reoperation following laser prostatectomy. 
However, when analysing the baseline characteristics of patients in whom 
laser prostatectomy failed and who subsequently required a second laser 
treatment or transurethral resection of the prostate, we found no significant 
difference compared to the other patients. Factors, such as differences in 
prostate tissue texture27 or those that influence the power density during the 
laser treatment will explain the differences in clinical outcome. 
Previous reports concerning results of laser prostatectomy described only a 
slight percentage of patients with retrograde ejaculation. In contrast, 
retrograde ejaculation occurred in 47% of our patients who had normal 
ejaculation before laser treatment, probably because in our study we were 
more accustomed to work with lasers and, therefore, applied more energy to 
the prostate, bladdemeck or middle lobe than when one first began laser 
prostatectomy. Furthermore, 12,6% of our patients who reported no erectile 
dysfunction before laser prostatectomy had absent or diminished erectile 
function after treatment. Sexual questionnaires were used to obtain this 
information, and no objective evaluation was performed. Therefore, it is most 
likely that some of these patients already had some degree of erectile 
dysfunction before laser treatment. 
Pressure-flow study analysis is the only method to demonstrate objectively 
relief of bladder outlet obstruction. Since Abrams and Griffith first reported 
urodynamic changes after surgical intervention for BPH," there have been 
few studies on this subject. To date only a limited number of studies have 
been presented using pressure-flow parameters for evaluation of treatment 
outcome after laser therapy. Bosch et al showed a decrease in detrusor 
pressure at maximum flow and urethral resistance relation after laser 
prostatectomy with the TULIP device.18 de Wildt17 and te Slaa16 et al also 
reported significant improvement in urodynamic parameters after laser 
prostatectomy with the TULIP device and 2 different side firing lasers 
(Urolase and Ultraline laser fibers). A randomised study by Kabalin et al 
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showed equal improvement in opening pressure and maximal detrusor 
pressure in both treatment arms.15 In our study pressure-flow analysis was 
performed at centers 1 and 5, and showed overall improvement in urodynamic 
parameters similar to that in the literature.15"18 Because pressure-flow analysis 
results were not inclusion criteria, some patients had no urodynamic 
obstruction preoperatively. There was no statistically significant difference 
between the 2 centers. Therefore, we believe that laser prostatectomy is the 
only documented alternative treatment modality today that can achieve 
urodynamic results comparable to those of transurethral resection of the 
prostate in a large series of patients. 
Conclusion 
Laser prostatectomy results in significant subjective and objective 
improvement, which is operator independent. However, minor differences 
may be noted, possibly due to variation of technique or different selection 
criteria. Despite the observation that perioperative morbidity seems less 
compared to transurethral resection of the prostate, there is a shift toward 
greater postoperative morbidity. Pressure-flow analysis shows that laser 
prostatectomy can relieve bladder outlet obstruction. Future studies should be 
focused on optimising dosimetry and improving laser technologies, resulting 
in minimal morbidity, and probably selecting a subgroup of patients who will 
benefit the most from this treatment modality. 
The urodynamic analysis program was developed at the UIC/BME Research 
Centre, Department of Urology, Nijmegen, The Netherlands. 
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Abstract 
Purpose: A urodynamic study was done to judge the capability of laser 
treatment to relieve bladder outlet obstruction 
Material and Methods: Advanced urodynamic studies with pressure-flow 
analysis were performed before and 6 months after laser treatment using 3 
different laser devices. 
Results: Forty patients showed significant improvement in all obstruction 
parameters (detrusor pressure at maximum flow rate, urethral resistance 
relation, theoretical cross-sectional urethral area, minimal detrusor pressure and 
linear passive urethral resistance relation) together with significant subjective 
improvement in international prostate symptom score. After treatment 82 to 
92% of the patients could no longer be considered to have obstruction. No 
difference in outcome among the devices used was found. 
Conclusions: Laser prostatectomy is indeed capable of relieving bladder outlet 
obstruction. 
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Introduction 
For more than 7 decades prostates have been enucleated surgically and for 
almost 6 decades they have been resected endoscopically. Results have been 
impressive and increasingly better, and the procedures are reasonably safe. In 
the 1980's many alternatives to prostatectomy have surfaced, from a 
pharmacological approach to numerous procedural alternatives, for example 
balloon dilatation, prostatic stents, hyperthermia and thermotherapy. To date, 
none of these alternatives has reached subjective and objective results 
comparable to those noted after enucleation or resection of the prostate. 
Nevertheless, the morbidity of the operations is still greater than that for any of 
these alternatives. 
Recently a new instrumental treatment modality for benign prostatic 
hyperplasia (BPH) became available that is laser treatment of the prostate. The 
advantages of laser treatment are the minimal hospital stay, minimal bleeding, 
no fluid absorption, rapidity of treatment, technical simplicity and chance of 
preservation of antegrade ejaculation.' Although present studies include few 
patients and the follow-up is short, the results after laser treatment are compara-
ble to those achieved after electroresection.2"7 To replace transurethral resection 
of the prostate by laser prostatectomy, the latter procedure should also be able 
to relieve outlet obstruction. In general patients are evaluated preoperatively and 
postoperatively by means of symptom scores, uroflowmetry studies, post-void 
residual volume, and prostate size. These parameters are associated with 
obstructive voiding but not with the grade of obstruction and, therefore, they 
cannot be used to determine objectively whether outlet obstruction is relieved.8" 
10
 To quantify the grade of bladder outlet obstruction, urodynamic investigation 
with pressure-flow analysis is considered the gold standard." We judged the 
obstruction relieving capabilities of laser treatment of the prostate. 
Patients and Methods 
Since November 1992 we treated 125 patients with 3 different laser systems: 
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the Intra Sonix TULIP device, the Bard Urolase fiber and the Heraeus Ultraline 
fiber. All patients underwent a screening program consisting of physical 
examination (including digital rectal examination), biochemistry (including 
prostate specific antigen [PSA]), and urine culture and sedimentation rate. 
Transrectal ultrasound of the prostate was performed with planimetrie 
measurement of the prostate volume. Furthermore, renal ultrasound was done 
to exclude hydronephrosis. All patients underwent a urethrocystoscopy to 
measure the prostate length, and to assess the size of the middle and lateral 
lobes. In case of a suspicious digital rectal examination, transrectal ultrasound 
or an elevated PSA level (greater than 10 ng./ml. or a PSA-density of more 
than 0.15), prostate biopsies were obtained to exclude malignancy. To evaluate 
the subjective parameters before and after the operation all patients had to 
complete an international prostate symptom score questionnaire and the 
symptom score had to be at least 12. Objective parameters were evaluated by a 
free urinary flow rate using a Dantec Urodyn 1000 uroflowmeter. The voided 
volume had to be at least 150 ml.. The post-void residual volume, measured by 
transabdominal ultrasonography, had to be less than 350 ml. If patients fit 
these criteria, they were eligible for laser treatment. 
Urodynamic investigations were performed with an 8F transurethral lumen 
catheter with an intravesical micro-tip pressure sensor. Abdominal pressure was 
recorded intrarectally with an 8F micro-tip sensor catheter. Before cystometry 
the bladder was emptied through the lumen of the transurethral catheter and 
then filled with sterile saline at body temperature and a filling speed of 50 ml. 
per minute with the patient in the supine position. During the entire recording 
the substraction of vesical and abdominal pressure was examined every minute 
by asking the patient to cough during the filling phase. When standing up to 
void and when lying down after voiding, substraction was again examined by 
coughing to ensure the catheters were not dislocated. The pressure and flow 
data were recorded with commercially available equipment. The digitally stored 
data were translated to a urodynamic analysis computer program, developed at 
our department. Precise fitting of the automatically computed curves, with 
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correction for pressure or flow artefacts, was done by hand. Patients with 
detrusor failure or urinary retention were excluded from this study. 
Different parameters were used to document obstruction, including the detrusor 
pressure at maximum flow rate (grading according to the Abrams-Griffiths 
nomogram), intersection of quadratic urethral resistance relation with the 
pressure axis of pressure flow ( urethral resistance relation ), ' parameters 
calculated from the passive urethral resistance relation12"14 (minimal detrusor 
pressure with ongoing flow and theoretical cross-sectional area of the urethra) 
and linear passive urethral resistance relation (an approximation of the 
resistance relation by means of a straight line through minimal detrusor pressure 
and detrusor pressure at maximum flow rate with grading according to the 
Schäfer nomogram).14 The majority of patients studied were classified as having 
urodynamic obstruction depending of the urodynamic parameter used. 
Before laser treatment, a suprapubic catheter was inserted for continuous flow 
through the endoscopic instruments. The day after laser treatment the patients 
were discharged from the hospital with the suprapubic catheter in situ. At the 
outpatient clinic the catheter was removed when voiding was satisfactory 
without a significant post-void residual volume. At 4, 12 and 26 weeks the 
patients were evaluated with blood studies and urinalysis, uroflowmetry, and 
international prostate symptom score, quality of life and sexual function 
questionnaires. At week 26 the urodynamic investigation, transrectal ultrasound 
of the prostate and cystoscopy were repeated.. The Wilcoxon signed-rank test 
was used for statistical comparison of the preoperative and postoperative data. 
Results 
To date 40 of the 125 patients treated were évaluable for urodynamic analysis 6 
months after laser prostatectomy. Mean patient age in this group was 63.8 years 
(range 51 to 76). Mean values at baseline for patient age, prostatic size, peak 
urinary flow rates, post-void residual volume, and international prostate 
symptom scores for the complete group are shown in Table 1. 
The changes in the parameters used are shown in Table 2. All patients had an 
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improvement in symptom scores. A mean international prostate symptom score 
at baseline of 21.7± 6.7 (range 12 to 35) improved to 6.3 ± 4.6 with an 
individual improvement of 15.4 ±8.1 at 6 months. Mean peak urinary flow rate 
improved from 8.0 ±3.1 ml. per second (range 2.0 to 14.0) preoperatively to 
Table 1. Baseline characteristics of 40 patients 
Age (y s.) 
Prostate vol. (cm3) 
Symptom score 
Maximum flow rate (ml/s) 
Post-void residue (ml) 
Mean 
63.8 ± 
46.9 ± 
21.7 ± 
8.0 + 
89.2 ± 
±Sd 
6.4 
15.9 
6.6 
3.1 
102.5 
(range) 
(51 - 76) 
(24- 38) 
(12- 35) 
( 2 - 14) 
( 0-350) 
17.1 ± 5.9 ml. per second (range 3.9 to 30) at 6 months. The mean individual 
improvement in peak urinary flow rate was 9.0 ± 6.2 ml. per second (range -3.1 
to 20.0). The post-void residual volume decreased from a mean 89.2 ± 102.3 
ml. (range 0 to 350) at baseline to 18.2 ± 38.4 ml. (range 0 to 190) with a mean 
improvement of 71.0 ± 102.3 ml.(range -135 to 350) at 6 months. All of these 
parameters demonstrated a statistically significant improvement (pO.0001). 
Table 2 also shows the improvements in mean values of the urodynamic 
parameters from the pressure-flow analysis at baseline and at 6 months, all of 
which were statistically significant (pO.0001). 
For each different fiber the changes in the parameters are shown in Table 3. No 
major differences in these parameters among the 3 different fibers were noted. 
For the Ultraline and Urolase fibers a statistical improvement was noted in all 
parameters. Although an absolute improvement was noted in all parameters, for 
the TULIP device there was no statistical improvement in post-void residual 
volume, detrusor pressure at maximum flow rate and minimal detrusor pressure. 
The few patients in the TULIP group (7) should be considered. 
Depending on what obstruction parameter was used, the incidence of 
preoperative urodynamic obstruction ranged from 65 to 90%. Postoperatively 
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Table 2. Urodynamic changes and symptom score improvement before and 6 
months after laser prostatectomy in 40 patients. (IPSS= symptomscore; PVR= 
post void residue; Min Pdet.= minimum detrusor pressure; URA= urethral 
resistance relation; A theo=Theoretical cross-sectional urethral area;L-
PURR= linear passive urethral resistance relation) 
IPSS 
PVR (ml) 
Max. flow (ml/s) 
Pdet at max. flow 
U RA 
Min. Pdet 
A
 theo (mm2) 
L-PURR 
Before 
21 7 ± 6 7 
89 2 ±102 5 
B0± 31 
76 7 ± 34 3 
48 5 + 22 4 
41 3 ± 23 9 
2 3 ± 1 1 
3 6 ± 1 3 
Mean ± Sd 
After 
6 3 ± 4 6 
18 2 ±38 4 
17 1 ± 5 9 
39 3 ±15 6 
187± 8 6 
1 7 3 ± 1 0 0 
7 5 ± 4 1 
1 0 ± 1 0 
Individual 
improvement 
154± 8 1 
71 0 ± 1 0 2 3 
9 0 ± 6 3 
37 4 ± 29 8 
29 8 + 22 6 
25 4 ± 231 
5 2 ± 4 1 
2 6 ± 1 3 
Ρ 
Value 
0 0001 
0 0001 
0 0001 
0 0001 
0 0001 
0 0001 
0 0001 
0 0001 
Table. 3 Mean improvement (plus or minus standard deviation) in different 
parameters for each different fiber at baseline and at 6-month follow-up 
IPSS 
Max. flow 
(ml/s) 
PVR (ml) 
Pdet at 
max. flow 
U RA 
Min. Pdet 
A t h e o 
(mm2) 
L-PURR 
Tulip (7 pts.) 
Before 
216±80 
8 4 ± 2 2 
68 ±70 
81 ±48 
53 ±35 
46 ±38 
2 3 ± 1 3 
3 7 ± 1 1 
After 
7 6 ± 5 2 
8 4 ± 5 4 
22 ± 40* 
46±11* 
21 ±8 
20 ±8* 
6 9 ± 3 7 
13 + 08 
Urolase (19 pts.) 
Before 
22 4± 6 0 
8 1 ± 3 3 
80 ±107 
72 ±31 
46 ±22 
40 ±20 
2 4 ± 1 0 
3 5 ± 1 4 
After 
6 0 ± 1 9 
163±44 
22 ±49 
40 ±19 
19± 9 
19± 10 
7 3 ± 3 8 
1 1 ± 1 2 
Ultraline 
Before 
20 8 ± 7 3 
7 6 ± 3 3 
111 ±111 
81 ±32 
50±16 
41 ±19 
2 1 ± 1 1 
3 8 ± 1 4 
(14 pts.) 
After 
6 1 ± 4 0 
175±78 
12±18 
36±12 
17± 8 
14±10 
8 1 ± 5 0 
0 7 ± 0 9 
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Table 4. Different criteria for grade of obstruction and percentage of patients 
matching these obstruction criteria before and 6 months after laser 
prostatectomy in complete group of '40 patients. 
Obstruction 
No. (%) 
Before After 
L-PURR : 
> 3 
3 
< 3 
URA > 29 cm H2O 
Min . Pdet > 29 cm 
A t h e o < 3.0 mm 2 
Pdet at max. flow: 
Obstructed 
Equivocal 
Unobstructed 
H 2 0 
20 (50) 
12 (30) 
8 (20) 
36 (90) 
26 (65) 
33 (83) 
32 (80) 
8 (20) 
0 (0) 
0 (0) 
3 (8) 
37 (92) 
4 (10) 
7 (18) 
4 (10) 
4 (10) 
20 (50) 
16 (40) 
200 
baseline 
Qmax (ml/s) 
Δ β months 
Fig. 1 Changes in detrusor presure (Pdet) at maximum flow rate (Qmax) before 
and 6 months after laser prostatectomy using Abrams-Griffiths nomogram" for 
obstruction in all 40 patients 
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8 to 18% of the patients still can be considered as having obstruction (Table 
4).Fig. 1 shows the preoperative and postoperative values for detrusor pressure 
at maximum flow rate in all patients using the nomogram of obstruction 
reported by Abrams and Griffiths." Fig. 2 gives a visual representation of the 
used urodynamic parameters in a pressure-flow plot before and after laser 
treatment. 
Pressure Flow + URA 
150 
(cmH,0) 
0 
Pressure Flow + URA 
) £ ^ 
flow(ml/s) 20 flow (ml/s) 20 
β Pressure Flow + PURR 
150 
Pressure Flow + PURR 
flow (ml/s) flow (ml/s) 
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Pressure Flow+ L-PURR Pressure Flow + L-PURR 
0 flow(ml/j) 20 0 flow (ml/s) 20 
Fig. 2 Pressure-flow analysis before and б months after laser treatment. A, with 
urethral resistance relation (URA) curve. B, with passive urethral resistance 
relation (PURR) curve. C, with linear passive urethral resistance relation (L-
PURR) curve and nomogram. Pdet, detrusor pressure. 
Discussion 
In view of all the new available treatment options, guidelines to standardise the 
assessment of BPH therapies are being developed, including among other things 
uroflowmetry (voided volume, maximum flow rate and post-void residual 
volume), blood studies and urinalysis (including PSA), prostate size and weight, 
international symptom score assessment, cystometry with simultaneous 
assessment of intravesical and intra-abdominal pressure for determination of 
detrusor pressure and pressure-flow studies.15'16 To achieve results similar to 
those of transurethral resection of the prostate new treatment modalities should 
have the ability to relieve outlet obstruction. To document changes in the grade 
of obstruction a considerable number of parameters have been suggested. 
Although symptom scores, uroflowmetry studies, post-void residual volume 
and prostate size are associated with outlet obstruction, there appears to be no 
clear correlation with the grade of outlet obstruction. Simultaneous 
measurements of intravesical pressure and flow rate during voiding enable one 
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to distinguish objectively between obstruction or no obstruction. Consequently, 
advanced urodynamics (including pressure-flow analysis) are considered the 
best methods to document (changes in) the grade of bladder outlet obstruction. 
Since Abrams and Griffiths in 1979 first reported urodynamic changes after 
surgical intervention for BPH," there have been few other studies about this 
subject.17"21 Studies concerning the evaluation of urodynamic changes in 
alternative BPH treatments are even more rare.22"25 Available data suggest that 
urodynamic changes, if any, are minimal. None of these studies has shown 
urodynamic changes similar to those after transurethral resection of the prostate. 
To date, to our knowledge only 2 studies have been presented using pressure-
flow parameters for evaluation of treatment outcome after laser therapy. The 
study of Bosch and Groen showed a decrease in detrusor pressure at maximum 
flow rate and urethral resistance relation after laser therapy of the prostate 
using the TULIP device.26 Detrusor pressure at maximum flow rate improved 
from 76 cm. water (range 26 to 200) at baseline to 39 cm. water (range 18 to 58) 
at 3 months and urethral resistance relation decreased from 42 (range 22 to 78) 
to 22 (range 11 to 35). In our study detrusor pressure at maximum flow rate 
changed from 76 cm. water (range 38 to 184) at baseline to 39 cm. water (range 
15 to 74), and the urethral resistance relation improved from 49 (range 23 to 
130) to 19 (range 7 to 40) at 6 months. We agree with the conclusion that 
TULIP laser treatment of the prostate is urodynamically effective for BPH. A 
randomised laser versus transurethral resection of the prostate study by Gill and 
Kabalin showed an equal improvement in opening pressure and maximal 
detrusor pressure in both treatment arms.28 They concluded that symptom scores 
and objective urodynamic parameters demonstrate laser prostatectomy to be 
effective treatment of bladder outflow obstruction secondary to BPH. Our 
results confirmed this conclusion. 
No consensus has been reached to date on which parameters describe best the 
grade of obstruction. We evaluated the currently most used parameters for 
IT 1A 1TTII ^_ 
analysis. " ' Border values used to determine obstruction or no obstruction 
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were linear passive urethral resistance relation of 3 or more, urethral resistance 
relation greater than 29 cm. water, minimal detrusor pressure greater than 29 
cm. water, theoretical cross-sectional urethral area less than 3.0 mm" and 
detrusor pressure at maximum flow rate in the obstructive area on an Abrams-
Griffiths nomogram. All of these parameters demonstrated a statistical 
significant improvement after laser treatment (Table 3). Individually, few 
patients had less pronounced improvement (Figs. 3 to 7). Patients who were 
treated during our learning curve (and might do worse) were also included in 
this study. 
The majority of our patients, based on different urodynamic parameters, can be 
considered to have obstruction. It appears that laser treatment is capable of 
relieving urodynamically verified outlet obstruction. Although symptoms 
improved in all patients, there was no clear correlation between the extent of 
obstruction relieved and improvement of symptoms (Figs. 3 to 7), which 
underlines again the discrepancy between objective and subjective parameters. 
It is also known that patients with poor urine flow due to weak detrusor 
contraction, are those who respond worse to prostatectomy.1719'20 Our study 
shows that patients considered not to have obstruction also improved well, 
depending on which parameter was used to determine obstruction. Although the 
changes among these patients are less pronounced, which is to be expected 
because they have less to gain, the symptomatic improvement is considerable 
(Figs. 3 to 7). Regarding laser treatment for BPH, studies in patients with less 
obstruction are mandatory to determine if laser is also capable of achieving 
substantial subjective and objective improvement. On the other hand, in 
symptomatic patients with less obstruction other minimal invasive therapies for 
example medical treatment or transurethral microwave therapy, should be 
considered. 
Comparing our study to the data in the literature on urodynamic changes after 
transurethral resection of the prostate, a similar improvement in urethral 
resistance relation is noted.17 The changes in detrusor pressure at maximum 
flow rate and in the curves of the pressure-flow plot after laser prostatectomy 
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Fig. 3 Correlation between improvement in symptom score (IPSS) and 
improvement in urethral resistance relation (URA, intersection of quadratic 
urethral resistance relation with pressure axis in pressure-flow plot in cm. 
water) for all 40 patients after laser treatment. A , patients who at baseline 
could not be considered to have obstruction. 
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Fig. 4 Correlation between improvement in symptom score (IPSS) and 
improvement in minimal detrusor pressure with ongoing flow in cm. water 
(Pvoidmin) for all 40 patients after laser treatment. A , patients who at 
baseline could not be considered to have obstruction 
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) area of urethra in mm? for 
all 40 patients after laser treatment. A , patients who at baseline could not be 
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Fig. 6 Correlation between improvement in symptom score (IPSS) and 
improvement in detrusor pressure (Pdet) at maximum flow rate (Qmax) in cm. 
water for all 40 patients after laser treatment. A. , patients who at baseline 
could not be considered to have obstruction 
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Fig. 7 Correlation between improvement in symptom score (IPSS) and 
improvement in linear passive urethral resistance relation (L-PURR, 
approximation of resistance relation by means of straight line through minimal 
detrusor pressure and detrusor pressure at maximum flow rate) for all 40 
patients after laser treatment. A , patients who at baseline could not be 
considered to have obstruction. 
(Figs. I and 2) are similar to changes after transurethral resection of the 
prostate.11,20 
A considerable number of studies concerning laser treatment have been 
published, and many different fibers and energy settings have been used. To 
date no major differences in outcome have been reported using these different 
fibers. The general results are the same and are comparable with results after 
transurethral resection of the prostate.2"7 In our study 3 different types of fibers 
were used. Although not randomised and with few patients in each group, no 
differences in the extent of obstruction relieved among these 3 fibers could be 
found (Table 3). Laser energy seems to be capable of relieving outlet 
obstruction. The method of applying the energy appears to be secondary, and 
the treatment success depends largely on the preference and skills of the 
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surgeon in using the various techniques. The different morbidity rates caused by 
the various fibers and techniques should also be considered. The long-term 
results may be different for each fiber or technique used and related to the 
ability to create cavities. 
Transurethral resection of the prostate still remains the gold standard in 
treatment of BPH to which all other new treatment modalities should be 
compared. The objective of surgical treatment for prostatic obstruction must be 
to relieve obstruction safely and effectively no matter what procedure or 
technique is used. The reasons for considering transurethral resection of the 
prostate as the most effective therapy are the excellent objective and subjective 
results reached and sustained for a long period. To date none of the alternative 
treatments has accomplished similar or even better results. With regard to laser 
prostatectomy, improvements in symptoms and uroflowmetry are impressive, 
and to a great extent comparable to the results reached after transurethral 
resection of the prostate.2"5 However, long-term effects are not yet available and 
only speculations can be made about the final effect in the future.29'30 A 
possibility to predict a long lasting effect might be the presence of a cavity on 
urethrocystoscopy or transrectal ultrasound of the prostate as a result of laser 
therapy. Moreover, the changes in obstructive voiding to nonobstructive 
voiding measured in a pressure-flow analysis can contribute to a more accurate 
prediction. 
We are aware that controversy still exists about whether or not to perform a 
complete urodynamic evaluation routinely in patients with BPH, and about the 
clinical relevance of precisely grading the obstruction. We believe that to date 
urodynamic investigations with pressure-flow analysis should first be 
considered as an essential research tool to evaluate best the outcome of 
alternative treatments for BPH. Moreover, we must determine the role of 
routine urodynamic investigations in the assessment of BPH in daily urological 
practice. More studies with different treatment modalities are needed to 
conclude if pressure-flow analysis can be used not only to demonstrate the type 
and grade of obstruction but also to select patients for different (alternative) 
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treatment options. Interestingly, Tubaro et al showed that the treatment outcome 
of transurethral microwave thermotherapy could be predicted from pressure-
flow analysis, making patient selection possible.31 Finally, to solve the question 
of which fiber or technique used is superior in providing long lasting relief of 
obstruction, randomised studies with obligatory urodynamic and pressure-flow 
analysis evaluation of treatment outcome are necessary. 
Conclusion 
Urodynamic evaluation with pressure-flow analysis of treatment outcome after 
laser prostatectomy shows that laser is capable of relieving outflow obstruction 
comparable to results obtained with transurethral resection of the prostate. 
No apparent difference in the ability to relieve obstruction was shown for the 
different fibers and techniques. To evaluate the ability to provide long lasting 
relief of obstruction for each different fiber, randomised studies with 
urodynamic evaluation and pressure-flow analyses are mandatory. 
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Benign Prostatic Enlargement. 
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Summary 
Objective: To determine if outlet obstruction can be adequately relieved after 
laser prostatectomy. 
Patients and Methods: Since November 1992, a total of 105 patients 
underwent laser treatment of the prostate because of complaints related to 
benign prostatic enlargement (ΒΡΕ). To date, urodynamic data from a study of 
pressure flow analysis are available for 79 patients both at baseline and at 6 
months after treatment. Patients were evaluated using changes in symptoms 
(IPSS symptom score), peak flow (Qmax), post-voiding residual volume 
(PVR), detrusor pressure at maximum flow (Pdet at Qmax), and the linear 
passive urethral resistance relation (LPURR). Moreover, patients with minimal 
bladder outlet obstruction were compared to patients with severe bladder outlet 
obstruction. 
Results There was a significant improvement in mean IPSS score from 21.3 at 
baseline to 5.3 at 6 month follow-up. The Qmax improved from 7.9 ml/s to 17.8 
ml/s, and the PVR decreased from 91.6 ml to 15.6 ml. At baseline, >80% of the 
patients were considered obstructed according to analysis of pressure flow, 
whereas 6 months after laser treatment, only 5% of the patients were still 
considered obstructed. A comparison of outcome between minimally obstructed 
patients and severely obstructed patients showed comparable improvements. 
Conclusion Laser therapy of the prostate was, according to urodynamic 
parameters, capable of relieving outlet obstruction and minimally obstructed 
patients also showed a significant relief of outlet obstruction. 
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Introduction 
Benign prostatic enlargement (ΒΡΕ) impacts significantly on the quality of life 
of the ageing man, primarily by producing bothersome urinary symptoms. The 
symptoms of ΒΡΕ are caused by a complex interaction between the prostate and 
bladder which gives rise to both filling and voiding symptoms.' As the prostate 
enlarges, urethral resistance may increase and consequently the ability of the 
bladder to generate pressure increases to maintain flow. An impaired bladder 
function may also present with symptoms similar to ΒΡΕ. Presently, the deci­
sion to treat rather than observe a given patient is based largely on the extent to 
which his symptoms interfere with daily activities. 
Open or transurethral prostatectomy (TURP) has been the "gold standard" for 
many years for the treatment of ΒΡΕ. In the last decade, new surgical and non­
surgical alternatives have become available to the urologist, including drugs, 
prostatic stents, balloon dilatation, high intensity focused ultrasound (HIFU), 
transurethral needle ablation (TUNA) and thermotherapy (TUMT).2"8 Until 
now, none of these alternatives has attained the subjective and objective results 
comparable to those obtained after surgical treatment of the prostate. 
Recently, laser treatment of the prostate became available for ΒΡΕ, the 
advantages of which are a minimal hospital stay, minimal bleeding, no fluid 
absorption, rapidity of treatment, technical simplicity of performance and the 
chance to preserve antegrade ejaculation.9"12 Although current studies have 
evaluated few patients over short follow-up periods, the results after laser 
treatment are comparable with those achieved after electroresection. 
The objective success of treatment is usually defined by an improvement in 
uroflowmetry variables such as urinary peak flow rate (Qmax) and residual 
urine volume (PVR). In recent years, urodynamic investigation with pressure-
flow analysis(PQ) has also played an increasingly important role in measuring 
objectively the results of different therapies.13 
To replace TURP by laser prostatectomy, the latter should also be able to 
relieve outlet obstruction. Although symptom scores, uroflowmetry studies, 
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PVR and prostate size are associated with obstructive voiding, there is no clear 
correlation with the grade of obstruction. Therefore, these parameters cannot 
determine objectively whether relief of obstruction is achieved.14"'6 To quantify 
the grade of bladder outlet obstruction, urodynamic investigation is considered 
the "gold standard".'7 
Patients and Methods 
Laser treatment of the patients was performed with the Urolase (Bard) or 
Ultraline (Heraeus) side-firing fibers, and the technique used has been described 
more extensively elsewhere.18 All patients underwent a screening programme 
comprising a history (including the IPSS symptom score), a physical 
examination (including digital rectal examination), biochemistry (including 
prostate specific antigen), urine culture and sediment, and transrectal and renal 
ultrasonography. Objective voiding parameters were evaluated by estimating 
free urinary flow rate, PVR and urodynamic investigations with PQ analysis. 
The inclusion and exclusion criteria are listed in Table 1. 
Table 1. Inclusion and exclusion criteria for laser treatment 
Inclusion criteria Exclusion criteria 
Prostate volume > 30 cm3 Prostatic carcinoma 
Age > 50 years Bacterial prostatitis 
Duration of symptoms > 3 Urethral stricture 
months 
IPSS >12 Neurogenic bladder dysfunction 
Peak uroflow < 15ml/s Urinary tract infection 
Use of drugs influencing bladder 
function 
History of TURP or TULIP 
Diabetes mellitus 
Bladder residual urine > 350 ml 
120 
The urodynamic investigations were performed with an 8F transurethral lumen 
catheter with an intravesical microtip pressure sensor (MTC, Drager, Germany). 
The pressure and flow data were recorded digitally with commercially available 
equipment (UD2000, MMS, Enschede, The Netherlands) and transferred to a 
urodynamic analysis program, developed at the UIC/BME Research Centre, 
Department of Urology, Nijmegen, The Netherlands. To obtain useful 
information from pressure flow curves, the detrusor pressure must be related to 
the corresponding flow (Figs 1 and 2) and these plots were evaluated by a visual 
inspection of the shape of these curves. In cases of high pressure and low flow, 
the patient was considered obstructed (Fig 2a). When there was a low pressure 
with a high flow, the patient was considered unobstructed (Fig 2b). However, to 
cmH20 о 
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~п?% 
Fig. 1 Urodynamic registration (Pves, vesical pressure; Pabd, intra-abdominal 
pressure; Pdet. detrusor pressure; flow, uroflowmetry) with magnification of 
the voiding phase: a, initiation of voiding with corresponding detrusor 
pressure; b, maximum uroflow with corresponding detrusor pressure; c, end of 
voiding with corresponding detrusor pressure. 
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Fig. 2 Pressure-flow relation (in the patient of Fig. 1) before (a) and after (b) 
treatment. (Pdet, detrusor pressure; flow, uroflowmetry); a, initiation of 
voiding; b, maximum uroflow; c, end of voiding. 
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Fig. 3 Maximal pressure at maximal flow (Pdet at Qmax) at baseline (black) 
and 6 months (white) after laser treatment presented in the Abrams-Griffiths 
nomogram. 
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quantify the grade of obstruction, classification is mandatory and the simplest 
way is to superimpose the plot on the Abrams-Griffiths nomogram.17 The point 
of Pdet at Qmax of this plot may fall in one of the three zones: obstructed, 
unobstructed or equivocal (Fig 3). 
More advanced methods allows obstruction to be further subdivided.13'19 
Schäfer presented the concept of linear passive urethral resistance relation 
(LPURR), connecting minimal opening pressure with pressure at maximum 
flow. Derived from this, for daily clinical practice, an obstruction classification 
was introduced (Fig 4).13 Precise fitting of the PQ curves, with a correction for 
pressure or flow artefacts, was performed manually. The urodynamic inves-
tigation was repeated 26 weeks after treatment. 
о 20 о 20 
Flow (mL/s) 
Fig. 4 Pressure-flow relation (in the patient of Fig. 1) before (a) and after (b) 
treatment. (Pdet, detrusor pressure; flow, uroflowmetry) and the LPURR 
curve: 0-11, unobstructed; III/IV, moderately obstructed; V/VI, severely 
obstructed. 
Since November 1992 , 105 patients (mean age 64 years, range 51-80) were 
treated because of complaints related to ΒΡΕ using laser delivered by a side-
firing fiber. Urodynamic data for 79 patients were available for analysis, the 
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missing 26 patients having either refused a second urodynamic investigation, or 
had not yet been evaluated at the 6 month follow up, or were impossible to 
catheterise (three patients). 
Results 
The mean IPSS symptom score improved from a 21.3 (± 5.7) at baseline to 5.3 
(±4.0) 6 months after laser treatment, with a mean individual improvement of 
16.0 (±7.0; range 0 to 30). There was an increase in mean Qmax from 7.9 ml/s 
(±3.0) before treatment to 17.8 (±6.2) after treatment, with a mean individual 
improvement of 9.9 ml/s (±6.6: range -3.1 to 28.1 ). The mean PVR changed 
accordingly from 91.6 ml (±88.8) to 15.6 ml (±36.6) 6 months after laser 
prostatectomy with, a mean individual improvement of 76.1 ml (±86.3 : range -
135 to 350). These data indicate that overall there was a change from a 
urodynamicaly obstructed flow before treatment to a urodynamically 
unobstructed flow after laser treatment. Indeed the changes in urodynamic 
parameters of the PQ analysis also show a significant improvement (Table 2). 
Using Abrams-Griffiths nomogram of obstruction, the baseline P^etat Qmax of 
66 patients (84%) was considered obstructed, whereas 13 patients (16%) fell 
into the equivocal zone. After treatment, only five patients (6%) were still 
considered obstructed, 37 patients (47%) fell into the equivocal zone and 37 
Table 2. Changes in urodynamic parameters of the PQ analysis of 79 patients 
Obstruction parameter 
Pdet at Qmax 
Obstructed 
Equivocal 
Unobstructed 
LPURR 
>3 
= 3 
<3 
Before 
Number 
66 
13 
0 
46 
19 
14 
% 
84 
16 
0 
58 
24 
18 
After 
Number 
5 
37 
37 
1 
3 
75 
% 
6 
47 
47 
1 
4 
95 
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patients (47%) were considered unobstructed (Fig 3). There was a similar 
improvement in the LPURR parameter, where at baseline, 65 patients (82%) 
were considered obstructed (LPURR > 3) and 14 patients (18%) did not meet 
the criteria for urodynamic obstruction. After laser treatment only four patients 
(5%) were considered obstructed, but the majority of patients (95%) were no 
longer obstructed (Fig 5). Although a few patients were still obstructed after 
treatment, all patients showed a decrease in bladder outlet obstruction variables. 
Analysis of the two side-fire fibers showed no statistical difference in subjective 
and objective parameters at baseline or at 6 month follow up. 
35 
30 
25 
Г. 20 
S 15 
10 
L-PURR 
Fig. 5 Values of LPURR before (black) and after (white) laser treatment versus 
the number of patients in each group. 
Discussion 
Before acceptance, the efficacy of alternative therapies for the treatment of ΒΡΕ 
has to be proven and be comparable to the "gold standard" of TURP. 
Furthermore, the most effective therapy must be selected for each individual 
patient. Most alternative therapies show urodynamic changes which are smaller 
than those after TURP. 20,21 Moreover, some treatments appear not to change 
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outlet obstruction, but to change the pressure-flow relationship in a different 
way.22 For these reasons, the disease in each patient must be classified 
objectively. The only method to evaluate voiding disturbance objectively is by 
the urodynamic registration of pressure and flow during voiding and its analysis 
according to well-defined algorithms.23·2'1 Various methods have been proposed 
for the clinical application of the PQ analysis.13·24'25 In cases of bladder outlet 
obstruction, elevated detrusor pressures may be achieved by compensatory hy-
perthrophy of the smooth muscle within the bladder wall. Although this adapti­
ve mechanism maintains relatively normal flow during the initial phases of the 
disease, the detrusor smooth muscle does not function entirely normally. As 
prostatic growth continues to increase urethral resistance, or as the bladder 
becomes less able to compensate, urinary flow decreases and bladder emptying 
is impaired. Moreover, many of the symptoms of ΒΡΕ may be aggravated by 
age-related abnormalities in bladder structure and function, which occur 
independently of outlet obstruction.25 Ageing of the bladder wall has been 
studied little, but probably contributes to the symptom complex commonly 
associated with prostatic enlargement. Lepor and Machi have shown that age-
matched women have voiding symptoms of a similar nature and severity to 
their male counterparts.26 
Analysis of the present data shows that in most patients laser prostatectomy was 
capable of producing impressive and significant objective and subjective 
improvements, not only in commonly used variables like symptom scores and 
free-flow indices, but also in variables derived from PQ analysis in the 
advanced urodynamic investigation.27 The results are largely comparable to 
those seen after TURP.28'29 Literature on the changes in pressure-flow variables 
after TURP are sparse. However, when compared to the available data, the 
changes after laser prostatectomy were very similar.27,30·31 
Laser treatment also has its individual treatment failures. Although all patients 
showed an improvement in symptom scores, in a few patients there was a 
decrease in Qmax or increase in PVR. Cystoscopy in these patients showed a 
126 
1 2 3 4 5 6 7 β 9 10 11 12 13 14 
350 
300 
250 ' 
100 
50 
0 _ L 1 _ L CLL J ^ 1 ι 
350 
300 
250 
•JJ200 
1С 
¡>150 
100 
50 
1 2 3 4 5 6 
f 
1. 1, 
7 8 9 10111213141516171819 
J 1. 
il 
l.llü 
1 2 3 4 5 7 8 9 10 11 12 13 14 1 2 3 4 5 6 7 8 9 10111213141516171819 
Patient 
Fig. 6 Individual improvement in IPSS scores (a, minimally obstructed + b, 
severely obstructed), Qmax at free flow scores (c, minimally obstructed + d, 
severely obstructed) and PVR scores (e, minimally obstructed + ƒ severely 
obstructed) in 14 minimally obstructive patients and 19 severely obstructed 
patients. Black, week 0 for IPSS, Qmax and PVR. White, week 26 for IPSS, 
Qmax and PVR 
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good cavity in both lateral lobes, but a large residual middle lobe, imposing and 
obstructive, was seen. In general, evaluation 6 months after laser treatment 
showed a significant improvement of the PQ values in conjunction with a 
significant symptomatic improvement (IPSS score). 
Several papers have reported that operative results are superior in patients with 
intravesical obstruction.29,30 The risk of attaining a less satisfactory outcome 
from TURP is increased threefold in the unobstructed patients, yet 75-80% do 
well. The question is whether this alone is reason enough for ascertaining the 
presence of an obstruction pre-operatively by pressure-flow studies. However, 
the question can be posed another way; If 25-30% of patients seeking medical 
attention for ΒΡΕ are indeed unobstructed, is there any reason to operate on 
them?30 The analysis of outcome in the present study in 14 minimally 
obstructed patients (LPURR < 3) showed a comparable improvement in both 
symptom scores and voiding parameters, comparable to the 19 severely ob­
structed patients (LPURR > 5) (Fig. 6). In view of the many available treatment 
modalities other than surgery, one should consider that these (minimally 
invasive) alternative treatments may also be applicable to this group of patients. 
Currently there is no agreement on the place of urodynamic studies in the 
evaluation of patients with ΒΡΕ, although most urologists agree that the main 
feature of the enlarging prostate is infravesical obstruction. As the results of 
surgery for BPH are generally favourable, there has been little enthusiasm for 
the use of resource-consuming investigations. Presently, most methods used for 
diagnosing infravesical obstruction are indirect and imprecise. Therefore, if an 
objective assessment of obstruction is desirable, the obstruction itself should be 
studied using urodynamic investigation with PQ analysis. Because simple 
methods are available for practical use to grade outlet obstruction, this is no 
reason for omitting this investigation. 
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Urinary tract infections following laser prostatec-
tomy: is there a need for antibiotic prophylaxis? 
Br J Urol, 77: 228,1996 
Summary 
Objective: To evaluate the incidence of urinary tract infections (UTIs) after 
transurethral laser therapy of the prostate and the need for peri-operative 
antibiotics. 
Patients and methods: One-hundred and sixteen patients with benign 
prostatic enlargement (ΒΡΕ) were treated with a Nd:YAG laser, using either 
the TULIP device, the Urolase fiber or the Ultraline fiber. The incidence of 
voiding complaints, UTIs and the need for catheterization after treatment 
were assessed. The first 43 patients (Group I) received no antibiotics peri-
operatively and the next 73 patients (Group II) received co-trimoxazol for 5 
days. 
Results: The patients treated using the TULIP device had more urinary 
complaints after treatment than those treated using the Ultraline and Urolase 
fibers. In Group I, 48% of the patients developed a UTI and in Group II the 
incidence of UTIs decreased to 30% after treatment. The incidence of UTIs 
was unrelated to the procedure performed. Although not statistically 
significant, peri-operative antibiotics tended to reduce the incidence of UTIs. 
Prolonged catheterization was correlated with the incidence of UTIs. In 
Group I, patients who were treated using the Ultraline procedure had their 
catheter removed after a mean of 24 days, compared with 21 days for those 
treated with the Urolase and 19 days with the TULIP device. In Group II, the 
patients needed catheterization for a mean of 17 days following Ultraline 
treatment and 16 days following the Urolase procedure. 
Conclusion: Antibiotic prophylaxis tended to decrease the incidence of post-
treatment UTIs. However, there was no clear association between the 
presentation and duration of complaints and the presence of UTIs. 
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Introduction 
Urinary tract infection (UTI) and septicaemia are important sequelae of 
transurethral surgery. Significant controversy surrounds the use of 
prophylactic antibiotics in prostatic surgery. Septicaemia occurs in only 0-4% 
of patients undergoing transurethral resection of the prostate (TURP). 
Studies on the role of antibiotic prophylaxis have focused on the incidence of 
UTI and some have shown that antibiotic prophylaxis decreased the incidence 
of UTIs 2'5 whereas others reported no decrease 6 '9 In these studies UTIs 
occurred in 5- 10% of patients even when antibiotics were used prophylacti-
cally. In a review, Chodak and Plaut concluded that no recommendations 
could be made regarding the use of prophylactic antibiotics.10 
Over the last three years transurethral laser therapy has been suggested as a 
new treatment modality for benign prostatic enlargement (ΒΡΕ).""14 Several 
devices have been developed and evaluated, amongst which the side-firing 
laser fibers are currently the most popular. At low power, deep coagulation of 
the prostate can be achieved, whilst at high power direct tissue vaporisation 
occurs. With our increasing experience of laser treatment, some patients 
apparently required prolonged periods of catheter drainage after treatment. 
Moreover, UTIs and epididymitis seemed to occur more frequently than in 
patients treated by TURP. 
The aim of this study was to evaluate the incidence of UTIs after transurethral 
laser therapy of the prostate and the need for peri-operative antibiotics. 
Furthermore, we examined whether there was a correlation between the 
presentation of UTIs, the duration of catheterization and the complaints 
observed. 
Patients and Methods 
Only those patients with sterile urine and undergoing transurethral laser 
prostatectomy were included in the study. Any patient with a UTI, urinary 
retention with an indwelling catheter or recent use of antibiotics within the 7 
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days preceding the operation were excluded. All pre-operative urine cultures 
were obtained by the midstream clean-catch method. 
Before treatment, the genitalia were cleaned with povidone-iodine solution 
and sterile water was used as the irrigation fluid. A suprapubic 16 Ch Foley 
catheter was inserted and the laser treatment performed using one of three 
techniques. With the TULIP device, laser energy was applied, under ultra-
sonographic guidance, to the prostate, drawing lines from the bladder neck to 
the veru montanum and causing deep coagulation. The first 11 consecutive 
patients were treated with this device. After this study, a randomised study 
was performed, using two side-firing laser fibers under direct vision. The 
Urolase fiber also achieves deep coagulation by delivering energy at pre-
determined areas of the prostate (2,5,7 and 10 o'clock positions). The 
Ultraline fiber enables vaporisation of prostate tissue and treatment was 
performed by "painting" the prostate. These techniques have been described 
in detail elsewhere.10"11 
The patients were discharged 1 day after treatment with the suprapubic 
catheter blocked. The patients were allowed to urinate spontaneously and the 
suprapubic catheter was removed when the patients were able to urinate 
adequately with a low post-voiding volume. 
The first 43 patients (mean age 65 years, range 51-85), including those treated 
with the TULIP device received no antibiotics peri-operatively (Group I) 
while the 73 patients (mean age 65 years, range 50-79) treated consecutively 
received co-trimoxazol peri-operatively for 5 days (Group II). In Group I, 13 
patients were treated with the Ultraline fiber, 19 with the Urolase fiber and 11 
with the TULIP device; in Group II, 31 patients were treated with the 
Ultraline fiber and 42 with the Urolase fiber. 
Urine cultures were taken during the follow-up at 2 and 4 weeks and after 
removal of the catheter. Every UTI was treated when the organism was 
identified. Antibiotics were also given when the patient developed fever > 
38°C became clinically bacteraemic, or developed a symptomatic UTI or 
epididymitis. The urine culture was considered to be infected when there 
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were > IO5 organisms/ml of a pure growth. Complaints were scored for their 
presence and duration, and scoring began on the day of discharge and 
continued until the patient was absolutely free of complaints. 
Although the study was not randomised, a statistical analysis could be 
performed because the same inclusion-criteria were used for both groups. The 
11 patients treated with the TULIP device were all in Group I and were 
therefore omitted from the statistical analysis. A joint logistic regression 
analysis (SAS Procedure LOGISTIC) was applied to investigate the 
relationship between the presence or absence of a UTI and antibiotic 
prophylaxis, laser type and the duration of catheterisation. 
Results 
After treatment, 21 patients (48%) in Group I and 22 patients (30%) in Group 
II developed a documented UTI. In Group I, eight (62%) patients treated with 
the Ultraline, nine (47%) with the Urolase and four (36%) with the TULIP 
procedure developed UTls. In Group II, the incidence was 35% (I 1/3 I ) in the 
Table 1. The average duration of catheterization. The type of procedure 
performed and the results of post-operative urine cultures in patients with 
(Group II) and with no peri-operative antibiotics (Group I). 
Procedure Duration of catheterisation in days (number of patients) 
Positive culture Negative culture Total 
Group I 
Ultraline 23 (8) 
Urolase 28 (9) 
Tulip 15 (4) 
Total 24 (21) 
Group II 
Ultraline 22(11) 
Urolase 19(11) 
Total 21 (22) 
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25(5) 
15(10) 
21(7) 
19(22) 
14 (20) 
15(31) 
15(51) 
24(13) 
21 (19) 
19(11) 
21 (43) 
17(31) 
16(42) 
16 (73) 
Ultraline and 26% ( 11/42) in the Urolase group. The mean duration to 
catheter removal was 21 days (range 2-72) in Group I and 16 days (range 3-
58 days) in Group II; with laser type, in Group I the mean durations were 24 
days (Ultraline), 21 days (Urolase) and 19 days (TULIP). In Group II, the 
mean duration of catheterization was 17 days for the Ultraline and 16 days for 
the Urolase group. For Group I, in the group of patients with a positive urine 
culture, the catheter was removed after a mean of 24 days, while in the remai-
ning patients the catheter was removed after 19 days; the results were similar 
in Group II (Table 1). 
To investigate the influence of antibiotics, laser type and duration of 
catheterization on the probability of developing a UTI a logistic regression 
was performed. According to the likelihood-ratio test, the three regression 
variables combined were significant (P=0,01). Using the Wald test for each 
variable, there was no significant relation with laser type (P=0,29), but the 
Table 2. Post-operative complaints and the presence of a urinary tract 
infection in patients with (Group II) and with no (Group I) peri-operative 
antibiotics. 
Urinary tract infection 
Group 1 
number of patients 
Complaints number (%) 
Frequency 
Dysuria 
Haematuria 
Pain 
Group II 
number of patients 
Complaints number (%) 
Frequency 
Dysuria 
Haematuria 
Pain 
Yes 
21 
15(71) 
16 (76) 
16 (76) 
7(33) 
Yes 
22 
12 (55) 
10(46) 
16 (73) 
8(36) 
No 
22 
12(55) 
12(55) 
12 (55) 
5(23) 
No 
51 
23 (45) 
22 (43) 
36(71) 
11 (22) 
Total 
43 
27 (64) 
28 (65) 
28 (65) 
12 (28) 
Total 
73 
35 (48) 
32(44) 
52(71) 
19(26) 
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probability of developing a UTI is significantly higher (P=0,03) with a longer 
duration of catheterisation and although not significant (P=0,07) there tended 
to be a lower probability of developing a UTI with the use of antibiotics. 
Patients with a UTI had complaints for a mean of 45 days (range 6-149) and 
similarly, for patients with no UTI, the mean was 45 days (range 0-95) (Table 
2). There was no clear relationship between the duration of the complaints, 
the type of complaints and the presence of UTIs. Table 3 shows the results of 
urine culture and the organisms cultured. Five patients (12%) in Group I 
developed epididymitis compared with seven patients (10%) in Group II. 
Discussion 
Transurethral resection of the prostate is the most common operation for 
bladder outlet obstruction and is one of the most frequently performed 
operations in men 65 years or older.15 Amongst other new, less invasive treat­
ments for ΒΡΕ, transurethral laser treatment of the prostate has become 
available recently. The first report on the use of lasers to treat ΒΡΕ were 
Table 3. Results of urine cultures 
Bacteria 
Escherichia coli 
Klebsiella pneumoniae 
Staphylococcus aureus 
Enterococcus faecalis 
Acinetobacter baumannii 
Proteus mirabilis 
Citrobacter freundii 
Enterobacter spp 
Klebsiella oxytoca 
Pseudomonas spp 
Coag. neg. Staphylococcus 
Staphylococcus epidermidis 
Group 1 
4 
4 
4 
3 
2 
2 
1 
1 
1 
1 
0 
1 
Group II 
3 
0 
2 
5 
1 
0 
1 
0 
1 
3 
1 
5 
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presented by Costello et al.16 In two recent papers reporting laser ablation of 
the prostate with different techniques " , 7 , it was concluded that the outcome 
of treatment was excellent and that the morbidity after laser treatment was 
minor. However, the majority of patients had voiding complaints, possibly 
due to UTIs. On the other hand, a difference in the severity of complaints was 
noted when different techniques were used. It was thought that these diffe-
rences may not be related to the presence of an infection. 
No standard exists in the urologie community regarding the use of prophylac-
tic antibiotics for TURP. The reported incidence of UTI in patients 
undergoing TURP ranges from 2.318 to 42%.19 In several studies 5·20-21 prophy-
lactic antibiotics were recommended and Childs stated that TURP should be 
classified as a contaminated procedure, with a 20% risk of infection, and also 
recommended prophylaxis.22 To define the prevalence of prostatic bacterial 
infection, Gorelick et al. conducted a study in which tissue from patients 
undergoing prostatectomy was submitted for quantitative bacterial tissue 
culture.23 These data showed a significant prevalence (21%) of prostatic 
infection in patients undergoing prostatic surgery. 
In patients with a sterile pre-operative urine culture, no peri-operative 
antibiotics are administered for TURP in our department. When transurethral 
laser therapy became available, it was also decided that peri-operative 
antibiotics would not be used in these patients. However, during follow-up 
many patients had irritative complaints for several days to weeks after 
treatment and the incidence of UTIs seemed high. 
In the present study, evaluation of the patients treated without peri-operative 
antibiotics showed that 48% of them developed a UTI. Indeed, compared to 
the incidence seen after TURP (mean 10-20%), this percentage is high. Three 
factors were evaluated to explain this high incidence; the presence of 
necrotic tissue after the procedure, the presence of an indwelling catheter and 
prolonged catheterization. Moreover, relationships between the complaints 
and the presence of a UTI were examined 
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The incidence of UTI was highest in the Ultraline group, followed by the 
Urolase and the TULIP group. However, adjusted for the use of prophylactic 
antibiotics and the duration of catheterization, there were no significant 
differences between those treated with the Ultraline and the Urolase fibers. 
The discrepancy in the incidence of UTIs for the three procedures was not 
related to the type of laser fiber but to the duration of catheterization. Al three 
fibers create extensive necrotic tissue, caused by coagulation. Thus the 
prostate turns into an ideal culture medium for bacteria, which may already be 
present in the prostate, as demonstrated by Gorelick et al.23 
The presence of an indwelling catheter may support the incidence of UTIs. In 
those patients treated without prophylactic antibiotics, the mean time to 
catheter removal was 21 days. In cases of infection, the catheter was 
removed at a mean of 24 days while in the remaining patients the catheter 
was removed a mean of 5 days earlier. Patients with a prolonged indwelling 
catheters are susceptible to infection with mixed cultures of organisms.4'24 In 
the 73 patients receiving prophylactic antibiotics a similar trend occurred; the 
mean duration of catheterization was 16 days, but was 21 days in infected and 
15 days in the uninfected patients. 
From the logistic regression analysis, it is concluded that this higher 
incidence of UTIs may be explained partly by a longer duration of 
catheterization. Recently Costa presented results of a randomised study to 
evaluate whether antibacterial prophylaxis is useful in laser ablation of the 
prostate.25 In agreement with the present study, 50% of the patients in a group 
receiving no prophylaxis developed bacteriuria. In patients receiving a single-
dose regimen of a difluoroquinolone, bacteriuria developed in only 10%, 
whereas 5% of those receiving a multi-dose regimen developed bacteriuria 
during follow up. In contrast to the present study, the median duration of 
catheterization was only 2-3 days; this may explain the difference in the 
results. On the other hand, infections may impair wound healing in the 
prostatic fossa and thus results in a need for prolonged catheterization. 
Although peri-operative antibiotics decreased the incidence of UTIs after 
143 
treatment, the incidence of UTIs remained at 30%. 
After laser treatment, significant epididymitis occurred in patients in both 
Group I and II. However, the incidence of epididymitis after TURP should 
not be underestimated. Epididymitis has been recognised as a complication of 
prostatic surgery for many years. Most urologists believe that the route of 
infection is through the lumen of the vas, and the incidence of epididymitis 
was estimated at 5 to 10%.26 Possibly, urethral catheterization has only an 
indirect effect on the incidence of epididymitis, by potentiating urinary 
infection. Because of the morbidity caused by epididymitis, any means which 
decreases the incidence of epididymitis should be employed. 
In the present study there was no evident relation between the presence or 
duration of complaints after laser treatment and the incidence of UTIs (Table 
2). Therefore, one cannot rely on the complaints presented by these patients 
to determine whether a UTI is present and causing the complaints. However, 
the duration of complaints and the type of procedure performed were 
associated. In an earlier phase, it was noted that voiding complaints and 
perineal discomfort were more pronounced in the TULIP group than in the 
Urolase group" and that this difference may be explained by the different 
procedure performed. During the insertion of the TULIP device, more tissue 
trauma may be caused than with other techniques. Moreover, the TULIP 
device requires a 48-F balloon to be filled with 0.1-0.2 Mpa of pressure, 
which may cause a commisurotomy and stretching of the capsule of the 
prostate. Finally, patients treated with the Ultraline procedure may have more 
complaints than those treated with the Urolase because a larger area of the 
prostate surface is treated, sometimes very close to the bladder neck. 
Compared to the TULIP group, the patients treated with the Ultraline fiber 
had fewer complaints. 
The high incidence of urinary tract infections after laser prostatectomy may 
have many causes. There was a poor relationship between complaints and the 
presence of UTIs. There is a paucity of reliable indicators to identify pre-
operative^ patients that will develop complaints post-operatively, or will 
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have an UTI. The major cause seems to be prolonged catheterization, but 
currently it is impossible to predict which patients will develop an infection. 
Peri-operative antibiotics tended to reduce the post-laser UTIs, though there 
was no relation with the type of procedure performed. However, because few 
patients were treated within each group, firm conclusions cannot be made. 
Because of the high rate of infection found in the present study and the 
decrease in infections in the subsequent group of patients with peri-operative 
antibiotics, we have decided to proceed with laser therapy under prophylactic 
antibiotics (co-trimoxazole 960 mg twice daily for 5 days). When considering 
the routine use of antibiotics the potential disadvantages must be considered, 
including added costs, selection of resistant organisms and allergic reactions. 
If antibiotics are administered, for how long should they be continued and 
which antibiotic drug should be chosen? These questions need to be answered 
in a randomised (placebo) controlled study. Furthermore, the laser therapy of 
the prostate should be modified so that the need for (prolonged) catheteriza­
tion is reduced. 
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Summary 
Purpose: The importance of the assessment of quality of life was studied in 
patients following laser prostatectomy. 
Material and Methods: Patients undergoing a laser prostatectomy were 
evaluated with the international prostatic symptom score (IPSS) 
questionnaire, uroflowmetry, post-void residual volume measurements and 
quality of life and sexual function questionnaires. 
Results: Data for 103 patients were evaluated. Overall, significant 
improvement in mean IPSS, maximum flow, post-void residual and quality of 
life score was noted. There seemed to be no subjective change in sexual 
function. There was a good relation between the IPSS and the quality of life 
score. However, there was no correlation between the quality of life score 
and the maximum flow, and only a low correlation between the IPSS and the 
maximum flow. 
Conclusion Laser prostatectomy significantly changes the quality of life. This 
may be more important for the patient than the improvement of voiding 
parameters alone. In the future (changes in) quality of life will probably 
contribute significantly in selecting patients with voiding complaints for 
treatment. 
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Introduction 
Benign prostatic hyperplasia (BPH) is a common condition among men, with 
an estimated prevalence as high as 85 %.' BPH can cause Bladder Outlet 
Obstruction (BOO) with a large scale of symptoms varying from only mild 
voiding or filling complaints to recurrent urinary tract infections, acute 
retention or even renal failure. The majority of patients will visit their 
physician with mild to moderate complaints of urinary difficulties, so called 
lower urinary tract symptoms (LUTS). The influence of these LUTS on 
patients' daily activities and consequently on their quality of life will make 
patients demand some treatment. Since men do not always perceive their 
LUTS as problematic, the prevalence of symptoms in the community is 
higher than the number of men who seek medical or surgical attention.2'3 
Thus, besides the presence of symptoms, bothersomeness of these symptoms 
seems to play an important role in diagnosis and treatment of patients with 
LUTS. Several studies noticed the importance of a bother score of several 
symptoms. Also a correlation between these bother scores, symptom scores, 
and quality of life was established.4'5 
Since decades the only treatment options for men, seeking help for LUTS as a 
result of BPH have been transurethral electroresection of the prostate (TURP) 
and open prostatectomy. During the last ten years several alternative 
treatments were introduced. These new treatment options were evaluated for 
their efficacy using symptom scores and objective measurements including u-
roflowmetry, post void urinary residual and sometimes even urodynamic 
investigations with pressure flow studies. The number of publications 
reporting on the effect of a particular treatment on quality of life is limited. 
One of these alternative therapies is the use of laser energy in the treatment 
of BPH. This treatment option has been evaluated extensively and results with 
respect to improvement in symptom scores and uroflowmetry data, 
comparable with TURP, are documented in several publications.6"8 However, 
little is known about the effect of laser treatment of the prostate on quality of 
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life. In the current study patients were evaluated pre- and post-laser treatment 
with quality of life and sexual function questionnaires in addition to 
symptom-scores and the objective measurements as uroflowmetry and post 
void urinary residual. 
Material and Methods 
From December 1993 through June 1995 103 patients with LUTS and BPH 
underwent a laser prostatectomy. Two different side firing laser devices were 
used: the Urolase and the Ultraline fiber. All patients were evaluated at 
baseline with history, physical examination, including digital rectal 
examination (DRE), laboratory investigations, including PSA, urine culture 
and urinalysis. Symptoms were evaluated using IPSS, a Quality of life 
questionnaire and a sexual function questionnaire. The IPSS is the Dutch 
translation of the AUA-7 questionnaire and asks for symptoms in filling and 
voiding phases. The last question is about the effect of these voiding 
complaints on quality of life. The Quality of life questionnaire (app.l) 
consists of three parts: part A contains six questions about the general impact 
on the patient's life and quantifies some symptoms (range 6 - 24); part В 
contains five questions about the bothersomeness of specific symptoms 
(range 5 - 25); and part С contains only one question about general 
improvement or deterioration over the last month (range 1 - 5). The sexual 
function questionnaire (app.2) inquires about changes in sexual function after 
the laser treatment. 
Furthermore, patients underwent transrectal ultrasonography (TRUS) of the 
prostate to document prostate abnormalities. In case of suspicion for prostate 
cancer ultrasound-guided biopsies were taken. The prostate volume was 
measured using the ellipsoid formula. To document changes in voiding 
parameters following laser prostatectomy uroflowmetry studies including 
post voiding residual volume measurements were performed. Patients were 
evaluated at baseline and at 3, 6 and 12 months postoperatively. The sexual 
function questionnaire was re-evaluated at 3 and 12 months. 
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Since earlier studies revealed no differences in clinical outcome using the 
Ultraline and the Urolase fiber the data were analysed as one group.9 
Statistical analysis: 
Differences for age, uroflowmetry data or residual urine volume, between 
patients who filled out all the questionnaires at follow up and patients who 
did not, were tested for statistical significance using the Wilcoxon test at each 
time of assessment. 
Correlations were tested for statistical significance using the Spearman rank 
correlation test. 
Changes after laser prostatectomy was tested for statistical significance using 
a two-way ANOVA with appropriate Tukey's contrast test for each variable 
separate. The independent variables were patient and day of assessment. The 
dependent variables were uroflowmetry parameters and the sum scores of the 
different questionnaires, respectively. 
Results 
There were no significant differences in baseline parameters, including age, 
between patients who did fill out the questionnaires at all times and patients 
who did not. When we look at improvement of uroflowmetry data and the 
effect of this on filling out the questionnaires there are no significant 
differences between patients who filled out the IPSS at all times and patients 
who did not. For the Quality of life questionnaire, however, there is a 
significant difference for the maximum flow at 3 months after treatment. It 
seems that patients who filled out the Quality of life questionnaire at all times 
had a significant higher maximum flow than patients who did not fill out this 
questionnaire at all times. This difference disappears at 6 and 12 months after 
treatment. 
Symptom questionnaire (IPSS) 
Of the 103 patients treated, 101 patients filled out the questionnaire at 
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baseline. At 3, 6 and 12 months postoperatively this number was 95, 99 and 
89, respectively. 
There is a significant decrease in symptom score from 21.3 (range 11 - 35, SD 
5.6) at base line to 8.0 ( range 0 - 23, SD 5.5) at 3 months , 6.2 (range 0 - 35, 
SD 5.5) at 6 months and 5.4 (range 0 - 20, SD 4.4) at 12 months after 
treatment.(Fig.l) 
At 6 months postoperatively only 3 patients did not improve in symptom 
score, which accounts for 3.1 %. 
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Fig. 1 Mean IPSS, quality of life score of the IPSS (IPSS-T), maximum flow 
(Qmax; ml/s) and post-void residual volume (PVR); χ 10 ml) at screening 
and 3, 6 and 12 months follow-up. 
Quality of life question of the IPSS 
This question was filled out by 67 of the 103 patients at baseline. At 3, 6 and 
12 months after treatment 56, 61 and 52 patients (who also filled out this 
question at baseline), respectively filled out this question. Like changes 
found in IPSS score, this question showed a significant drop in the score 
from 4 (range 1 - 6, SD 0.95) at baseline to 1.7 (range 0 - 6, SD 1.5) at 3 
months, to 1.3 (range 0 - 4, SD 1.2) at 6 months and to 1.1 (range 0 - 3, SD 
0.9) at 12 months after treatment.(Fig.l) 
At 6 months postoperatively only 9 patients of the 61 did not improve in 
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score, which accounts for 14.8 %. 
Quality of life questionnaire 
This questionnaire was filled out by 86 of the 103 patients at baseline. At 3, 6 
and 12 months after treatment, 82, 83 and 74 patients (who also filled out this 
questionnaire at baseline), respectively filled out the questionnaire. When 
taking the sum score of this questionnaire there is a significant decrease from 
25.2 (range 11 - 40, SD 6.3) at baseline to 18.2 (range 11 - 37, SD 6.5) at 3 
months, to 15.1 (range 11 - 37, SD 5.0) at 6 months and to 13.8 (range 11 -
26, SD 3.5) at 12 months after treatment. If we look at the separate parts 
(A,B) of this questionnaire there is a significant decrease from 12.3 (range 6 -
21, SD 3.2) and 12.9 (range 5 - 21, SD 3.9) at baseline, to 9.9 (range 6 - 2 1 , 
SD 3.5) and 8.3 (range 5 - 22, SD 3.6) at 3 months, to 7.9 (range 6 - 16, SD 
2.5) and 7.2 (range 5 - 21. SD 2.9) at 6 months and to 7.2 (range 6 - 14, SD 
1.8) and 6.6 (range 5 - 14, SD 2.1) at 12 months postoperatively. The score on 
part С of the questionnaire fluctuates from 3.4 (range 2 - 5, SD 0.7), to 1.5 ( 
range 1 - 5, SD 0.9) at 3 months, to 1.9 (range 1 - 5, SD 1.1) at 6 months and 
to 2.5 (range 1 - 4, SD 0.9) at 12 months after treatment.(Fig. 2) 
qol-a qol-b qol-c qol-tot 
Fig. 2 Mean score of the different parts and the sumscore of the quality of life 
questionnaire at screening and at 3, 6 and 12 months follow-up 
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At 6 months postoperatively only 6 patients of the 83 did not improve in the 
sum score of this quality of life questionnaire, which accounts for 7.2 %. 
Sexual function questionnaires. 
Overall there was no significant change in how the patients experienced their 
sexual function three months and one year after treatment in comparison with 
the measurement at baseline. Of the 35 patients who said there was a change 3 
months after laser prostatectomy, 21 patients (60%) said that there was an 
improvement and 14 patients (40%) stated that there was a deterioration in 
sexual functioning. Twelve months after laser prostatectomy there were 17 
patients out of a total of 30 who stated that there was an improvement and 13 
patients stated that there was a deterioration in sexual functioning. 
Uroflowmetry data 
In 102 of the 103 patients a uroflowmetry with ultrasound guided 
measurement of the residual urine volume was performed at baseline. At 3 
months after treatment 100 patients performed a uroflowmetry and in 99 
patients the residual urine volume was measured. At 6 and 12 months 
postoperatively 97 and 91, respectively had uroflowmetry, and 92 and 86 
patients, respectively had a residual urine volume measurement. 
There is a significant improvement in maximum flow from 7.9 ml/s (range 2 -
15, SD 3.0) at baseline, to 19.1 ml/s (range 5 - 45, SD 6.9) at 3 months, to 
17.2 ml/s (range 3 - 37, SD 6.5) at 6 months and to 17.7 ml/s (range5 - 40, SD 
7.5) at 12 months after treatment. The same improvement was seen for the 
residual urine volume, with a decrease from 84 ml (range 0 - 385, SD 80.9) to 
27.6 ml (range 0 - 200, SD 36.6) at 3 months, to 16.4 ml (range 0 - 200, SD 
31.0) at 6 months and to 25.6 ml (range 0 - 165, SD 37.6) at 12 months 
postoperatively . There was no statistically significant difference between the 
data at 3, 6 and 12 months after treatment for both the maximum flow and the 
residual urine volume. (Fig. 1) 
At 6 months postoperatively only 7 patients of the 97 did not improve in 
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maximum flow, which accounts for 7.2 %. 
3a 
3b 
DIPSS26 
Fig. 3 Relation between improvement in IPSS (DIPSS26) and a) quality of life 
score (part A)(DQOLA26); and b) quality of life score (part B)(DQOLB26) 
at 6 months 
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With the Spearman rank correlation test there is a significant correlation 
between the sum score of the IPSS and the separate scores of part A and В of 
the quality of life questionnaire of r=0.50 and r=0.56, respectively at baseline; 
r=0.64 and r=0.62, respectively at 3 months; r=0.50 and r=0.63, respectively 
at 6 months; and r=0.59 and r=0.61, respectively at 12 months after laser 
treatment. (Fig 3) The IPSS quality of life question also correlated 
significantly with the sumscore of the IPSS, and with the scores of part A and 
В of the Quality of life questionnaire with respectively r=0.66, r=0.51 and r= 
0.56 at 6 months (Fig 4). There is a significant correlation at all evaluation 
points. 
Besides a weak correlation of r=0.39 between the IPSS and the maximum 
flow rate at 6 months postoperatively no relation is found between the IPSS 
and the quality of life scores on one hand and the maximum flow rate on the 
other hand at baseline and follow up. Also the changes in IPSS sum score and 
the total Quality of life sum score after laser treatment do not show any 
relation with the change in uroflowmetry parameters postoperatively. (Fig 5) 
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Fig. 4 Relation between improvement in the single quality of life question of 
the IPSS (DIPST26) and a) the IPSS (DIPSS26); b) quality of life score (part 
A) (DQOLA26); ande) quality of life score (part B) (DQOLB26) at 6 months 
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5a 
DIPSS26 
5b 
Fig. 5 a) Relation between improvement in ¡PSS (DIPSS26) and maximum 
flow (Qmax) ( DQMAX26) at 6 months; and b) relation between improvement 
in the sumscore of the quality of life questionnaire (DQOLT026) and 
maximum flow (Qmax) ( DQMAX26) at 6 months 
160 
Discussion 
The degree to which the patient is bothered by urinary difficulties, rather than 
symptoms per se, or the degree of the decrease in flow may be the most 
important influence on the decision of a patient to seek medical attention for 
the problem. Whether treatment is advantageous when there are significant 
objective findings of obstruction but little impairment in the quality of life or 
vice versa is not clear. Several reports already stressed the importance of 
bothersomeness of LUTS and the effect ofthat on quality of life.4'10" Fowler 
et al found that men who are bothered by symptomatic BPH are most likely to 
experience a dramatic improvement from transurethral resection of the 
prostate.12 Therefore studies on effect of treatment in patients with LUTS and 
BPH, have to use symptom questionnaires and especially bothersome and 
quality of life questionnaires in addition to objective parameters such as 
uroflowmetry and pressure-flow studies. 
In a study of Sagnier et al10 the IPSS sum score was highly correlated with 
the AUA-bother-score (r=0.85) and also the separate quality of life question 
of the IPSS correlated well with the ALIA- botherscore (r=0.60). A good 
correlation between the IPSS sumscore and the separate quality of life 
question of the IPSS was also reported (r=0.74)." In the present study we 
found also a significant correlation between the sum score of the IPSS and the 
separate scores of part A and В of the quality of life questionnaire. 
Furthermore, according to the literature, there seems to be only a low 
correlation between symptom scores and uroflowmetry data in a community-
based sample of men13 as well as in men with the clinical diagnosis of BPH.14 
The current study observed only a weak correlation between the sum score of 
the IPSS and maximum flow rate only at 6 months after laser treatment. No 
relation was found at the other evaluation points. There was also no relation 
found between the sum score of the quality of life questionnaire and 
maximum flow rate at baseline and follow up. Despite this observation we do 
see a significant improvement in all these parameters after the laser treatment 
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of the prostate (Figi and 2). 
There are only a few reports of changes in quality of life after treatment for 
LUTS. A prospective study of BPH treatment choices in 546 patients 
suggested that men with the same level of symptoms may not be equally 
bothered, and that patients perception of quality of life must be taken into 
account when one is considering treatment options.15 In a separate report of 
an uncontrolled study at least 60% of consecutive surgical patients reported 
that the primary reason for prostate surgery was symptom reduction and 
improvement in quality of life.16 Lukacs et al17 reported improvement in 
quality of life after treatment with an alpha blocker, although this study was 
uncontrolled. Emberton et al18 performed a study on the effect of 
prostatectomy on symptom severity and quality of life. It was concluded that 
changes in symptom severity were highly correlated with bothersomeness and 
disease specific quality of life. They stated furthermore that prostatectomy is 
effective in reducing symptoms in most men and that men who experienced a 
substantial reduction in symptoms were more likely to report a favourable 
outcome. To our knowledge the current study is the first which reports on 
quality of life after laser prostatectomy. The quality of life data have 
limitations, because quality of life questionnaires are not validated yet. The 
proceedings of the third international consultation on BPH therefore could not 
recommend a quality of life questionnaire at this moment.19 Naturally we 
realise that a validated international bothersome and quality of life 
questionnaire has to be developed. Since there appeared to be a good relation 
between the single quality of life question of the IPSS and the Quality of life 
questionnaire used in this study, we wondered whether only the single quality 
of life question of the IPSS questionnaire would be sufficient to document 
changes in quality of life adequately in these patients. Although there is a 
significant correlation between this single quality of life question of the IPSS 
and the sum score of the IPSS and the score of part A and В of the quality of 
life questionnaire, the correlation is to low to state that this single question 
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can replace the a more differentiated questionnaire. Moreover several studies 
already showed that there are geographical or cultural differences in the 
prevalence of symptoms and in symptom severity. Guess et all showed a 
difference in prevalence of symptoms between Scottish men and men from 
Minnesota. Scottish men reported less symptoms but a slightly greater 
amount of bother was associated with a given level of symptoms. Also the 
ICS-BPH study concluded that in various countries specific LUTS may be 
presented in a distinct way.21 The perception of specific LUTS appeared to be 
associated with the country of origin. As a result probably each country with 
its own cultural background and specific health care delivery system has to 
validate the efficacy and quality of life aspects of new treatment modalities 
for LUTS. 
In conclusion, this study showed only a weak correlation between symptom 
score and uroflowmetry parameters, no correlation between Quality of life 
and uroflowmetry data, and a strong correlation between quality of life and 
symptom scores. Laser treatment of the prostate does not only change 
objective parameters but also changes the quality of life. The latter may be 
more important for the patient than the increase in maximum flow rate. In the 
future quality of life questionnaires and bothersomeness of particular 
symptoms will probably be more important in selecting patients for treatment 
of LUTS as a result of BPH than other parameters. 
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Appendix 1 
Patients Quality of Life Questionnaire 
part A 
1. How many problems do you have with your voiding pattern? 
1. none 
2. little 
3. moderate 
4. much 
2. Do your problems with voiding interfere with your normal daily activities? 
1. no 
2. slightly 
3. moderate 
4. much 
3. Do your problems with voiding interfere with your normal social life? 
1. no 
2. sligthly 
3. moderate 
4. much 
4. Did you ever had to void without controlling the time of voiding? 
1. never 
2. yes, 1 or 2 time(s) per month 
3. yes, 1 or 2 time(s) per week 
4. yes, every day 
5. Did you ever wet your clothes? (because of the urge to void) 
1. never 
2. yes, 1 or 2 time(s) per month 
3. yes, 1 or 2 time(s) per week 
4. yes, every day 
6. Did you ever wet your bed? 
1. never 
2. yes, 1 or 2 time(s) per month 
3. yes, 1 or 2 time(s) per week 
4. yes, every day 
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part В 
For the next questions you must choose one of the answers which will show 
how troublesome the problem in that question was over the last month. 
1. terminal dribbling or wetting your clothes 
1. no problem 
2. very small problem 
3. small problem 
4. a problem 
5. large problem 
2. unpleasant sensation of a full bladder 
1. no problem 
2. very small problem 
3. small problem 
4. a problem 
5. large problem 
3. Fear that you cannot void when you have a full bladder 
1. no problem 
2. very small problem 
3. small problem 
4. a problem 
5. large problem 
4. Concern about the long distance you have to cover before you can void. 
1. no problem 
2. very small problem 
3. small problem 
4. a problem 
5. large problem 
5. Being embarrassed about having to go to the toilet very frequently. 
1. no problem 
2. very small problem 
3. small problem 
4. a problem 
5. large problem 
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partC 
Are your voiding complaints over the last 2 to 3 months 
1. very deteriorated 
2. slightly deteriorated 
3. unchanged 
4. slightly improved 
5. very improved 
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Appendix 2 
Sexual function questionnaire 
1. Did the laser treatment changed your sexual life? 
1. no 
2. yes 
2. If you answered yes, you find it 
1. satisfying 
2. rather satisfying 
3. rather unsatisfying 
4. unsatisfying 
169 

Chapter 6 
Review of laser application in 
benign prostatic obstruction 
Based on : 
E. te Slaa, J.J.M.C.H. de la Rosette. 
Lasers in the treatment of benign prostatic obstruction: Past, 
Present and Future. Eur Urol, 30: I-IO, 1996 

Abstract 
Lower urinary tract symptoms caused by benign prostatic obstruction (BPO) 
has been, and still is, treated by performing a transurethral or open 
prostatectomy. During the last decade many alternative treatments have been 
introduced and one of these new modalities uses laser energy in the ablation 
of prostatic tissue. When reviewing the literature on laser treatment of the 
prostate using side-firing laser devices, this procedure has proven to be safer 
and almost as effective as transurethral resection of the prostate (TURP). But 
although severe complications as TUR syndrome, incontinence and the need 
for blood transfusions have not occurred during laser prostatectomies, 
morbidity consisting of irritative voiding complaints and long catheterization 
duration have been reported by several authors. With the development of the 
contact laser probe and the interstitial laser technique some of these problems 
are (partly) solved, but also these new techniques still have considerable 
limitations which may disappear with future developments of newer laser 
probes and refining of existing laser techniques. Also, a better understanding 
and control in the laser-tissue interaction may help in reducing morbidity and 
inducing a more effective treatment. 
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Introduction 
Lower urinary tract symptoms caused by male bladder outlet obstruction has 
presented a clinical problem throughout medical history. Already three 
centuries ago it was suggested that prostatic enlargement could result in 
mechanical obstruction of the bladder outlet tract. Consequently, relieve of 
bladder outlet obstruction can be attained by removal of obstructing prostatic 
tissue. Until a decade ago, the only generally accepted treatment modality to 
achieve disobstruction was prostatectomy. In spite of the proven safety and 
efficacy of this procedure, the morbidity caused by the operation has led to a 
universal search for acceptable alternatives. Many types of treatment have 
been introduced in the wave of new technologies; some have been the subject 
of initial enthusiasm but have subsequently fallen by the wayside (balloon 
dilatation, stents, hyperthermia).1,2·3 
One of the new thermal therapies is the use of laser technology in the ablation 
of prostatic tissue. Laser has been used in the treatment of prostatic disease 
since about 15 years. Beisland and Sander were among the first when they in 
1981 used laser irradiation of the prostate capsule after transurethral electro-
resection of the prostate in the treatment of localised prostate cancer.4 Later 
in 1985, Shanberg et al described the results of prostatotomy using Nd-YAG 
laser in patients with voiding symptoms secondary to benign prostatic 
hyperplasia.5 The laser light was delivered through an end-firing bare fiber 
which was brought in contact. To test the safety of laser energy in the 
treatment of benign prostatic enlargement, Kandel et al performed animal 
studies using a bare fiber to deliver the energy via a perineal urethrostomy.6 
With the end-firing bare fibre it was difficult to aim the beam at the prostatic 
lobes. The development of a side-firing device solved this problem. 
Following the canine feasibility studies with a free beam side-firing system 
under cystoscopic control by Johnson et al7 and with the transurethral 
ultrasound-guided laser-induced prostatectomy (TULIP) system in which 
transurethral ultrasound is used to guide the laser beam by Roth et al8, the 
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first laser prostatectomies performed in men were reported by Costello et al. 
Since then the laser was introduced for the treatment of symptomatic benign 
prostatic obstruction (BPO), and numerous treatment devices have been 
developed and reported on, and this technology has achieved an important 
place in our urologie surgical armamentarium. This article reviews current 
laser applications in the treatment of (BPO) and possible future uses of lasers 
in this field. 
Types of laser application 
A variety of approaches have been put forward to perform a laser 
prostatectomy. Before discussing these approaches in more detail, it is 
essential to be aware about the parameters that may influence laser-tissue 
interaction. Laser light is a unique form of energy with characteristic and 
variable tissue effects. When the laser beam hits the tissue, it will be partly 
absorbed, reflected, transmitted and dispersed. Depending on several factors 
such as colour of the prostatic mucosa, blood perfusion and tissue texture of 
the prostate, more or less laser light will be absorbed. The aim of a laser 
prostatectomy can be defined as the relief of symptoms, caused by obstructive 
prostatic tissue, by the application of laser energy. Removal of abundant 
tissue is possibly the key mechanism. The tissue removal can be obtained in 
two different ways: (1) indirectly by heating the tissue to a maximum of 
100°C, thus causing the coagulated tissue to slough after the procedure, or (2) 
instantaneously by vaporising the tissue while the temperatures rise over 
300OC. 
One of the first devices developed to apply laser energy to the prostate was 
the TULIP system. It combines a real-time ultrasound transducer and a 
Nd:YAG laser delivery system with a urethral probe. Several investigators 
have reported their experience with this device.10"13 Although their results 
were very encouraging, currently it is not being used anymore. The majority 
of patients treated with TULIP will experience substantial improvements in 
subjective and/or objective parameters, however, the procedure appeared to 
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be cumbersome and the morbidity considerable.1211 With the introduction of 
side-firing flexible fiber delivery systems, laser treatment of the prostate 
gained acceptance as an alternative treatment of BPO. The non-contact side-
firing laser technology has made the procedure user-friendly and time-
efficient for all urologists. These fibers mainly possess coagulation 
properties, and most experience is reported on the use of the Urolase side-
firing fiber. Costello et al. where among the first to study the application of 
laser energy using side-firing techniques in the treatment of BPO. Overall 
laser treatment using the Urolase fiber results in an impressive improvement 
in uroflow and a significant decrease in symptoms.14"18 The results where so 
encouraging that numerous side-firing fibers were introduced for the 
treatment of BPO.15"19·20 As a result of this early experience, laser 
prostatectomy became popular with many urologists because it was 
considered to be associated with a morbidity lower than that resulting from 
transurethral resection of the prostate (TURP) while maintaining an excellent 
objective and subjective outcome. Although in the initial reports morbidity 
was considered to be relatively low, it still appeared to be considerable. There 
appeared to be a prolonged need for catheterization following side-firing laser 
treatment. During this period, often irritative voiding complaints for several 
weeks were found. The need for prolonged catheterization can be explained 
by the laser light effect itself. When a Nd:YAG laser beam is incident on 
prostatic tissue at power densities sufficient to coagulate the prostate, the 
gland shrinks to a minor extent due to the coagulation effect on protein and to 
the dissociation of the tissue. The prostate becomes rigid. This is followed by 
a period of cellular infiltration and swelling of the tissue. The patients will 
almost universally have a period of retention, lasting on average of 1-3 
weeks.' " ' Therefore, it was suggested that one should move away from 
purely coagulative techniques, which do not debulk the prostate to any 
measurable extent, toward a more vaporising-oriented approach.22 This 
treatment modality causes tissue to convert into vapors of water and 
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hydrocarbons, thus creating immediate cavitation. Several approaches have 
been developed to achieve this aim. Some companies provided fibers to be 
used in contact and/or a noncontact mode,15'1923 while one company 
developed a laser probe especially developed to be used in contact only. 4 
Narayan et al have presented their results, using the Ultraline fiber in contact 
and noncontact.25 The main finding of their study was that transurethral 
evaporation of the prostate, in the short term, provides symptomatic relief and 
improvement in urine flow comparable to that with TURP. De la Rosette et 
al., however, could not confirm the early recovery of adequate spontaneous 
micturition and diminution of the symptoms.15 It seems that in fact these side-
firing fibers posses only minimal vaporising abilities. Obviously only pure 
contact laser prostatectomy is the practical way of achieving adequate 
vaporisation. Shanberg et al. were among the first to describe a method for 
laser prostatectomy wherein an end-fire Nd:YAG laser fiber was placed in 
direct contact with he prostatic tissue.5 To achieve adequate ablation, 
Sapphire-tip probes have been developed as a more effective method for 
direct contact vaporisation of tissue. The contact of the delivery system with 
the tissue results in a higher power density than is usually achieved with a 
free-beam approach. In addition, the contact tip may be coated with an 
infrared absorber, or it may become slightly coated with carbon after contact 
with the tissue. This, therefore increases the absorption of laser light at the 
fibertip and, as a result of using the fiber in contact, induces very high 
temperatures at the prostatic surface. This promotes the tendency to vaporise 
tissue. Watson presented his results on patients treated with the SLT contact 
system, using the MTRL 10 probe.24 This author concluded that the patient is 
disobstructed immediately, and that indwelling catheters can frequently be 
removed the next day. The incidence of urinary tract infection and dysuria is 
low. However, this system also has its disadvantages. Until now, the primary 
limitation has been that, even with some of the design changes and 
improvements, vaporisation of the prostate has been relatively slow and 
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tedious, especially when a large amount of tissue is involved. Contact laser 
treatment of the prostate theoretically is appealing because the technique 
results in immediate tissue vaporisation: thus, therapeutic results do not 
depend upon secondary tissue destruction. In view of the limitations of the 
present contact probes, new developments are awaited to continue to increase 
efficacy of energy transmission. Currenlty it is recommended to treat only 
prostatic volumes of 40 cm3 or less. Finally, Muschter and Hofstetter 
developed a device to be used for intraprostatic laser application.26 In contrast 
to any heat treatment where energy from a source inside the urethra is 
delivered to the periurethral prostatic tissue, interstitial energy delivery would 
not affect the urethra. As a consequence, there would be no destruction of the 
urethra with sloughing of necrotic tissue, thus avoiding all related problems, 
such as irritation. The necrotic material was expected to be resorbed with 
time, leading to an atrophic, shrunken gland. Few authors have reported their 
IPSS 
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Fig 1. IPSS symptom score, Qmax fml/s), and PVR (10 χ ml) at baseline and 
after 3, 6, and 12 months of follow-up. Data from te Slaa et al45 
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experiences with the interstitial laser coagulation using bare fibers or the 
technique described.27'28 The results thus far are similar to those with side-fire 
laser coagulation of the prostate and there is a similar prolonged period of 
postoperative suprapubic catheter drainage. Because the potential advantage 
of this technique over free-beam laser coagulation is the preservation of the 
prostatic urethra, a reduction in postoperative voiding discomfort is found.29 
Recent experience 
Laser techniques have evolved through the experience of many investigators. 
Although several clinical studies were conducted on early techniques, well-
designed clinical studies have lagged behind the progress in surgical methods. 
It is, therefore, difficult to determine which modifications in technique have 
improved clinical efficacy, morbidity, and safety. The results achieved thus 
far will be discussed in the following section. Because most devices 
eventually show similar improvements in objective and subjective 
parameters, we will not go into details concerning this aspect of laser 
prostatectomy. In Fig. 1 the results of a large number of patients treated by 
laser prostatectomy are presented. 
Safety 
The safety of any new device is of obvious importance. Safety should be 
guaranteed for the user as well as for the patient. The main concern of safety 
for the physician during the laser is guaranteed by standard laser safety 
precautions. A special room for laser treatment is prepared, while all people 
during the treatment wear safety glasses. Moreover, in case of any technical 
problem, the majority of modern laser energy sources are provided with an 
automatic emergency program, resulting in termination of the emission of 
laser energy. 
The safety for the patient should be expressed in the incidence of 
complications caused by the laser treatment itself, either by the instruments 
used or the laser energy applied. In general, laser prostatecomy has minimised 
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the majority of complications such as bleeding, TUR syndrome, and 
incontinence.1726 None of these problems has been seen in the multicenter 
trials of side-firing laser techniques. Less severe complications such as 
urethral stricture also seem to be less common. This will be discussed in more 
detail in the Morbidity section. The incidence of fistulas is only known from 
case reports. 
As more experience has been gained, more aggressive lasing has been 
performed using higher powers, longer times and more applications without 
compromising safety.30 It is fair to conclude that laser is safe in use. It is one 
of the reasons why the safety of laser devices in general makes them very 
appealing as an alternative to TURP. 
TURP versus laser 
The early clinical results of laser treatments are superior to all of the 
alternative treatments for BPO. Laser prostatectomy has rapidly become a 
widely used procedure, primarily because of its ease to use, the minimal 
bleeding and the impressive safety profile in comparison to TURP. However 
to be able to challenge the predominant TURP as an appropriate surgical 
option for treatment of BPO, laser therapy should provide results comparable 
to TURP. 
To compare the efficacy of laser prostatectomy with TURP, this is only 
possible by performing randomised controlled trials. Several studies have 
been conducted, and the urolase fiber has undergone the most extensive 
clinical trials.1316'31"33 The level of improvement in the symptom scores was 
significantly greater for the TURP group than for the laser-treated group. The 
objective improvement is expressed in uroflowmetry results. The absolute 
improvement is less for the laser-treated group than for the TURP group; 
however, the difference between the increases in maximum urinary flow for 
the two treatment groups was not statistically significant. Although 
uroflowmetry results are associated with obstructive voiding, these 
parameters are not associated with the grade of obstruction, and, therefore, 
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they cannot be used to determine objectively whether outlet obstruction is 
relieved.14 To quantify the grade of bladder outlet obstruction, urodynamic 
investigation with pressure/flow analysis is considered the gold standard. To 
judge the obstruction-relieving capabilities of laser treatment of the prostate, 
urodynamic studies need to be performed before and after treatment. Several 
studies indicate that laser is indeed capable to relieve BPO and that the 
urodynamic results are comparable to results obtained with TURP. " 
Moreover, no apparent difference in ability to relieve obstruction was shown 
for different fibers and techniques.18 However, one has to keep in mind that 
the types of devices used in comparative studies between laser treatment and 
TURP are limited. As over ten different devices are available at present, one 
would expect that these would differ in terms of response and outcome. The 
question as to the type of applicator that should be used is fundamental. To 
our surprise, the results achieved with these fibers are more or less similar. 
One might think that the general effect of laser light on tissue would be most 
important, not the device or technique used. However, several authors showed 
that different devices and/or techniques used, really differ in their abilities to 
BPO efficacious.18,39 Therefore, one may conclude that only those devices as 
studied in the aforementioned papers and using the outlined power setting can 
claim dis-obstructive capabilities. 
Morbidity 
Despite many surgical and technical improvements, the rate of total morbidity 
related to TURP has remained at approximately 20%.40~Λ2 Therefore, a variety 
of alternative minimally invasive treatment modalities are under 
investigation. The major complications such as incontinence, transfusion, and 
TUR syndrome have not occurred during laser prostatectomy (Table 1 ). The 
fluid shifts occurring during laser prostatectomy are minimal.43 With the 
exception of bladder-neck contractures, the incidence of post operative 
urethral strictures appear to be almost nil after laser treatment. Presumably, 
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Table 1. Morbidity and retreatment rates after TURP and different kinds of 
laser application. (n.m.= not mentioned; * all during 'learning curve' period) 
Morbidity TURP40"*2 Side-firing Contact Interstitial26,27 
fiber1 5"1 8 ·" fiber24 
Tranfusion% 
Tur-syndrome% 
Catheterization,days 
Irritative voiding complaints% 
Urinary tract infections% 
Bladder neck contractures'^ 
Urethral strictures% 
Incontinence0/«) 
Erectile dysfunction% 
Retrograde ejaculation% 
Retreatment% 
2.5-14 
0.8-1.5 
2-5 
6-15 
2.3-14 
2.8 
0.6-6.3 
0.2-19.1 
0-40 
55-90 
12-15 
after 8 yrs 
0-1.3 
0 
5-21 
20-85 
30-50 
0-5.8 
0.4 
0 
0-13 
20-47 
0-8.8 
after 1 yr 
0 
0 
2-3 
<10 
<10 
n.m. 
n.m. 
0 
n.m 
35 
n.m 
0 
0 
5-14 
13 
35 
1.7 
5.4* 
0 
0 
7 
<1 
after 1 y 
this is due to the shorter procedure and to the use of a cystoscope that is 
considerably smaller than a conventional resectoscope. Bladder neck 
contractures seem to occur at similar rates. 
The main drawback of laser prostatectomy is the incidence of posttreatment 
irritative voiding complaints and catheter-dependent retention. Depending on 
type of fiber and technique used, up to 50% of patients experience, during 2-6 
weeks, marked difficulties in voiding.15 This is presumably due to the thermal 
injury and delayed destruction that occur after treatment. Another reason may 
be irritation of the trigone following laser prostatectomy, resulting in 
hyperactivity of the bladder which may cause bladder cramps. This is 
endorsed by the finding that when using the interstitial lasing technique or the 
SLT contact system, only few patients suffered irritative symptoms.24'26 
Fortunately, these symptoms have always resolved and can be controlled by 
oral medications. Also the catheter-dependent retention may vary from 0 days 
to 8 weeks, depending on the devices and techniques used. In general, 
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techniques achieving immediate formation of a cavity, obviously do not 
require prolonged catheterization. Moreover, a different time interval is 
suggested, depending on the type of catheter inserted. It is noticed that 
following transurethral catheter placement, this can be removed at an earlier 
stage that following suprapubic catheter placement. 
Bleeding occurring at the time of surgery or after treatment is markedly 
reduced by the laser procedure. Transfusion, continuous bladder irrigation, 
and delayed clot retention have been shown to be involved to a much lesser 
extent after laser treatment than after TURP. Moreover, the procedure has 
also been successfully performed in patients taking coumarin without 
interrupting their anticoagulation.44 
One should also address the changes in sexual function following laser 
treatment. In general, retrograde ejaculation occurs much less frequently in 
such cases than after TURP. In a recent study performed in the Netherlands, 
the retrograde ejaculation ratio appeared to be 47%.45 Also impotence has 
been reported after laser treatment, but its incidence also appears to be 
significantly lower than after TURP. The proportion of diminished or absent 
erectile function in the aforementioned study was estimated to be 12.6%. 
These changes in sexual functions may be explained by a damage of the 
periprostatic nerves following laser treatment. However, it is suggested that 
also psychological factors may play an important role in this respect. 
Retreatment 
The objective success of treatment is usually defined by an improvement in 
objective and subjective parameters. The success of a treatment also depends 
on the necessity and the incidence of retreatment, and the interval between the 
initial treatment and the period of retreatment. The retreatment rate of TURP 
has been documented in several retrospective studies. One of the best known 
is the Manitoba Study performed by Roos et al.46 The study revealed a rising 
percentage of patients undergoing a second prostatectomy (2.3-4.3%, 8.9-
9.7%, and 12.0-15.5% after 1, 5, and 8 years, respectively). A population-
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based study by Chute et al. even showed that within a 30-day period after 
operation, 1.8% of the patients needed repeated prostatectomy.'17 The results 
achieved with laser treatment thus far are exciting and very promising. Short 
term follow-up shows a low retreatment percentage, ranging from 1.4% to 
17.6% depending on the device used and the follow up period. The results of 
a multicentric Dutch study show that at 1 year follow-up, 4.7% (n=ll) of 
patients had a TURP, a second laser treatment was performed in 1.7% (n=4), 
a bladder neck incision was required in 1.3%. while a internal urethrotomy 
had to be performed in 0.4% (n=l).45 The largest experience is documented 
by Costello et al.17 who had a continuing experience with the use of Nd:YAG 
laser fiber prostatectomy over a period of 4 years. The results showed a 
sustained reduction in symptoms and maintained improvement in 
uroflowmetry parameters with stabilisation of these parameters occurring 
within 12-36 months. Following laser ablation of the prostate in 198 patients, 
only 1% of patients needed treatment for a bladder-neck stenosis. A revision 
surgery was required in 8% (n=16) of patients, respectively at 6 weeks (n=5), 
3 months (n=3), 6 months (n=4), and 12 months (n=4). These results 
demonstrate the low incidence of retreatment following laser prostatectomy. 
Durability 
Although the design of most devices differ substantially, there are nonetheless 
some physical similarities. Either coagulation necrosis, direct vaporisation, or 
a combination of the two can be obtained using each device with the 
appropriate dosimetry protocol. A factor associated with tissue destruction is 
the amount of energy delivered to the prostate that will eventually be 
absorbed by the prostate gland. This depends on a number of variables, such 
as reflection of laser light, changes in tissue characteristics during lasing, 
tissue cooling via increased prostatic blood flow, the colour of the prostatic 
mucosa, and loss of power output due to fibertip decrease during the laser 
procedure. Several studies have been performed to investigate the 
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posttreatment decrease in the quality of the laser fibers. Indeed a 
difference in durability was found between the different fibers tested. On the 
other hand, the SLT contact fibers can be reused between five and ten times. 
If no tissue effect is noticed anymore, it should be replaced. In case of the use 
of interstitial laser treatment, the reuse of the applicators seems to be feasible. 
To lower expenses of laser treatment, it would help if we could reduce the 
price of the fiber per treatment. The reuse of most side-firing fibers is not 
recommended, whereas this seems to be possible for the SLT contact system 
and the interstitial applicators. 
Costs 
Many issues are important regarding the costs of two procedures. Besides the 
cost of the procedure, any resulting complications, and the reoperation rate 
should be included. Also issues such as time lost from work are important but 
difficult to study. Moreover the costs involved in the purchase of a laser 
system, the devices used, room power requirements, and safety training of 
personnel involved in using the laser need to be considered as well. Also the 
costs may vary from institution to institution and from country to country. 
Reducing the number of hospital days is obviously helpful but may not have a 
great impact on the total hospital cost. Indeed the fibers are still expensive, 
often costing the equivalent of the room charge for 1 or more days in the 
hospital. If more than one fiber is required, any hospitalisation cost benefit of 
the laser procedure could be quickly negated. A reusable device provides 
significant savings, depending on the durability and the number of times it 
can be reused. Costs could even be reduced significantly if general or regional 
anesthesia is not required. Laser treatment using intravenous sedation and a 
perineal block has been used successfully performed.50 In our department, we 
have some experience in performing interstitial laser treatments under a peri-
prostatic block. Indeed the vast majority of the patients tolerates this approach 
very well, and thus we are extending our initial experience. 
We think that the costs of laser treatment and TURP seem more or less 
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comparable. Moreover cost analysis is very complex and many issues in 
addition to simple hospitalisation costs must also be considered. Therefore, 
we may conclude that currently no final answer is available whether laser 
treatment is more cost effective than TURP. 
Perspectives 
Urologists are traditionally in favor of utilising newer forms of therapeutic 
energy in clinical practice. Specially benign diseases of the prostate may be 
the first clinical entities where patients may actually profit from these 
advances. Within the last years, Nd:YAG laser prostatectomy has become a 
popular treatment alternative for the management of bladder outlet 
obstruction due to benign prostatic hyperplasia. 
Given time, patients can be expected to achieve excellent voiding outcomes 
following laser prostatectomy, whether measured by objective flow rates and 
postvoiding residual urine volumes or determined by subjective assessment of 
symptom score improvement and postoperative patient satisfaction. Overall 
efficacy has been shown to be comparable and often indistinguishable from 
electrocautery resection by multiple investigators world-wide. Not only is this 
procedure efficacious, but increasing numbers of patients with follow up 
periods of 3 and 4 years or longer are now demonstrating the long-term 
durability of laser prostatectomy which appears not significantly different 
from electrocautery resection. 
However, laser prostatectomy also has its disadvantages. First of all, a 
somewhat confusing array of laser fibers, laser beam configurations, and 
operative techniques are being offered to the urological community. Which 
type of applicator to use is a fundamental question and depends on the 
intended immediate laser effect, the morbidity caused, the efficacy, and last 
but not least the costs. A detailed discussion of basic principles and technical 
aspects is beyond the scope of this article, but most 'experts' will agree that 
the clinical improvements are independent of the type of device used. The 
major difference between these systems are the ease of use and the morbidity 
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caused. The major drawback of the TULIP system was the difficulty to 
perform a laser treatment using this device, while a prolonged need for 
catheterization and persisting irritative voiding complaints was observed. 
These were the major arguments why most colleagues, although a clinical 
significant improvement could be documented, refrained from this treatment 
modality. A similar trend may be noticed regarding the currently used side-
firing fiber techniques. Although the results are impressive and retreatment is 
acceptably low, the morbidity is considerably high. The duration of 
catheterization is at average 1-2 weeks. Moreover, in almost half of these 
patients, irritative voiding may occur. The major advantages of the SLT 
contact system and the interstitial laser approach are obvious. In case of the 
use of SLT contact probes, an immediate cavitation is created following 
vaporisation of the adenomatous tissue, thus resulting in a decreased need for 
catheterization. However irritative complaints still may be observed in a 
significant number of patients during the first weeks after treatment. In case 
of the interstitial laser coagulation approach, still a prolonged catheterization 
time can be observed; however, by preserving the urethral mucosa the 
morbidity is minimal. 
How to overcome the current shortcomings of laser prostatectomy? To be 
accepted as an alternative to TURP, a successful early catheter removal 
within 24h after the visual laser ablation of the prostate, without significant 
morbidity, is required. Indeed vaporisation appears to allow an earlier 
removal of catheters and a reduction in postoperative discomfort.2'1 However, 
contact devices are relatively slow and tedious in use and are generally felt to 
be suitable only for smaller glands. An improved SLT- contact probe 
(VaporMax) was recently introduced to overcome these problems (Fig.2). 
In contrast to the MRTL-10 probe, the energy can be delivered at an angle of 
90°. In case of the use of the interstitial laser coagulation device, another 
approach may be recommended to overcome the shortcomings of this 
treatment. In a recent study by Talja et al, the use of a self-reinforced spiral 
stent was presented, showing an effective and safe method to prevent 
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postoperative urinary retention after laser prostatectomy. 
Fig. 2 a Different kinds of laser fiber tips. From left to right: the Vapor Max, 
the MRTL-10, the chisel (a contact probe for bladder neck incisions), and a 
side-firing fiber, b VaporMax. The contact probe which delivers the laser 
energy at an angle of 90 °. 
Finally important issues regarding laser prostatectomy are the reuse of laser 
fibers and the performance of a treatment under local anaesthesia. Both seem 
to be within reach of the aforementioned treatment options and should be 
pursued. Moreover, we need to improve our understanding concerning the 
laser-tissue interaction. When using a vaporising approach such as the SLT 
contact system, this understanding is not really necessary because "what you 
see is what you get" . However, in case of the use of all other techniques such 
an understanding of the mechanisms of action as well as a better guided 
treatment are mandatory. During every treatment, the optimum intraprostatic 
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temperature should be achieved to obtain the requested result, namely 
adequate coagulation. The Indigo ILC system is currently evaluated using a 
so called 'temperature-sensing' system. In order to perform an effective 
treatment, temperatures should be sufficiently high, but not too high to avoid 
charring which makes the treatment inefficient and out of control. The 
optimal temperature for coagulation is estimated to be around 100° C. It is 
well known that the achieved tissue temperature not only depends on the 
power input by the treatment device but also by the energy absorption of the 
tissue. A well perfused area in the prostate will require a higher energy dose 
to achieve and maintain a certain temperature than a poorly perfused area. 
Thus is seems logical that each puncture in the prostate may require a 
different energy input to reach the same predictable volume of coagulation. 
To overcome this variability caused by the tissue characteristics, a 
thermosensor is build in the diffuser tip of the fiber of this new interstitial 
treatment device(Fig.3). During treatment the temperature is monitored 
continuously, and temperature and power output form a feedback loop which 
maintains a temperature of 100° С independent of perfusion or any other 
tissue characteristic. 
We may conclude that following the introduction of laser energy to treat 
patients with benign prostatic enlargement, laser therapy has evolved rapidly. 
Although the results following side-firing laser treatment are excellent, the 
morbidity caused seems to be a major drawback. The prolonged need for 
catheterization can be overcome by using (newly developed) contact laser 
devices. Another approach to overcome posttreatment retention is the use of 
temporarily placed prostate stents. Finally interstitial laser applicators provide 
good results while the posttreatment irritative voiding complaints are only 
minimal. An ingenious feed back mechanism is being provided to achieve a 
safe and highly efficient treatment in all patients. 
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Addendum 
Personal View 
It has been many years since Malcolm McPhee called surgical lasers 
"machines in search of a disease". In urology this remained true until five 
years ago, when this disease seemed to be benign prostatic obstruction 
(BPO)asa result of 
benign prostatic hyperplasia (BPH). Since the first reports of laser 
prostatectomies in men published by Costello', it became clear that laser 
treatment of the prostate could indeed replace the transurethral 
electroresection of the prostate (TURP). Many studies 2'6 reported about the 
efficacy of laser prostatectomy in the treatment of BPO. In several 
randomised studies 7"9 the results were almost comparable or even equal to 
results after TURP. Furthermore the complications, which are well-known 
after TURP (such as transurethral resection syndrome, bloodtransfusions, clot 
retention, urethral strictures and incontinence) were only incidental seen after 
laser prostatectomy. Moreover laser prostatectomy is easier to learn when 
compared to TURP, and could be performed as an outpatient procedure even 
under local anaesthesia. This progress of the laser in the treatment of BPO 
resulted in the statement "laser is here to stay" at the AU A meeting in 1994. 
These statements were never made for other alternative treatments such as 
balloon dilatation, hyperthermia, and prostatic stents. 
But with more experience and investigations, more data came available 
revealing that also laser prostatectomy had its drawbacks. In contrast to 
TURP it will take about 4 to 6 weeks and sometimes up to 3 months after 
laser treatment before the optimal result is established. Following a TURP 
procedure, patients will have a good result almost immediately after removal 
of the indwelling catheter. Furthermore there is a prolonged catheterization 
duration, irritative voiding complaints for 4 to 6 weeks and a higher rate of 
urinary tract infections following laser treatment of the prostate. To overcome 
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these problems several techniques and different types of fibers were 
developed resulting in contact tips for direct vaporisation and fibers for 
interstitial laser coagulation. It seemed that each new technique resulted in 
solving one problem and creating another. Contact tips for vaporisation 
appeared to create a direct cavity in the prostatic urethra and as a result 
catheterization duration was shortened, but the procedure is tediously slow 
and at this moment only suitable for small prostates. The same holds true for 
the interstitial laser coagulation, which leaves the mucosa of the prostatic 
urethra intact and as a result irritative voiding symptoms are less. But also 
this technique has a long catheterization duration. Thus at this moment laser 
treatment of the prostate is by no means the optimal treatment for BPO. This 
statement is supported by the fact that at this moment there is no optimal 
laser procedure, reflected by the numerous different laser devices and 
techniques which are available today. Also the ongoing development of new 
fibers, new treatment methods and the use of different laser sources clearly 
shows that still much needs to be done in order to develop this laser 
technology. Furthermore other new technologies as thermotherapy, 
transurethral needle ablation (TUNA), high intensity focused ultrasound 
(HIFU) and electrosurgical vaporisation are arising at the horizon. On the 
other hand we have to acknowledge that there is only five years of experience 
with laser treatment of the prostate. Whereas in the beginning of the TURP-
era (1926) there was a mortality rate of 25 % and it took about 40 years for 
the TURP to become the golden standard. 
At the moment it is my strong feeling that there is no laser procedure which 
could replace the TURP as golden standard in the treatment of BPO. But that 
does not mean that there is no place at all for lasers. For example patients 
with cardiac diseases and/or who are using anticoagulant drugs have a high 
risk of developing complications during or after TURP. Laser treatment of the 
prostate is an almost bloodless procedure with no fluid resorption during the 
procedure. For these cases preferably laser treatment may be recommended. 
Because laser treatment of the prostate is still a developing technology it is at 
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this moment difficult to advise urologists, who are interested in performing 
laser prostatectomies, which laser source, type of fiber(s) or technique they 
should use. Maybe combining different technologies of laser prostatectomies 
will be the final solution. On the other hand laser experts seem to return to 
resection of prostatic tissue, using the laser as a cutting knife.10 Indeed the 
early results are again very promising but more experience with this 
technique is needed to judge its place in the treatment of BPO. 
Concerning these developments, urologists may ask themselves if it is wise to 
start at all with laser prostatectomies at this moment. Maybe it is better to just 
wait for the research centers to come with a more advanced laser procedure or 
an other alternative for TURP. 
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Summary 
Summary 
The use of heat, whatever the source, be it microwaves, high intensity 
focused ultrasound, radiofrequency or laser light, to treat benign prostatic 
hyperplasia (BPH) has emerged as the main challenge to the "gold standards" 
being transurethral resection of the prostate and open prostatectomy. 
Although these "gold standards" proved to be safe and effective, the 
morbidity and costs involved in the treatment of BPH were the main reasons 
for the search for alternative treatments. 
This thesis reports on one of these new heat treatments in BPH: laser 
prostatectomy. The laser fibers were subject of investigations, furthermore 
efficacy and morbidity of the use of laser light on the prostate were 
investigated in several studies. 
Laser energy is partially absorbed by the prostatic tissue and then converted 
to heat which produces thermal damage. The amount of energy absorbed by 
the prostatic tissue is not the same as the amount provided by the laser source. 
This depends on a number of variables, one of those is loss of transmission in 
the laser fiber and the deflecting mechanism. During a laser procedure, 
changes in the laser fiber may occur due to deterioration of parts of the laser 
fiber that transmit or deflect the laser light, resulting in a loss of transmission. 
In the first part of chapter 2 transmission loss is demonstrated in different 
types of side firing laser devices following a laser procedure. Transmission 
measurements were performed in a laboratory setting. Visual inspection of 
the fiber tips appeared to show only a correlation with transmission loss for 
one specific type of fiber. There was no correlation between the total amount 
of kJoules provided by the laser source and transmission loss of the fiber. In 
the second part of chapter 2 the use of a power meter provided more insight 
because transmission measurements could now be performed under clinical 
conditions, that is, under water with high power input. Eight types of side 
firing devices were investigated prior to treatment. These fibers were 
compared to the results of measurements of a bare fiber at 60 W. input. Three 
types of fibers were tested before and after a laser procedure. The 
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transmission strongly varies between new fibers and also between different 
samples of one fiber during clinical use. A significant correlation between 
visual inspection and transmission was noted only for a specific type of fiber, 
however the situation for one particular fiber may be different. Therefore, 
power measurements during clinical treatment will contribute to a more 
controlled procedure and to a better comparison of clinical laser postatectomy 
studies. In the third part of chapter 2 the influence of the transmission loss of 
laser fibers on clinical outcome was investigated. Three types of laser fibers 
were studied. A relation between the amount of transmission loss and the 
clinical outcome could not be found for all three types of fibers. The fibers 
were only measured at the end of the procedure and compared to the 
transmission of a new fiber, of the same type. However, loss of transmission 
is not a linear process and therefore this can be a reason for not finding a 
relation with clinical outcome. Furthermore the number of non responders in 
this study was very small, making it very difficult to find any significant 
relation. 
The clinical results are discussed in chapter 3. The first part presents a study 
that shows significant improvement in objective and subjective parameters 
for both side firing devices investigated. No statistically significant difference 
was found in the clinical outcome of laser prostatectomies performed with 
both devices. In the second part, a multicenter study is presented with data of 
233 patients from 5 centers where laser prostatectomies were performed with 
one type of side firing laser device. Although there were some differences in 
clinical outcome, all centers showed significant improvement in clinical 
outcome parameters after laser prostatectomy. Furthermore it was clear from 
this study that morbidity after a laser procedure was significant, with irritative 
voiding complaints for 4 to 6 weeks in up to 50% of all patients and urinary 
tract infections in 21.1%. 
Although the improvements in uroflow parameters are significant, the 
desobstructive abilities of laser prostatectomy were questioned. To 
investigate these abilities urodynamic investigations are needed. In chapter 4 
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the results of advanced urodynamics before and 6 months after laser 
prostatectomy are presented. Before laser treatment 65 to 90% of the patients 
were considered to be obstructed, depending on what obstruction parameter 
was used. After treatment 5 to 18% were still considered to be obstructed. A 
comparison of the outcome between minimally and severely obstructed 
patients before treatment showed comparable improvements, concerning 
symptom score and uroflowmetry parameters. 
Chapter 5 presents the morbidity of laser prostatectomy. In the first part the 
incidence of urinary tract infections tended to be, although not significantly, 
lower when perioperative antibiotics were used. There seemed to be a 
relation between the duration of postoperative catheterization and the risk of 
developing urinary tract infection. A relation between urinary tract infections 
and irritative voiding complaints, however, could not be found. The second 
part reports on the quality of life. Data of 103 patients were evaluated and 
showed a significant improvement in quality of life after laser prostatectomy. 
No relation was found between the maximum flow and the quality of life. 
Finally, chapter 6 gives a review of laser prostatectomy and future 
developments especially in fiber technology, that might contribute to 
maintain the achieved objective and subjective improvement with a lower 
postoperative morbidity. 
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Samenvatting 
Samenvatting 
De gouden standaard in de behandeling van benigne prostaat hyperplasie 
(BPH) is de chirurgische verwijdering van het prostaatadenoom via 
transurethrale weg dan wel door middel van een open prostatectomie. Deze 
ingrepen hebben gedurende de laatste decennia bewezen veilig en effectief te 
zijn, echter de morbiditeit van deze ingrepen en de aanzienlijke kosten van de 
behandeling van BPH voor de gezondheidszorg hebben geleid tot de 
ontwikkeling van alternatieve behandelingsmethoden. 
Dit proefschrift beschrijft één van deze nieuwe behandelingen voor BPH, te 
weten de laser prostatectomie. Naast het verrichten van basaal onderzoek van 
de laser fibers, zijn ook de effectiviteit en de morbiditeit van de laser 
behandeling van de prostaat onderzocht in verschillende studies. 
Laser energie wordt maar gedeeltelijk door het prostaatweefsel geabsorbeerd 
en vervolgens omgezet in warmte. Hierdoor kan thermische schade van het 
weefsel ontstaan. De hoeveelheid energie die door de prostaat wordt 
geabsorbeerd is niet gelijk aan de hoeveelheid die door de laserbron wordt 
geleverd. Eén van de oorzaken is het verlies van transmissie in de laser fiber 
en in het reflectie mechanisme in de tip van de fiber. Onderdelen van de laser 
fiber welke het laserlicht transporteren of afbuigen, kunnen tijdens de laser 
behandeling verontreinigt raken. Hierdoor ontstaan veranderingen in de fiber 
en fibertip, waardoor toename in transmissieverlies kan worden veroorzaakt. 
In het tweede hoofdstuk wordt het verlies van transmissie in twee 
verschillende types zijwaarts-schijnende laserfibers gepresenteerd, nadat deze 
zijn gebruikt voor een laserbehandeling van de prostaat. De transmissie 
metingen werden verricht onder niet klinische omstandigheden. Er leek alleen 
voor één type laserfiber een correlatie met het transmissieverlies te bestaan. 
Er bestond geen relatie tussen de totaal geleverde hoeveelheid kJoules en het 
verlies in transmissie van een laserfiber. In het tweede deel van hoofdstuk 2 
wordt de power meter geïntroduceerd waardoor het mogelijk wordt om 
transmissie metingen te verrichten onder klinische omstandigheden, dus 
onder water en met een hoge power input. Acht soorten, nieuwe, zijwaarts-
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schijnende laserfibers werden onderzocht. De resultaten van de transmissie 
metingen werden vergeleken bij een input van 60 Watt met die van een fiber, 
die geen tip heeft met een afbuigmechanisme zodat de invloed van zo'n tip, 
die voor alle acht onderzochte fibers anders is, kon worden vastgelegd. Drie 
soorten laserfibers werden onderzocht voor en na een laserbehandeling. De 
transmissie varieerde sterk tussen de 8 nieuwe laserfibers en ook tussen 
verschillende fibers van één en dezelfde soort tijdens een laserbehandeling. Er 
bestaat een significante relatie voor één type laser fiber tussen de visuele 
beoordeling van de fibertip en de mate van transmissieverlies. Echter over 
één aparte laser fiber kan aan de hand van het visuele aspect van de fibertip, 
niets over de mate van transmissieverlies worden gezegd. 
Transmissiemetingen tijdens een laserbehandeling dragen bij tot een betere 
controle van de laserprocedure en het beter vergelijkbaar maken van de 
resultaten van studies over laserbehandeling van de prostaat. Het laatste deel 
van hoofdstuk 2 beschrijft de invloed van het transmissieverlies van 
laserfibers op de klinische resultaten van een laserbehandeling. Drie 
verschillende soorten laserfibers werden onderzocht en voor alle drie bestond 
er geen verband tussen de mate van transmissieverlies en de klinische 
resultaten. In deze studie werden de transmissiemetingen alleen aan het einde 
van een laserbehandeling verricht en vervolgens vergeleken met de 
transmissie van een nieuwe laserfiber van hetzelfde type. Het feit dat 
transmissieverlies van een laserfiber tijdens de laserbehandeling geen lineair 
proces is, kan een reden zijn dat er geen verband met de klinische resultaten 
werd gevonden. Daarnaast was het aantal nonresponders in deze studie erg 
klein, zodat een significante relatie sowieso moeilijk te vinden is. 
Hoofdstuk 3 beschrijft de klinische resultaten. In het eerste deel wordt een 
studie beschreven waarin laserbehandeling van de prostaat met twee 
verschillende zijwaarts-schijnende laserfibers was onderzocht. Er bestond een 
significante verbetering in objectieve en subjectieve parameters na de 
laserbehandeling. Er was geen verschil tussen de twee onderzochte 
laserfibers. Het tweede deel van dit hoofdstuk beschrijft een multicentrische 
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Studie van 233 patiënten uit 5 centra. In alle centra werd de laserbehandeling 
verricht met eenzelfde type zijwaarts-schijnende laserfiber. Ondanks enkele 
verschillen in klinische resultaten tussen de centra, was er een significante 
verbetering in subjectieve en objectieve parameters na laserbehandeling voor 
alle centra. De morbiditeit van de laserbehandeling was significant, met 
irritatieve mictieklachten gedurende 4 tot 6 weken postoperatief in bijna 50% 
van de patiënten en urineweginfecties in 21,1%. 
Ondanks duidelijke verbetering in uroflowmetrie parameters, is 
urodynamisch onderzoek met "pressure-flow" analyse noodzakelijk voor het 
aantonen van desobstructieve mogelijkheden van een laserbehandeling van de 
prostaat. In hoofdstuk 4 worden de resultaten gepresenteerd van geavanceerd 
urodynamisch onderzoek verricht voor en 6 maanden na een 
laserbehandeling. Voor de behandeling waren, afhankelijk van de gebruikte 
parameters, 65 tot 90% van de patiënten urodynamisch obstructief. Na 
laserbehandeling van de prostaat was dit nog maar 5 tot 18% van de 
patiënten. Verder bleek dat patiënten die voor de laserbehandeling minimaal 
obstructief waren, vergelijkbare verbetering in uroflowmetrie parameters en 
symptomscore hadden, als patiënten die tevoren ernstig obstructief waren. 
Morbiditeit na een Iaserbchandeling wordt beschreven in hoofdstuk 5. De 
incidentie van urineweginfecties wordt verminderd, echter niet significant, 
door het gebruik van perioperatieve antibiotica. In deze studie bestaat er een 
verband tussen de duur van postoperatieve catheterisatie en de kans op het 
ontwikkelen van een urineweginfectie. Er bestond geen relatie tussen de 
irritatieve mictieklachten en de aanwezigheid van een urineweginfectie. 
Kwaliteit van leven voor en na laserbehandeling werd onderzocht in 103 
patiënten. Er was een duidelijke verbetering in kwaliteit van leven als gevolg 
van de laserbehandeling. Er werd in deze studie geen verband gevonden 
tussen de maximale flowsnelheid en kwaliteit van leven. 
In hoofdstuk 6 wordt een overzicht gegeven van de literatuur van 
laserbehandelingen van de prostaat. Tevens worden nieuwe ontwikkelingen, 
vooral in fibertechnologie, beschreven welke in de toekomst mogelijk kunnen 
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bijdragen tot vermindering van de morbiditeit, als gevolg van een 
laserbehandeling van de prostaat, zonder de effectiviteit te beïnvloeden. 
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Stellingen behorende bij het proefschrift 
Laser prostatectomy in the treatment 
of benign prostatic enlargement 
door 
Eduard te Slaa 
Nijmegen, 27 mei 1997 
I. Ondanks verschil in bundelkarakteristieken en afbuigmechanisme is er 
geen verschil in de klinische resultaten na laser behandeling van de 
prostaat met diverse side-firing laser fibers, {dit proefschrift) 
II. Laser behandeling van de prostaat met side-firing laser fibers 
veroorzaakt urodynamisch bewezen desobstructie bij het merendeel van 
de behandelde patiënten, {ditproefschrift) 
III. Laser behandeling van de prostaat met side-firing laser fibers is niet 
zonder morbidrteit. {dit proefschrift) 
Г . Een normaal aspect van de fibertip van een side-firing laser fiber, 
gedurende een laser behandeling, betekent niet dat er geen tranmissie-
verlies aanwezig is. {ditproefschrift) 
V. Bij LUTS is de hinder die een patient van een symptoom heeft (bother-
score) belangrijker dan het symptoom zelf. {dit proefschrift) 
VI. Pas als de morbiditeit na laserbehandeling van de prostaat afgenomen is 
en de lange termijn resultaten goed blijven, kan de TURP van zijn troon 
gestoten worden, {ditproefschrift) 
VII. Verbetering van symptoom scores is niet gerelateerd aan verbetering van 
objectieve parameters na een laser behandeling van de prostaat met side-
firing laser fibers, {ditproefschrift) 
VIII. Niet alle fracturen dienen door een algemeen of orthopaedisch chirurg te 
worden behandeld; een enkele keer komt er een uroloog aan te pas. 
Bij het overwegen van een penisverlenging ter vergroting van het 
mannelijk ego, moet men zich wel bedenken dat in dezelfde prijsklasse 
een kleine sportieve oldtimer kan worden aangeschaft, hetgeen een zelfde 
invloed kan hebben. 
Gezien de huidige ontwikkelingen in de voetbalsupporterswereld wordt 
de uitspraak "voetbal is oorlog" wel erg letterlijk genomen. 
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